DUKE UNIVERSITY MEDICAL CENTER
Claude D. Pepper Older Americans Independence Center

Kenneth Schmader, M.D.
Principal Investigator
  919-660-7500   kenneth.schmader@duke.edu
Michelle Cooley
Program Administrator
  919-660-7551   michelle.cooley@duke.edu
     
CENTER DESCRIPTION

The overall goal of the Duke Claude D. Pepper Older Americans Independence Center (Duke OAIC) is to support research and training that improves the independence of older Americans by focusing on our theme to understand and optimize reserve and resilience. This theme is founded on the insight that independence in older adults is related to an individuals ability to withstand or recover from functional decline following acute or chronic health stressors. We conceptualize resilience as a dynamic response observed and measured after a stressor is applied.  We define resilience as the ability to resist or recover from adverse effects of a stressor; reserve is the pre-stressor capacity, in multiple domains, to adapt to a stressor.  Our approach includes better understanding of the underlying mechanisms as well as the creation of new interventions for optimizing reserve and resilience across the lifespan

Our overall strategy for the OAIC is to serve as a sustained resource to our investigators through a broad range of training and research studies; the goal is to address knowledge gaps in our focus with an emphasis on translational and interdisciplinary research. We recruit and develop early stage investigators in aging research related to our focus and utilize the substantial strengths of the Duke academic and health system environment to advance our focus. 

The Duke Pepper Center has been at the forefront of geriatric research and training focused on the development of interventions to improve the functional status of older adults and the support of research that identifies risk factors predictive of functional decline. The Duke Pepper Center originally began its funding as a Geriatric Research and Training Center (GRTC) in 1991. The GRTC was originally funded with three research cores and support for junior faculty and pilot projects, which reflects the organization of the current OAIC structure. One year later, Duke was awarded a Pepper Center and, at the direction of the National Institute on Aging, the two programs were combined into one. Initial Pepper Center support focused on the development of promising interventions to promote the independence of older Americans and faculty development. Since then, the Duke OAIC has produced an impressive portfolio of relevant research and innovations in faculty development.

The goals of the Duke Pepper Center are:

  1. To advance our knowledge of measures, mechanisms and analyses of reserve and resilience in older adults through an integrated research program
  2. To develop and evaluate interventions that optimize reserve and resilience in older adults.   
  3. To identify and develop the next generation of researchers who will become leaders in aging and geriatrics research related to the Duke OAIC focus.
  4. To support pilot studies needed to design successful, more definitive research studies related to the Duke OAIC focus. 

CORES
Leadership and Administrative Core (LAC)
Leader 1:    Kenneth Schmader, MD   kenneth.schmader@dm.duke.edu
Leader 2:    Cathleen Colón-Emeric, MD, MHS   cathleen.colonemeric@duke.edu
The Leadership and Administrative Core (LAC) provides the scientific leadership and administrative infrastructure to create a robust environment for aging and geriatrics research in our theme. The Leadership and Administrative Core promotes the development of early investigators with interests in aging and geriatrics research and ensures the coordination, integration, funding, and translation of research within the Duke OAIC, a mission that supports our ultimate goal of improving the independence of older adults. The specific aims of the Leadership and Administrative Core are to: 1) to provide overall coordination and administration of the Duke OAIC 2) to stimulate, monitor, sustain and evaluate the progress of the OAIC towards achieving its research and education goals 3) to assess scientific opportunities for innovative research in our theme with an emphasis on translational and interdisciplinary research 4) to utilize and develop resources effectively to meet the goals of the Duke OAIC.

Research Education Component (REC)
Leader 1:    Cathleen Colón-Emeric, MD, MHS   colon001@mc.duke.edu
Leader 2:    Kimberly Johnson, M.D.   kimberly.s.johnson@duke.edu
Leader 3:    Barrett Bowling, M.D.   barrett.bowling@duke.edu
The objective of the Research Education Component (REC) is to develop the next generation of researchers who will become leaders in integrating basic science and clinical insights into innovative interventions promoting reserve and resilience in late life. Guided by educators in the Aging Center with nationally recognized expertise in curriculum development and evaluation, the REC measures the impact of OAIC programs on Scholars' career progression using innovative evaluation methods such as nominal group sessions. We have well established, close partnerships with multiple partner programs across the university (e.g., the Duke Clinical Translational Science Award Center (CTSA) KL2 program, NIA T32 aging training grant, NIA Roybal Center, NIMHD REACH EQUITY Center) . The School of Medicine offers excellent professional development programs, research leadership training, and grant-writing education and support services that are utilized by our scholars. Examples of REC training activities include our Intervention Development in Elderly Adults (IDEA) Workshop, Works-In-Progress sessions, Health Care Disparities Research Curriculum and “Pepper Shakers” networking events with faculty and scholars The specific aims of the Research Education Component are to: 1) to deliver an aging research curriculum around promoting physical reserve and resilience, while providing multiple opportunities for feedback, networking, and peer support; 2) to train and support mentors to enhance the quality of translational research mentoring across disciplines; 3) to provide mentored research experiences to prepare a diverse group of aging researchers focusing on physical resilience in older adults

Pilot and Exploratory Studies Core (PESC)
Leader 1:    Heather E. Whitson, MD   heather.whitson@duke.edu
Leader 2:    Susan N. Hastings, MD   susan.hastings@duke.edu
The Pilot/Exploratory Studies Core (PESC) emphasizes physiological reserve at the cell/tissue/organ level, which we hypothesize is a key contributor to resilience at the whole person level. The PESC impacts public health by performing studies that develop knowledge to maintain or recover independence in older Americans, by promoting reserve and resilience in the face of chronic and acute stressors. The PESC places emphasis on the development of novel interventions that will bolster resilience. PESC continues to support studies that conduct crucial resilience-related pilot work prior to the stage of intervention (e.g., development of measures or model systems). Our mentoring approach and OAIC environment train awardees to strategize as to how their lines of research may translate into improved human outcomes. We use small exploratory pilot monies as a rapid response mechanism to take advantage of cutting edge areas. The PESC solicits and selects high quality pilot studies from across Duke University Medical Center using a rigorous, multi-stage process that incorporates internal and external review. The PESC carefully monitors study progress and assists in the development of larger grant proposals from pilot study findings. The Duke PESC includes several highly innovative features: 1) the Pilot Grants Workshop, developed by OAIC Director Kenneth Schmader and frequently requested in national venues, 2) the inclusion of patient/community representatives on the Review Panel that selects pilots, 3) the Data Integration Working Group, which is a central hub for scientific development, oversight, and translation, and 4) mechanisms that support the science and careers of unfunded pilot study applicants. The specific aims of the Pilot/ Exploratory Studies Core are to: 1) to advance top quality science related to late-life reserve and resilience; 2) to attract and nurture a diverse cadre of outstanding investigators equipped to pursue promising new directions in aging research related to our theme; 3) to build and sustain relationships with critical stakeholders to maximize the impact and translation of the work conducted through this and future OAICs

Analysis (AC)
Leader 1:    Sarah Peskoe, PhD   sarah.peskoe@duke.edu
The Analysis Core (AC) serves as the central resource for data management and biostatistical analyses for research to understand and optimize reserve and resilience. The AC provides specialized research expertise in study design, data collection and management, development of statistical analysis plans, analytic support, and interpretation/dissemination of results to OAIC scholars and faculty. The AC promotes novel lines of research by developing new methods specifically targeted to detect and measure reserve and resilience. Finally, the AC supports training objectives by developing fellow and faculty understanding of biostatistics and research methodology—critical areas of the research enterprise that are typically a knowledge gap in basic, translational, and clinical researchers. The AC works closely with OAIC investigators, the two Resource Cores (Molecular Measures Core and Physical Measures Core), the PESC and REC to direct study design and analysis and to insure studies are properly powered and address targeted research questions. Furthermore, the AC is uniquely positioned to expand studies to evaluate additional or emerging hypotheses, including those that support methodologic investigations in statistical science, a unique goal of this Core. The specific aims of the Analysis Core are to: 1) to provide data management and analytic support to funded and proposed projects, pilots, and OAIC investigations 2) to provide training and mentoring to OAIC Scholars and faculty 3) to develop and disseminate biostatistical analytic methodologies to advance the study of resilience and reserve.

Health and Mobility Measures Core (HMC)
Leader 1:    Katherine Hall, Ph.D.   katherine.hall@duke.edu
Leader 2:    Amy Pastva, PT, MA, PhD   amy.pastva@duke.edu
The Health and Mobility Measures Core (HMC) provides whole-person health and mobility measurement capabilities to advance our theme of understanding and optimizing physical reserve and resilience. The HMC serves as a central resource for Duke OAIC investigators and the broader Duke community seeking consultation, mentoring, training, and innovation for valid, sensitive, and reliable whole-person level health and mobility measures. A panel of 8 members, with complementary expertise in measurement across multiple domains, comprises the Core and provides highly integrated, customized support to investigators supported by our Research Education Component, Pilot/Exploratory Studies Core, Externally Funded Projects, and the larger Duke Community engaged by the Duke OAIC. The HMC supports investigators by meeting regularly throughout the full spectrum of project development, from early phase planning, to final interpretation of findings, to subsequent grant preparations, to dissemination and/or implementation. These meetings concurrently involve members of the Analysis and Molecular Measures Cores to assure maximal synergy. The specific aims of the Health and Mobility Measures Core are to: 1) to provide centralized intervention development and measurement expertise, including consultation and mentoring to advance our thematic investigations of physical reserve and resilience 2) to develop measurement protocols and train personnel in administration and data collection 3) to identify gaps in reserve and resiliency measures and develop and/or adapt innovative new measurement approaches for related outcomes

Molecular Measures Core (MMC)
Leader 1:    Virginia B. Kraus, MD, PhD   vbk@duke.edu
Leader 2:    James Bain, PhD   james.bain@duke.edu
Molecular profiling can uniquely discover biomarkers, and predict and monitor traits and processes to understand and optimize reserve and resilience. The goal of the Molecular Measures Core (MMC) is to promote an understanding of the means to optimize whole person reserve and resilience through analyses of molecular factors indicative of cellular and tissue level ability to withstand and recover from stressors. The MMC complements the whole person level analyses offered through the Health and Mobility Measures Core and is inter-dependent with the Analysis Core, which is responsible for statistical analysis and modeling of data generated by the Health and Mobility Measures Core and MMC. The MMC has extensive molecular profiling capabilities for body and cell-culture fluids and tissue extracts, including inflammatory, metabolic, biochemical, senescent, genomic/epigenomic, and extracellular vesicle markers. The MMC has capabilities to expand and adapt existing core capabilities to facilitate the many needs of the novel investigator-initiated research projects affiliated with our Duke OAIC. The current development project is a translational research project to test in vivo and in vitro resilience to stressors that uses a senescent model system to test interventions to promote resilience, The specific aims of the Molecular Measures Core are to: 1) to perform molecular analyses to support researchers and scholars, and harmonize markers across Duke OAIC research projects 2) to develop new molecular profiling and testing capabilities to evaluate resiliencies in the setting of stressors including SARS-CoV2 3) to conduct systems pathway analyses to identify biological pathways indicative of resilient phenotypes 4) to provide research-oriented mentorship, consultation and training on principles and methods of molecular analyses, in collaboration with PESC and REC

CAREER DEVELOPMENT
REC Scholar, Research & Grants Funded During Pepper Supported Time Years /
Publications
 
Sonali Advani, MBBS, MPH
Assistant Professor of Medicine / Department of Medicine
Deprescribing intervention to reduce inappropriate antibiotic exposure and improve resilience in older adults
Specific Aim 1: To develop and implement a deprescribing intervention to reduce inappropriate treatment of ASB in hospitalized older adults. Hypothesis 1: Our deprescribing intervention leveraging the UA with pharmacist support will reduce inappropriate antibiotic use in older adults with ASB. Specific Aim 2: To assess the feasibility, safety, and acceptability of this deprescribing intervention in older adults. Hypothesis 2: Our deprescribing intervention focusing on older adults with ASB will be safe, feasible, and acceptable. Reducing inappropriate treatment of ASB is a key priority for the American Geriatrics Society, CDC, and AHRQ. The CDC has identified "urinalysis" as a key opportunity to improve antibiotic use, and recommends developing criteria to differentiate between ASB and symptomatic urinary tract infection (UTI).
  • SHEA Research Scholar Award (Society for Healthcare Epidemiology of America)

2022-2024 /
5 (total)
4 (1st/Sr)
 
Leah Acker, MD, PhD
Medical Instructor / Department of Anesthesiology
Pilot testing of a non-invasive neuroimmune modulation tool— transcutaneous auricular vagus nerve stimulation (taVNS)—to enhance perioperative cognitive resilience in older adults
The objective of this pilot proposal is to identify and quantify barriers to a feasible, high-fidelity randomized controlled trial (RCT) of self-administered taVNS to prevent POD in older surgery patients. The rationale for this pilot study is that understanding feasibility challenges early will allow us to carefully design a future RCT with maximal clinical impact. Aim 1: Measure the fidelity and tolerability of preoperative self-administered taVNS in anxious surgery patients age = 65. Aim 2: Quantify the feasibility of recruiting and retaining anxious surgery patients age = 65 to self administer preoperative taVNS with high fidelity. Exploratory aim: Assess the dose-relationship between taVNS and anxiety, heart rate, and inflammation.
  • The Role of the Aging Brain-Heart-Immune Axis in Postoperative Delirium

2022-2024 /
3 (total)
0 (1st/Sr)
 
Kimberly Hreha, EdD, OTR/L
Assistant Professor / Department of Orthopaedic Surgery
Evaluating Physical Resilience and Best Practices in Vision Rehabilitation of Stroke Patients: A Mixed Methods Approach
Aim 1: Identify which strategies best support accessibility and tolerability of assessment and study enrollment protocols. Aim 2: Obtain feasibility data and explore facilitators and barriers of physical resilience measurement.
  • Influence of Vision Impairments on Dementia in Stroke Survivors: A Longitudinal Analysis

2022-2024 /
1 (total)
0 (1st/Sr)
 

Past Scholars
Corey Simon, Orthopaedic Surgery (2018-2020)
Nazema Siddiqui, MD, MHS, Obstetrics and Gynecology (2018-2020)
Anthony Sung, MD, Senior Fellow in the Duke Center for the Study of Aging and Human Development, Center for the Study of Aging and Human Development, Institutes and Centers (2018-2020)
Brian James Andonian, MD MHSc, Department of Medicine, Division of Rheumatology and Immunology (2020-2022)
Ming-Feng Hsueh, PhD, Department of Orthopaedic Surgery (2020-2022)
Daniel Parker, MD, Department of Medicine (2020-2022)

PILOT/EXPLORATORY PROJECTS (8 Pilot Projects Listed)
1. Project Title: ApoE: A new target to improve aged bone healing
  Leader: Gurpreet Baht, PhD
  Aim 1: Develop a therapeutic intervention to improve aged bone fracture healing. In our recent study, we showed that lowered circulating ApoE levels in knockout mice were associated with improved aged fracture repair. To test whether temporarily lowering circulating ApoE levels during fracture healing will improve fracture outcome, we will perform fracture studies with small molecule reverse agonists to a nuclear receptor that controls ApoE expression. Aim 2: Identify the immunophenotypic differences in the fracture calluses of aged mice treated with inhibitors of ApoE expression. We hypothesize that ApoE-based age-associated changes in fracture repair are due to changes in the immunophenotype of the fracture callus.
 
2. Project Title: Resilience after heart transplant or LVAD in patients with advanced heart failure
  Leader: Adam DeVore, MD MHS
  Aim 1: Determine the feasibility of a comprehensive assessment to predict resilience and to describe normative values in patients with advanced heart failure. We will enroll approximately 50 patients undergoing evaluation for heart transplant or LVAD at Duke. We will collect information on the completion rate of each assessment during the study protocol and collect qualitative data from the study teams on feasibility and study burden. Aim 2: Describe at what time point after surgery patients with advanced heart failure recover using assessments of physical, cognitive and psychosocial health.
 
3. Project Title: Mechanisms underlying variation in primate physiological reserve
  Leader: Elaine Gomez Guevara, PhD
  Aim 1: Measure oxidative stress and telomere dynamics across the lifespan in species of Lemur (fast maturation, shorter lifespan than Propithecus, while sympatric) and Propithecus (extreme longevity for body size in nature, very slow development, low rate of actuarial senescence, evidence for enhanced somatic maintenance). Lemur catta, the ring-tailed lemur, and Propithecus coquereli, Coquerel’s sifaka, will be monitored at the Duke Lemur Center. Aim 2: Validate inflammatory biomarkers as age-related markers in these models.
 
4. Project Title: Understanding the role of IL-15 signaling in podocyte resilience and survival
  Leader: Gentzon Hall, MD PhD
  Hypothesis: A functioning IL-15/IL-15R axis is essential for homeostatic prosurvival signaling in podocytes, and impaired IL-15 signaling reduces podocyte resiliency to proapototic stimuli, increasing risk of glomerulosclerosis .Aim 1: To characterize the effects of IL-15/IL-15R knockdown a) on podocyte resiliency and loss in response to proapoptotic stimuli and b) on signaling through three prosurvival transcriptional regulatory pathways. Aim 2: To characterize the effects of targeted IL-15/IL-15R KD on pronephric integrity and function in DBP-GFP zebrafish.
 
5. Project Title: Personalized Targeted Nutrition via StructurEd Nutrition Delivery Pathway to Improve Resilience in Older Adult Trauma Patients – SeND Home
  Leader: Krista Haines, DO, MABMH
  Our long-term goal is to improve resilience for critically ill older adults who suffer trauma. The overall objective of the current proposal is to fully develop the SeND Home program through a formal feasibility, acceptability, and fidelity trial using an iterative design. We will accomplish our goals through the following aims: Aim 1: Assess the feasibility, fidelity, and acceptability of SeND Home for older adult trauma patients. We will enroll 40 older patients and follow them post-discharge using SeND Home using a 3:1 randomization. We will determine feasibility by measuring the ability to recruit and enroll the target number of patients, maintain 90% enrollment over a three-month period, and adherence rates to the study protocol. We will test acceptability by interviewing patients and stakeholders. We determine fidelity by measuring the proportion of inventions delivered according to the study protocol. Aim 2: Establish a plausible range of nutrition related outcomes for patients participating in SeND Home. Aim 3: Identify key barriers to nutrition delivery for older adult trauma patients in the hospital and discharge setting.
 
6. Project Title: Individual and dyadic factors associated with older dialysis patients’ physical resilience
  Leader: Nicole DePasquale, PhD, MSPH
  Aim 1. Explore and describe individual (patient and care partner) and dyadic factors influential for patients’ physical resilience. Each member of the care dyad will separately complete semi-structured, qualitative interviews to allow for an in-depth exploration of experience, feelings, perceptions, attitudes, and behaviors regarding patients’ physical resilience, or ability to maintain, regain, or optimize physical function, following dialysis initiation and factors influencing it. Aim 2. Identify dyadic care types associated with different degrees of physical resilience. Each member of the care dyad will separately complete a survey containing measures that complement interview questions in Aim 1. Quantitative survey data obtained from Aim 2 will facilitate examination of similarities and differences in care dyads’ qualitative accounts. These patterns will enable identification of dyadic care types, or groups of care dyads distinguished by contributing factors to and demonstrated levels of physical resilience.
 
7. Project Title: Development of a Risk Assessment Tool to Enhance Physical Resilience in Older Adults following Orthopedic Surgery for Acute Injury: A Feasibility and Acceptability Pilot Study
  Leader: Laura Pietrosimone, PhD and Trevor Lentz, PhD
  Aim 1: Determine the feasibility and acceptability of remotely measuring multidimensional psychological distress, social needs, mobility, and physical function following surgery for lower extremity fracture in older adults. We will conduct a pilot observational cohort study of older adults (?65 years-old) undergoing surgery for ankle fracture (n=15) at Duke Health. Subaim 1a will establish the feasibility of recruitment and retention of older adults in a study that uses remote assessment methods post-surgery. Subaim 1b will assess the feasibility and responsiveness of remotely administered patient-reported measures not commonly used older adults including psychological measures (grit scale, OSPRO Yellow Flag Assessment Tool, SPARE psychological screening tools, STarT MSK tool) and social needs screening (HealthLeads screening tool). Subaim 1c will determine the feasibility and acceptability of remote mobility monitoring and functional assessments (e.g., TUG, gait speed) to establish functional recovery. Pilot data will inform the suitability of using these methods and measures in a future fully-powered cohort study.
 
8. Project Title: The role of pericytes in postoperative neurocognitive disorder during aging
  Leader: Ting Yang, MD, PhD
  The central hypothesis is that pericytes are a key cellular target in protecting the BBB integrity and ensuring neurologic sequalae from systemic inflammatory injury in the aging brain. The Objective is to identify the role and the molecular mechanisms for preserving pericytes function following a predictable stressor (i.e. surgery) thus enhancing brain resilience to long-term cognitive decline during aging. Aim 1: Determine the role of pericyte loss in transitioning from acute to long-lasting cognitive decline during aging. Aim 2: Identify the impacts of aging related pericytes transcriptomic changes on BBB function.
 
DEVELOPMENT PROJECTS (3 Development Projects Listed)
1. Project Title: Cellular senescence burden as a molecular indicator of resilience
  Leader: Virginia Kraus, MD PHD
  Core(s):
 

Stress elicits the Senescence Associated Secretory Phenotype (SASP) and the upregulation of lysosomal hydrolases. These cellular senescence responses have recently been discovered to be physiological tissue repair and remodeling responses. The complex systems of tissue repair and remodeling comprise the molecular foundation for resilience. We established the model system and markers in the classic @I38 human fibroblast cell line. These recent exciting insights define a beneficial role in tissue repair for SASP, the increased expression and secretion of a suite of inflammatory cytokines, growth factors, and proteases. When senescence reverts from an acute and transient state, such as in wound healing, to a chronic state with accumulation of senescent cells, the well-known phenomena of aging, including loss of reserve and resilience, are observed. In fact, the SASP is very similar to the inflammatory and coagulation markers associated with frailty and mortality in the elderly. Clearance of senescent cells in mouse models reduces expression of SASP factors in tissue and delays aging. The Specific Aims of this project are: Aim 1) To develop a panel of molecular markers indicative of senescent cell burden based on markers associated with SASP, soluble lysosomal exoglycosidases able to be detected in serum that might be a marker of a senescence process, and microRNAs we identified, through Duke OAIC pilot funding, as associated in elders with high function and longevity; and Aim 2) To evaluate the expression and interdependence of these factors in an in vitro model system followed by analyses of these factors in the CALERIE cohort and in future collaborations with other Duke OAIC projects. We hypothesize that methods that are senomorphic (change senescence) promote resilience.

 
2. Project Title: Testing the resilience of the latent class trajectory model when the conditions of the model are not met
  Leader: Carl Pieper, DrPH and Jane Pendergast, PhD
  Core(s): Analysis (AC)
  The objective of this project is to examine factors which impact the validity of discovering and defining latent classes of change under two types estimation models: commonly latent class trajectory model and Generalized mixed models. Both models are in wide use in assessing latent classes of trajectories, but make different underlying assumptions about the data structure. Initially, in the analysis of a panel data set, we observed that the 2 model types gave different results. We were surprised by the magnitude of the differences and research implications of these initial findings. In a deeper dive into the causes of the differences we observed, we learned that mis-specification of the error structure of the replicate observations led to incorrect definition of the number of classes contained in the data. The mis-classification occurred even in the presence of small correlations (0.1). These findings have implications for the validity of the findings derived under statistical packages used in the field. We demonstrated this both in simulations, where external factors could be controlled, and in real data. Using simulation, we plan to extend these investigations into other analytic issues commonly observed in longitudinal investigations change.
 
3. Project Title: Developing Resiliency Related Health Data Science Capacity
  Leader: Juliessa Pavon, Katherine Hall
  Core(s):
  The goal of this DP is to (Aim 1) develop and build resiliency related health data science capacity in our OAIC, and (Aim 2) grow geriatric and resilience-focused research capacity within the larger Duke community. (Aim 1): This work is directed at two vulnerable, high-risk patient populations in which we intend to identify physical and psychosocial stressors as a potential target for intervention, to identify a resilience phenotype, and to work with key stakeholder providers to translate findings to practice. The DP is housed in the HMC because of Dr. Pavon’s HMC role, but represents an inter-core (HMC and AC) collaboration with Duke’s Center for Actionable Health Data Science (Duke Forge). Methods. We will link Duke geospatial data with EHR clinical data to identify patterns of potentially modifiable clinical factors that may be most characteristic of patients recovering from hip fracture or congestive heart failure who exhibit resilience (days out of hospital, that approximates time spent in good health between hospitalizations) within/across geographic areas identified as disadvantaged. DP methods will be guided and developed by HMC Core faculty Pavon and Dupre, AC Core faculty, and Dr. Ricardo Henao (Forge’s Principal Data Scientist) in collaboration with Forge’s expert informaticists, biostatisticians, and electrical and computer engineers. Forge teams are renowned for signal processing, pattern recognition, machine learning, and predictive modeling of complex biological and clinical data. This project will employ machine learning techniques, e.g., relevance vector machines, to develop descriptive and probabilistic models. Methods (Aim 2): We will use the synergy of our OAIC to grow and develop resilience focused capacity within the OAIC and larger Duke community. AC faculty and Forge will provide the quantitative expertise and use machine learning and other advanced analytic techniques to develop descriptive and predictive models (Data to Knowledge) which will subsequently be shared with OAIC scholars and clinicians (Knowledge to Practice) for dissemination and development of promising data-driven interventions. The proposed DP will build an infrastructure and system-wide relationship that will serve investigators and clinical practice in the years to come and further one of Dr. Pavon’s career goals as a Geriatrics Health Informatics Scientist.
 
RESEARCH (22 Projects Listed)
1. Project Title: PHYSICAL RESILIENCE PREDICTION IN ADVANCED RENAL DISEASE
  Leader(s): BOWLING, CHRISTOPHER BARRETT
    DURHAM VA MEDICAL CENTER
    VA I01HX002704 / ( 2019 - 2023 )
  Core(s):
  ABSTRACTBackground: Older Veterans with advanced chronic kidney disease (CKD) face complex decisions to initiateor forgo dialysis in the context of uncertainty about their future health and physical function. Making thesedecisions is complicated by the course of advanced CKD which is characterized by frequent health events thatfurther worsen function. Decisions support tools are needed that are specific to the clinical course of advancedCKD and predict outcomes that matter most to these patients, such as physical function. Characterizing howpatients bounce back from health events, such as illnesses or injuries that result in emergency department(ED) visits or hospitalizations may be key to predicting future functional status. This approach draws from thenovel geriatric concept of physical resilience, defined as one s ability to resist or recover from functional declinefollowing a health stressor. Objectives: To help older Veterans make informed decisions about kidneydisease treatment by better characterizing physical resilience and identifying patient factors associated withphysical resilience to develop a prediction tool for physical resilience in advanced CKD. This addresses theHSR&D priority of Patient-Centered Care domain. To do this, we propose Physical REsilience Prediction inAdvanced REnal Disease (PREPARED), a prospective cohort study of older Veterans with advanced CKD withthe following Aims:1. To characterize physical function trajectories before and after an acute health stressor in order to define physical resilience among older Veterans with advanced CKD.2. To identify associations between patient characteristics and physical resilience trajectory and potential candidate variables for prediction model development.3. To develop a prediction tool for physical resilience (where this quantity has been defined in Aim 1).4. To determine the association of physical resilience with short-term mortality.Methods: We will conduct a longitudinal cohort study of 800 Veterans = 70 years old, with an estimatedglomerular filtration rate (eGFR) < 30 ml/min/1.73 m2 (excluding dialysis or transplant), and 90-day probabilityof hospitalization = 50% (based on the Care Assessment Needs [CAN] score). Telephone assessments willinclude brief validated measures of function every 8 weeks, and within 14 days following a stressor for up to 6calls. In Aim 1, we will characterize physical resilience, first by identifying latent classes of physical resiliencetrajectories using general growth mixture modeling. Next, among the subset from the physical resilience latenttrajectory class we will fit a piecewise linear mixed effects model to quantify resilience. In Aim 2, we willdetermine how the physical function trajectory is moderated by person-level health and psychosocial factorsand organ system-level physiologic factors. This information will be used to identify potential candidatevariables for our prediction model in Aim 3. The purpose of Aim 4 is to determine the prognostic importance ofphysical resilience by examining the relationship between experiencing a stressor and physical resilience with6-month mortality. Impact: The proposed study addresses the most pressing clinical dilemma in this complexcondition that disproportionately affects older Veterans. Data on physical resilience from the proposed studywill be used to develop a practical tool to address a vital question that CKD patients, their families, andproviders face when making treatment decisions. Limiting uncertainty about future health by predictingresilience will support individualized and patient-centered decision-making for kidney disease. Next steps: Wewill develop a clinical trial to test the use of our physical resilience prediction tool and work with our local andnational operations partners (Durham VA Renal Service, Office of Geriatrics and Extended Care, Renal FieldAdvisory Committee) to implement physical resilience assessment into care for these patients.
 
2. Project Title: EXPLORING THE EFFECTS OF EXERCISE TRAINING ON PTSD SYMPTOMS AND PHYSICAL HEALTH IN OLDER VETERANS WITH PTSD
  Leader(s): HALL, KATHERINE SHEPARD
    DURHAM VA MEDICAL CENTER
    VA I01RX003120 / ( 2020 - 2024 )
  Core(s):
  Posttraumatic stress disorder (PTSD) is prevalent among military Veterans, and affects over 30% of older, Vietnam-era Veterans. These servicemembers have endured nearly 40 years with these symptoms, and as a result, have significantly poorer health, higher rates of chronic disease and obesity, and an excess mortality rate 3 times higher than the general population. Clearly PTSD is more than just a psychological disorder. There is evidence to suggest that the pathway from PTSD to poor health is mediated by behavioral risk factors, such as exercise. Structured exercise is a highly effective, pluripotent strategy for the prevention, treatment, and management of chronic physical and psychological health conditions in older adults. To date, only a few pilot studies of exercise and PTSD have been published, and all suffer a major limitation: a singular focus on outcomes above the neck. These studies do not report the impact of exercise on physical health- and mobility-related outcomes that contribute to long-term impairment and disability in Veterans with PTSD. There have been no studies of exercise and PTSD done in older adults, representing a significant research gap. This research examines a wellness-based approach to promoting health in older Veterans with PTSD, targeting exercise, a major modifiable risk factor. The objective of this study is to compare the impact of a supervised exercise program on PTSD symptoms and related health outcomes versus a healthy aging attention control group (HA-ATC). This study will be a randomized controlled trial of a 6-month, supervised exercise program among 188 Veterans 60 years of age with PTSD at the Durham VAHCS. Participants will be randomly assigned to Supervised Exercise or HA-ATC. The exercise arm will include 3 weekly exercise sessions, each one lasting approximately 60 minutes, led by an exercise specialist. The HA-ATC will receive a health education program and materials modeled on the 10 KeysTM to Healthy Aging curriculum and the National Council on Agings Aging Mastery Program. The HA-ATC will include an 8-week face-to-face group program followed by 4 monthly sessions, the latter of which will be further supplemented with mailed informational packets, email newsletters, webinars, and group video telehealth sessions. Participants in the Exercise intervention arm will receive an individualized exercise prescription based on the individual s exercise history, current exercise capacity, personal preferences, and current health status. This will be a multicomponent program that includes a selection of 8 to 12 strengthening, balance, and flexibility exercises targeting the major muscle groups as well as primary joints. Participants will also be instructed in endurance exercise, including treadmill walking or recumbent bicycle. The exercise protocol will consist of a 5-10 minute warm-up, followed by a series of progressive aerobic and strengthening exercises, and will end with a 5 minute cool-down. The primary outcome for this study will be PTSD symptoms assessed with the CAPS-5. Physical function, another outcome of primary interest will be measured objectively with a Physical Performance Battery. This test battery assesses aspects of daily function including balance (single leg stance), gait speed (4 meter walk), and chair stands (# in 30 seconds). Aerobic endurance, the investigators primary functional outcome, will be assessed with the 6-minute walk test (6MWT). Secondary outcomes include depression, sleep, and cognitive function. Outcomes will be assessed at baseline, 3 months, and 6 months. Assessments will be repeated 12 weeks post-intervention (9 months) to examine whether any observed exercise intervention effects are maintained. Mixed linear models will be used to compare outcomes for the two study arms.
 
3. Project Title: Novel mechanisms of microRNA-mediated anabolic effects in age-related osteoarthritis
  Leader(s): HSUEH, MING-FENG
    DUKE UNIVERSITY
    NIH K01AG078445 / ( 2023 - 2028 )
  Core(s):
  Abstract Osteoarthritis (OA) is the most prevalent degenerative disease in older adults with the incidence rising rapidly after age 50 and leveling off after age 70. OA is also one of the common causes of chronic pain and the leading cause of physical disability in older adults. Currently, there is an unmet need for therapeutic strategies to improve the outcome for patients with OA. Our latest work identifies a list of microRNAs (miRNAs) in human cartilage and demonstrates a strong association with a robust anabolic effect. This effect is joint-specific and follows a distal-proximal axis gradient (high in ankle and low in hip). Studies show that a joint's identity is maintained by synovial cells and that there is a distinct miRNA profile in different joints. Together, this suggests that the miRNAs we identified in cartilage may originate from synovium and be involved in maintaining joint homeostasis. In Aim 1, I will determine the synovial cell types that express these regenerative miRNAs within human joints and the effects of age on the expression of these miRNAs. In Aim 2, I will determine the signaling pathways responsible for the miRNA-mediated anabolic effects in cartilage and the effects of age on these pathways. I will conduct gene set enrichment analysis to determine miRNA-mediated pathways and then use proteomics to validate these pathways. Through this project, I will determine the miRNA-mediated mechanisms by which synovial cells promote endogenous anabolic effects in the human joint. The key career enhancement of this award will be the training in computational bioinformatics to analyze the complex datasets generated by the project, and further training in aging biology to understand how aging impacts the regeneration process. To facilitate progress toward independence, the training plan will include the coursework/workshops in computational bioinformatics and aging biology, extensive internal and external scientific meetings, and career professional development activities and mentorship. The research and career development plan detailed in this proposal will be conducted with a team of outstanding mentors. Dr. Yi-Ju Li, a professor of Biostatistics & Bioinformatics and an expert in statistics and bioinformatics, will serve as the primary mentor and focus on the training in bioinformatics, statistics, and professional skill development. Drs. Cathleen Col n -Emeric, Virginia Kraus (Duke), and Patrik nnerfjord (Lund University, Sweden) will serve as co-mentors; they will facilitate training in translational aging research, OA research, and proteomics, respectively. The environment at the Duke University and Duke Molecular Physiology Institute, where the main research activities are located, are ideal for the research and training activities outlined in this proposal. This award will enable me to elucidate the novel contributions of miRNAs to joint tissue homeostasis. Advancements in this area of research have the potential to develop as new therapeutic strategies aimed at improving the quality of life for patients with OA.
 
4. Project Title: Influence of Vision Impairments on Dementia in Stroke Survivors: A Longitudinal Analysis
  Leader(s): HREHA, KIMBERLY PATRICE
    DUKE UNIVERSITY
    NIH K01HD106010 / ( 2023 - 2026 )
  Core(s):
  PROJECT SUMMARY/ ABSTRACT This is an application for a K01 Mentored Research Scientific Development Award. The goal of the proposed project is to provide the candidate with the advanced skills needed to establish an independent research program examining the visual health needs of stroke survivors also living with dementia. To facilitate this long-term goal, the candidate proposes a comprehensive training plan, combining formal coursework and meetings overseen by her mentors, participation in applied training experiences and involvement in seminars and workshops. Specific training goals include: (1) gain advanced knowledge in the epidemiology and mechanisms of post-stroke dementia, (2) learn neuropsychological and clinical assessment of dementia, (3) acquire skills and training in clinical research methodology and statistical analysis, using both cross sectional and longitudinal data and (4) productively participate in career advancement and leadership development activities. The training plan will be executed in coordination with the set of research activities mentioned above, which are based on preliminary data collected by the applicant. The preliminary data show a lack of research on whether the presence of specific types of vision impairment and ocular deficits increase the risk of post-stroke dementia. The candidate will expand on these findings by using data from the Atherosclerosis Risk in Communities stroke cohort to complete the following aims: (1) characterize the prevalence and outcomes associated with vision impairment(s) among stroke survivors with and without dementia; (2) determine how pre-existing vision impairments impact the development of dementia, among those with stroke; and (3) determine the effect and downstream consequences of post-stroke vision impairment in persons without pre-existing vision impairment. The primary hypotheses include that: (1) the odds of developing dementia are higher for stroke survivors with pre-existing vision impairment, compared to stroke survivors with normal vision; (2) stroke survivors with vision impairment preceding the stroke are more likely to develop dementia earlier, compared to stroke survivors with normal vision; and (3) the impact of post-stroke vision impairment on dementia development is stronger for those with functional impairment, compared to those without functional impairment. The expected findings will provide critical insight into the types of vision impairment and ocular deficits experienced by people with post-stroke dementia, including more information on the significance of distinguishing between pre- and post-stroke visual impairments and the expected differential impact on dementia. Results from this research will be used to develop a subsequent R01 research proposal that will facilitate the candidate s transition into an independent researcher focused on analysis of existent data and prospective enrollment to optimize the independence and community participation of stroke survivors with vision impairments and dementia.
 
5. Project Title: DEPRESCRIBING CENTRAL NERVOUS SYSTEM MEDICATIONS IN HOSPITALIZED OLDER ADULTS
  Leader(s): PAVON, JULIESSA M
    DUKE UNIVERSITY
    NIH K23AG058788 / ( 2019 - 2024 )
  Core(s):
  This K23 Career Development Award in Aging focuses on the development of Dr. Juliessa Pavon, a hospital-based geriatrician, and on reducing central nervous system (CNS) medication use in hospitalized older adults.Dr. Pavon s long-term goal is to improve the resilience of older adults against the acute stressors ofhospitalization. She has built her research program on investigating hazards of hospitalization, and a majorthreat is high-risk medication exposure. Sub-optimal CNS medication use during hospitalization is a keymodifiable risk factor for poor health outcomes; common classes include opioids, anxiolytics, anti-depressants,antipsychotics, and hypnotics. Our preliminary data suggests that nearly 40% of hospitalized older adults areexposed to anxiolytics and 60% to opioids during their hospital stay. De-prescribing is a systematic process oftapering or reducing medications. Interventions to facilitate de-prescribing that target specific medicationclasses, like CNS medications, or specific populations, like those with existing cognitive impairment, have notbeen well-studied in the inpatient setting. This gap represents a key opportunity to reduce potentiallyinappropriate CNS medications and their debilitating side effects in vulnerable patients--in line with the NationalInstitute of Aging s priorities to improve medication use in older adults. Dr. Pavon s K23 award proposes todevelop and pilot test a de-prescribing intervention that is informed by a theoretical model of behavioralchange. Aim 1 results will inform the epidemiology of the problem and identify target populations forrecruitment. Aim 2 will use qualitative methods to examine barriers and facilitators of hospital de-prescribing.Results will inform the intervention delivery strategies best suited to facilitate CNS medication de-prescribing ina well-tolerated, feasible manner. Aim 3 will develop and pilot test a multi-component hospital-based de-prescribing intervention that uses health informatics for content delivery, and provider behavior change andpatient activation strategies. This work will advance understanding of 1) which patients and CNS medicationclasses to target for de-prescribing interventions, 2) whether there are unique barriers to de-prescribing in thehospital setting, and 3) the optimal delivery strategy for safely de-prescribing. During this K23 grant period, Dr.Pavon will also complete additional training in Markov modeling statistical techniques, interventiondevelopment, health informatics, and leadership. Dr. Pavon s mentor team will provide scientific support withexpertise in aging, pharmacology, hospital medicine, and research methodology. This career developmentplan will give Dr. Pavon the skills in conducting intervention development studies within the hospital setting.This training and resulting data will establish Dr. Pavon as a strong candidate for an R01 intervention designedto facilitate de-prescribing of CNS medications for the nearly 1 in 2 older adults that will experience exposure toa CNS medication during hospitalization.
 
6. Project Title: METABOLOMIC & RADIOGRAPHIC MARKERS OF FRACTURE RISK AMONG OLDER ADULTS WITH DIABETES
  Leader(s): LEE, RICHARD H.
    DUKE UNIVERSITY
    NIH K23AG058797 / ( 2018 - 2023 )
  Core(s):
  ABSTRACTAmong its medical complications, type 2 diabetes mellitus in older adults is associated with atwo-fold increase in the risk of hip and other low-trauma bone fractures. Paradoxically, thisincreased risk occurs despite a higher average bone mineral density. This increased fracturerisk is likely multifactorial, stemming from metabolic dysfunction that results in both increasedfalls risk and decreased bone strength. However, fracture risk stratification currently is limitedlargely to bone density testing and clinical risk tools that do not perform adequately for adultswith diabetes. Because bone is both a metabolic and structural tissue, metabolomics andbiomechanical analyses would be particularly useful for developing and assessing newmeasures of fracture risk. The objective of this application is to develop and evaluateradiographic and laboratory biomarkers of fracture risk among older adults with diabetes,utilizing biomechanical and translational measures. The proposed research has the followingaims: 1) Determine the association between metabolomic profiles and incident clinical fractureamong older adults with diabetes; 2) Compare geometric and biomechanical measures at thefemoral neck and intertrochanteric region among older adults with diabetes, with and without hipfracture. This application builds upon the prior published work and clinical expertise of thePrinciple Investigator, Dr. Richard Lee, and provides him additional research skills to assist withhis career development goal of understanding the interaction of chronic medical conditions onthe bone health of older adults, focusing on diabetes. Dr. Lee is a dual-trained Geriatrician andEndocrinologist with expertise in metabolic bone disease. The primary training goals of thisproposal include the following: 1) Develop laboratory and analytical skills in translational sciencethat will be used in the development and evaluation of clinical biomarkers, including omicstechnologies; 2) Acquire principles and skills in biomechanical engineering and materialsscience to integrate with clinical and epidemiological analyses. By integrating biomechanicalengineering and metabolomics approaches with epidemiologic research to identify new markersof fracture risk, this application addresses a significant source of morbidity and mortality amongan increasing proportion of older adults.
 
7. Project Title: Longitudinal Characterization of the Older Adult Trauma Patient Experience
  Leader(s): HAINES, KRISTA
    DUKE UNIVERSITY
    NIH K23AG065464 / ( 2020 - 2025 )
  Core(s):
  PROJECT SUMMARY This proposal presents a five-year research career development program focused on describing the comprehensive long-term experience of trauma from the perspective of older adults and their family caregivers. The candidate is currently an Assistant Professor of Surgery at Duke University and acute and critical care trauma surgeon, with previous research experience in trauma-related outcomes and healthcare disparities, and has now chosen to focus on aging research, qualitative analysis, and health-related quality of life (HRQoL) research with a diverse mentoring committee of investigators with expertise in geriatrics, gerontology, surgery, critical care, and qualitative research. The proposed experiments and didactic training will provide the candidate with a unique set of skills that will help her transition to independence as a surgeon-scientist and enable her to fill a significant experience gap in the field of research dedicated to the older adult trauma patient population. Traumatic injury currently effects 5.4 million older adults each year in the United States representing 23% of all trauma admissions, and these numbers are projected to climb as the population ages. The consequences resulting from trauma to older adults are magnified when compared to younger age groups. Older adults have an increased likelihood of death as a result of trauma, with one-third of patients with presenting with multisystem trauma dying prior to leaving the hospital. Indeed, trauma is the 5th leading cause of death in older adult patients. Recent research suggests that the impact of trauma on older patients, their family members, and health care systems is dramatic. Despite these findings, very few high-quality studies have been conducted to describe the long-term experience of trauma from the perspective of these patients and their respective caregivers. Indeed, very little is known from the patient perspective regarding post-discharge trajectories through care facilities, the impact of functional limitations, and what factors are associated with poor outcomes. Compounding this problem is that it remains unknown which existing quality of life measurement instruments may be optimal for older adult trauma patients. These gaps in knowledge regarding this patient population serve to make the process of informed, shared decision making about goals of care challenging for older patients, their family caregivers, and clinicians. This proposal will characterize the one-year patient healthcare experience of older adult trauma patients and their family caregivers using a concurrent nested mixed-methods study design, using both qualitative and quantitative methods consisting of a survey and concept elicitation interviews. Specifically, the work of this proposal will 1) identify aspects of quality of life (QoL) among older adult trauma patients and how these change over time, 2) characterize the caregivers experience over one year, and 3) identify a core set of both patient- and caregiver-reported HRQOL measures that address key domains identified through the interviews, and determine which measures are most effective at different time points post-trauma.
 
8. Project Title: DEPRESCRIBING FOR OLDER DIALYSIS PATIENTS
  Leader(s): HALL, RASHEEDA K
    DUKE UNIVERSITY
    NIH K76AG059930 / ( 2018 - 2023 )
  Core(s):
  ABSTRACTThis is a Beeson Emerging Leaders in Aging career development award (K76) for Dr. Rasheeda Hall, MD,MBA, MHS. Dr. Hall is a nephrologist who conducts aging research at Duke University, and her long-term goalis to become a leader in geriatric nephrology and develop effective interventions targeting geriatric conditionsin older dialysis patients. Compared to older adults without kidney disease, older dialysis patients are morelikely develop severe cognitive impairment, experience more falls, and have more frequent hospitalizations.These adverse outcomes are also known to be associated with potentially inappropriate medications, and olderdialysis patients are highly susceptible to adverse effects of potentially inappropriate medications because ofaltered medication clearance due to absent kidney function and common occurrences of hypotension and mini-strokes. Given this susceptibility, reduction of potentially inappropriate medications is a logical goal forimproving quality of care for these vulnerable patients. The objective of Dr. Hall s proposed research is todevelop an evidence-based strategy to reduce inappropriate prescribing in older dialysis patients. Theresearch aims are to: 1) identify the prevalence of specific potentially inappropriate medications and the extentto which there is an association with hospitalization risk in prevalent older dialysis patients, 2) identify elementsof a deprescribing intervention that are acceptable to nephrologists, primary care providers, and patients, and3) determine the feasibility of a deprescribing intervention tailored for older dialysis patients. This work willprovide evidence to support a definitive clinical trial of deprescribing in dialysis units. Effective deprescribinginterventions have the potential to reduce hospitalizations and ameliorate geriatric syndromes in dialysispatients which is consistent with NIA s mission. Complementary to this research, this career developmentaward will solidify Dr. Hall s transition to research independence through coursework and mentoring to: a) fillknowledge gaps in directing a team of statisticians, interpretation of pharmacoepidemiologic data, advancedmethods in handling bias in observational data, timely qualitative analyses, execution of a pilot study, andclinical trial design; b) enhance her leadership skills; and c) successfully compete for a R01. Duke University isthe ideal environment for Dr. Hall to pursue this research career development because of the strong agingresearch expertise housed in its Center for Aging and affiliated Pepper Center, as well as, rich resourcesavailable through Duke s Clinical and Translational Institute.
 
9. Project Title: Stress Reactivity and Low Back Pain in Older Adults: Influences on Disability (ReLOAD)
  Leader(s): SIMON, COREY
    DUKE UNIVERSITY
    NIH K76AG074943 / ( 2022 - 2027 )
  Core(s):
  PROJECT SUMMARY/ABSTRACT This application for the Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76) is for Dr. Corey Simon, a physical therapist and geriatric pain researcher specializing in low back pain. Low back pain is one of the world s most disabling conditions for older adults, with more than 75% reporting persistent disability 1-2 years after onset. A novel disability mechanism among older adults with low back pain is high stress reactivity, which is an acute physiologic response characterized by abnormal changes in blood biomarkers after stressful encounters. High stress reactivity is linked to poorer health outcomes including disability in other chronic conditions; and accumulating research suggests high stress reactivity is mediated by abnormal thoughts and feelings and is modifiable through biobehavioral interventions. However, stress reactivity research in older adults with low back pain is lacking. This proposal in an innovative 5-year research program that builds upon Dr. Simon s pilot study demonstrating exciting preliminary associations between stress reactivity, physical function, and psychological distress. This proposal will utilize novel laboratory stress reactivity tests, patient-reported outcomes, and qualitative interviews to: 1) Identify and quantify stress reactivity in older adults with low back pain; and 2) For the purpose of reducing disability risks, develop a biobehavioral intervention that targets high stress reactivity in older adults with low back pain. This program will test his central hypothesis that older adults with low back pain and high stress reactivity are at greater risk for disability due to negative thoughts and feelings and poor coping strategies. In addition, this program will provide Dr. Simon with advanced career development in stress reactivity science, behavioral intervention development, and research leadership. Upon completion of this program, Dr. Simon will be poised to facilitate the development of an NIA-funded clinical trial (R34/R01) to test the efficacy of his innovative biobehavioral rehabilitation intervention for older adults with low back pain that targets high stress reactivity. Collectively, this program is the next step in Dr. Simon s long-term goal to become an international leader in the development of targeted interventions to eradicate disability in older adults with low back pain.
 
10. Project Title: Duke Roybal Center
  Leader(s): COLON-EMERIC, CATHLEEN S; STRAUMAN, TIMOTHY J;
    DUKE UNIVERSITY
    NIH P30AG064201 / ( 2019 - 2024 )
  Core(s):
  DUKE ROYBAL SUMMARY: Mobility is fundamental to active aging. Intimately linked to health status and quality of life, the self-initiated day to day movements of older adults are shaped by their behavior and their environment. The number of older Americans is rapidly increasing and there is a critical need to build and accelerate research capacity to test and scale behavioral interventions, programs and practices that promote healthy aging in general and mobility in particular. To address this need, we propose to establish an NIA Edward R. Roybal Center at Duke University with the theme of Accelerating Translational Behavioral Intervention Research on Aging and Mobility. Our goal is to catalyze researchers across disciplines to develop and test innovative behavioral interventions to optimize mobility for older adults. These interventions will aim to foster independence and community participation, reduce unplanned health service use, and enhance quality of life. Our center aims are to (1) develop the next generation of scientists committed to programs of translational research using interventions grounded in behavioral or social science principles to improve mobility and promote independent living of older adults; (2) use an experiential learning-based approach to behavioral intervention development and implementation; and, (3) accelerate translation so interventions can be successfully developed, validated, and scaled across NIH Stage Model levels. Our three overarching aims will be met by the Center s two cores, designed to enhance the research infrastructure for behavioral intervention development, stimulate new research collaborations, and promote translational behavioral research in aging and mobility. The Management and Administrative Core will coordinate the Center s activities; promote interactions and networking among pilot awardees, Center scientists who represent all levels of the NIH Stage Model, and collaborating partners; integrate with our long-standing NIA-funded Pepper and Demography and Economics of Aging Centers; and use experiential learning activities (e.g. intensive lab- based intervention development and grant writing workshops) to engage investigators in learning the practical research skills necessary for conducting intervention research from problem conception to implementation. Our Pilot Core will use a novel accelerator model that provides awardees with support and practical experience in working with a dedicated research team to conduct pilot research that is feasible, rigorous, and informs theory- based intervention development. We will leverage a skilled implementation team to foster the development and testing of behavioral interventions to benefit older adults with efficient project management for progression to more advanced levels in the NIH Stage Model. This approach was proven effective in our CTSA and builds from the Pepper Center s success on innovation in aging and mobility. The Duke Roybal Center will become a central resource for behavioral intervention development and implementation, accelerating the translation of research into practice, products, and policies that positively impact the daily activities of older adults.
 
11. Project Title: EPIGENETIC MECHANISMS PROMOTING LONGEVITY
  Leader(s): KRAUS, VIRGINIA
    DUKE UNIVERSITY
    NIH R01AG054840 / ( 2018 - 2023 )
  Core(s):
  AbstractCirculating small regulatory RNAs (sRNAs) are short non-coding RNAs (typically ~19-25nt in size). They mediatea broad spectrum of biological processes through regulation of gene expression. Our experimental evidenceindicates that serum levels of miRNAs (one form of sRNA) change considerably, the vast majority increasingwith age. The ability of circulating sRNAs to travel among tissues enables them to transmit signals and regulatea broad spectrum of biological functions. sRNAs exist in a variety of RNase-insensitive ribonucleoprotein or lipidcomplexes, or are encapsulated inside different types of extracellular vesicles. Consequently, in contrast tomessenger RNA, sRNAs are protected from extracellular RNases and are measurable and stable in samplesstored for decades. Despite numerous recent developments, we are far from understanding the role of sRNAsin aging. An understanding of their role in aging mammals, and in humans in particular, is still very limited dueto the increased complexity and longer life-spans of mammals compared with invertebrates. This projectleverages existing human sample resources from three completed NIH-funded studies (EPESE, STRRIDE andCALERIE), to discover and validate longevity-associated miRNAs in humans. Our preliminary analysis of 175circulating microRNA--in the NIA-funded Duke Established Populations for Epidemiologic Studies of the Elderly(Duke EPESE) community-based cohort of elders--identified 32 differentially expressed circulating miRNAs(p<0.05) associated with longevity; in all cases, their concentrations at baseline were higher in long-termsurvivors (>10 years) compared with age, sex and race matched but short-term survivors (<2 years); a subsetof these miRNAs predicted longevity independent of age, gender, race and functional status. The Duke EPESEcohort was aged 71 and older at the time of blood sampling and now has 25 years of longitudinal mortality data(through 2016) with which to address key questions about sRNAs and longevity in humans. sRNA discoveriesin Duke EPESE will be validated in plasma and muscle samples from completed human clinical trials of relevanceto longevity that investigated the health-promoting effects of exercise (STRRIDE cohort) and caloric restriction(CALERIE cohort). A human three-dimensional muscle tissue organ system will be used to understand theirmechanisms of action (with and without simulated exercise and caloric restriction), by testing sRNA mimics andinhibitors. Our preliminary analyses of 7 of our top longevity-related miRNA in this model system demonstratedproduction and secretion of all of them by muscle and statistically significantly increased secretion of two of themwith simulated muscle exercise. Together our approach will permit us to determine if sRNAs associated withlongevity are favorably modulated in tissue and blood in humans by exercise and/or caloric restriction, and ifthey appear to mediate any of the observed health benefits of these interventions. The totality of the data(generated in vivo and in vitro), will be systematically examined to identify pathways of sRNA action in humansand profiles of sRNA that could serve as biomarkers to predict longevity status.
 
12. Project Title: GENOMIC ANALYSIS OF THE CALERIE TRIAL TO GENERATE NEW KNOWLEDGE FOR GEROSCIENCE
  Leader(s): BELSKY, DANIEL WALKER
    COLUMBIA UNIVERSITY HEALTH SCIENCES
    NIH R01AG061378 / ( 2019 - 2024 )
  Core(s):
  SUMMARYThe graying global population makes interventions to extend healthy lifespan (healthspan) a public heathpriority. Therapies targeting basic biological processes of aging show proof-of-concept in animals: early-to-midlife intervention can delay disease onset and prolong healthspan. But translating these geroprotectivetherapies to humans faces the barrier that human clinical trials of midlife geroprotective therapy wouldrequire decades of follow-up to measure healthspan extension. An alternative is a short-term acceleratedgeroprotector trial that tests if geroprotective intervention can slow the rate of biological aging. Biologicalaging is the gradual and progressive decline in system integrity that occurs with advancing chronologicalage. This process is thought to be the root cause of increases in morbidity and disability in later life. Newresearch shows that biological aging can be measured in humans and that measures of biological agingpredict human healthspan. Geroprotective therapies that target basic biological processes of aging arehypothesized to slow the rate of biological aging. But this has not been tested. Our study will test if the best-established geroprotective intervention in animals, long-term caloric restriction, slows the rate of biologicalaging in midlife humans, who are still young enough for age-related disease to be delayed or prevented.We will conduct new assays of stored biospecimens from the National Institute on Aging's recently-completed CALERIE Trial, which randomized 220 non-obese adults to 25% caloric restriction (CR, N=145)or ad libitum normal diet (AL, N=75) for a period of 2 years. We have already shown that CR slows aging-related deterioration in organ-system integrity. Now, we propose to extend this test to genomic measures ofbiological aging. We will assay whole-genome DNA methylation (using Illumina chips) and gene expression(using RNA sequencing) from blood samples collected at CALERIE baseline, and at 12-, and 24-monthfollow-ups. We will use this 3-time-point repeated-measures multi-omics dataset to test (i) Does CR slowsthe rate of biological aging as measured from DNA methylation (ii) Does CR cause changes to geneexpression in the pathways known to mediate healthspan-extending effects of CR in animals, e.g. themTOR pathway (iii) Do changes to DNA methylation and gene expression mediate effects of CR on organsystem functioning We will share the multi-omics data we generate with the CALERIE Biorepository,making the resource freely available to all interested researchers. The proposed project will generate newknowledge about effects of caloric restriction on biological aging in humans and test proof of concept for anaccelerated geroprotector trial design that can speed translation of new age-delaying therapies fromanimals to humans. Open data sharing through the CALERIE Biorepository will enable research beyond thescope of this project to improve understanding of caloric restriction and advance the field of geroscience.
 
13. Project Title: FUNCTIONAL LIMITATIONS AND DISABILITY AMONG MIDDLE-AGED ADULTS
  Leader(s): BOWLING, CHRISTOPHER BARRETT
    DUKE UNIVERSITY
    NIH R01AG062502 / ( 2020 - 2023 )
  Core(s):
  Project summary/Abstract The burden of functional limitations (restrictions in basic physical actions) and disability (problems with daily activities and life participation) may be more common in middle-aged US adults than previously recognized. However, studies of middle-age populations have not typically included functional assessments. The Coronary Artery Risk Development in Young Adults (CARDIA) study provides a unique opportunity to study functional status in a diverse, aging cohort. The Year 35 in-person exam is scheduled for 2020 and 2021, at which time, participants will be 53 to 65 years old. We propose a CARDIA ancillary study to obtain measures of function by self-report and physical performance to be paired with the existing data collected from early adulthood through middle age to address the following aims: 1. To quantify the burden of functional limitations and disability in middle age and assess the degree to which this can be attributed to the accumulation of chronic conditions, 2. To assess domains of functional limitations and disability captured by physical performance versus self-report, 3. To identify health-related risk factors in early adulthood for functional limitations and disability in middle-age, 4. To identify health-related, socioeconomic, and psychosocial factors that contribute to between- and within- race differences in functional limitations and disability among middle-aged adults. We will add measures of physical performance (fast and usual gait speed, single leg balance, timed chair stands, 6-minute walk test, and grip strength) to the CARDIA Year 35 exam (projected N=3,270; 1,563 black, 1,707 white). Also, self- reported functional limitations (Patient-Reported Outcomes Measurement Information System [PROMIS] Physical Function Short Form 20a) and disability measures (basic and instrumental activities of daily living) will be added to the Year 35 exam and annual telephone calls (1 call prior to and 2 after the Year 35 exam). As studies of younger populations have not often included functional assessments, the conceptualization, measurement approaches, risk factors, and implications of functional limitations and disability are poorly understood. Filling this knowledge gap by adding appropriate functional measures to an ongoing population based cohort, that represents the next wave of aging black and white adults will lead to new approaches to prevent functional decline and improve population health.
 
14. Project Title: Physical Rehabilitation for Older Patients with Acute HFpEF-The REHAB-HFpEF Trial
  Leader(s): KITZMAN, DALANE W
    WAKE FOREST UNIVERSITY HEALTH SCIENCES
    NIH R01AG078153 / ( 2022 - 2027 )
  Core(s):
  Acute decompensated heart failure (ADHF) is the leading cause of hospitalization in older persons, and is associated with marked physical disability, poor health-related quality of life (HRQOL), frequent rehospitalizations, loss of independence, high mortality, and enormous health care costs. However, most of the trials testing a wide range of medications and strategies in ADHF have been neutral. In our recently completed NIA-funded phase 2 trial (REHAB-HF), an innovative, early, transitional, tailored, and progressive multi-domain physical rehabilitation intervention produced a large improvement in the primary outcome of Short Physical Performance Battery (+1.5 points) in older patients with ADHF. At baseline, the participants (53%) with HF with preserved ejection fraction (HFpEF), had significantly worse impairments in physical function, frailty, HRQOL, and depression than those with HF with reduced EF. They also appeared to derive greater benefit from the intervention, with ~50% larger effect sizes in physical function, frailty, HRQOL, and depression. Patients with HFpEF also appeared to have much greater reductions in rehospitalizations and death and potential for reduced medical resource use. The finding of potentially greater benefit in HFpEF is noteworthy as HFpEF is highly relevant to older persons and has the most urgent need for new treatments since it is: 1) the most common form of HF, nearly unique to older persons, and disproportionately affects older women and Black persons; 2) increasing in prevalence; 3) accepted as a geriatric syndrome; 4) associated with marked impairments in physical function and HRQOL and high rates of frailty; 5) has high morbidity and mortality which are worsening over time; and 6) has limited evidence-based treatments. The phase 3 REHAB- HFpEF trial will focus on this large, growing, vulnerable, underserved population. The 5-year, randomized, attention-controlled, single-blinded trial will enroll 880 older adults age >60 years with ADHF and HFpEF across 20 geographically dispersed clinical centers. We will test the hypothesis that the innovative REHAB-HF intervention will improve the clinically compelling combined primary endpoint of all-cause rehospitalizations and mortality during 6-month follow-up, the most vulnerable time period following ADHF hospitalization (Aim 1) and the secondary endpoint of prevalence of major mobility disability, a clinically meaningful outcome in trials of older adults, at 6-months (Aim 2). We will also assess the intervention s impact on HRQOL, frailty, depression, physical activity, and health care costs. Our diverse, cohesive, multi-disciplinary team and experience from the phase 2 trial will ensure efficient and effective execution and dissemination. REHAB-HFpEF directly addresses the key recommendations of several recent NIA and NHLBI sponsored workshops. Its results could improve key outcomes that are meaningful to patients, caregivers, health systems, and payers. The trial has strong potential to change clinical guidelines, reduce health care costs, and influence national coverage decisions for the large, growing, underserved, high-risk population of older patients with acute HFpEF.
 
15. Project Title: MECHANOTRANSDUCTION IN MENISCUS HEALTH AND REPAIR
  Leader(s): MCNULTY, AMY L
    DUKE UNIVERSITY
    NIH R01AR073221 / ( 2019 - 2023 )
  Core(s):
  ABSTRACT.Meniscal injuries are a significant clinical problem as each year 850,000 meniscal surgeries are performed in theUnited States and nearly twice as many worldwide. Meniscal tears in the avascular inner zone of the tissue donot heal well with suturing or conservative treatments and can ultimately lead to the development of osteoarthritis(OA). Therefore, new strategies are needed to enhance endogenous meniscus repair and tissue regeneration.The menisci play a critical biomechanical role in the knee, providing load support, joint stability, and congruity.Meniscus tissue is maintained through a balance of anabolic and catabolic activities of meniscus cells. Thesecellular activities are controlled not only by biochemical factors in the joint but also by physical factors associatedwith joint loading. Mechanobiology, which is the influence of mechanical factors on the biologic response of cells,is important in converting physical signals into metabolic and inflammatory responses in meniscus. However,the mechanisms by which mechanical signals are transduced in meniscus cells have yet to be identified. Ouroverall goal is to identify critical meniscus mechanotransduction pathways and modulate thesepathways to promote meniscus repair and prevent OA development.Our work has shown that transient receptor potential vanilloid 4 (TRPV4) is a critical component in cartilagemechanotransduction and metabolism. The activation of TRPV4 can block IL-1 induced catabolic responses andalso increases cell migration and proliferation, which are important processes to enhance tissue repair. Whilewe have found that TRPV4 is expressed in the meniscus, the function of this mediator in meniscus health anddisease is currently unknown. In this proposal, we will determine how mechanotransduction occurs throughTRPV4 in meniscus and identify modulators of this pathway that will be used to enhance tissue repair and preventOA development. We hypothesize that mechanotransduction by TRPV4 plays a key role in meniscus metabolismand can be modulated to enhance meniscus repair and prevent the development of OA. In this proposal, we willdetermine the effects of mechanical stimulation on TRPV4-mediated metabolism in healthy meniscus cells.Next, we will elucidate alterations in TRPV4-mediated mechanotransduction pathways in meniscus pathology.Finally, we will enhance integrative meniscus repair and prevent the development of OA by modulation ofmechanotransduction pathways. In this proposal, we will identify the key signaling pathways downstream ofTRPV4 that may function as novel drug targets to 1) treat patients with immobilized joints to simulate exerciseand maintain joint health; 2) enhance meniscus tissue regeneration using tissue engineering strategies; and 3)enhance meniscus repair and prevent the development of OA. Novel therapeutic targets identified in thisproposal can subsequently be developed into drugs to enhance meniscus repair and prevent the developmentof OA.
 
16. Project Title: The role of kidney epithelial cells specific EP4 receptors in blood pressure control
  Leader(s): YANG, TING
    DUKE UNIVERSITY
    NIH R01DK132619 / ( 2022 - 2027 )
  Core(s):
  Hypertension is a common chronic disease with a significant impact on public health, yet its basic pathogenesis is not fully understood, and new therapeutic targets are needed. A beneficial role for prostanoids in hypertension was suggested because non-steroidal anti-inflammatory drugs (NSAIDs), which block the production of all prostanoids, can cause sodium retention and exacerbate hypertension. Among prostanoids, PGE2 and its EP4 receptor (EP4R) have been implicated in blood pressure control, but these mechanisms are unknown. Our previous work showed that conditional deletion of EP4R from all tissues in adult mice dramatically exacerbated Ang II-dependent hypertension. However, the elimination of EP4R from vascular smooth muscle cells, endothelial cells, and macrophages had no impact on hypertension development. By contrast, specific removal of EP4R from whole renal epithelia recapitulated the phenotype of exacerbated hypertension, indicating that EP4R attenuates hypertension by direct actions in the renal epithelium. Recent single-cell sequencing studies demonstrated that EP4R expression in renal epithelia is enriched in the collecting duct (CD). CDs have pivotal roles in final urinary sodium excretion through the actions of the epithelial sodium channel (ENaC). Our preliminary studies showed that mice with EP4R deletion in renal epithelia throughout the nephron had increased responsiveness to ENaC inhibitor, and PGE2 inhibits the ENaC activity in isolated CDs. Thus, we hypothesize that EP4R resists the development of hypertension through actions in the CD to reduce sodium reabsorption via ENaC. The project s objective is to identify mechanisms underlying the anti-hypertension effects of EP4R and to exploit them for new treatments of human hypertension. Our Aims are: 1) Identify cell specificity for EP4R actions in kidney epithelia to resist hypertension. We will generate mice with EP4R deleted from entire CDs, principal cells, or intercalated cells, respectively, to assess the consequences of these genetic alterations on blood pressure, sodium homeostasis, and ENaC function in hypertension; and 2) Determine the mechanisms of ENaC regulation by EP4R. We will perform patch-clamp electrophysiology in isolated CDs to characterize EP4R downstream signaling pathways that mediate its powerful effects on attenuating the development of hypertension. Successful completion of the proposed research is expected to identify the mechanisms underlying the antihypertensive actions of EP4R. The long-term goal is to identify novel therapeutic targets for essential hypertension.
 
17. Project Title: Role of pericytes in postoperative neurocognitive disorder during aging
  Leader(s): YANG, TING
    DUKE UNIVERSITY
    NIH R03AG078882 / ( 2022 - 2024 )
  Core(s):
  ABSTRACT Perioperative neurocognitive disorders (PNDs) include acute delirium and long-lasting cognitive decline. These complications have become highly prevalent in our geriatric population, especially following common surgical procedures such as orthopedic fracture repairs. Delirium impacts over 50% of older adults after orthopedic surgery, which is often performed in frail patients including those with pre-existing dementia. Delirium and dementia have bidirectional relationships even though they have distinct pathophysiologies. To-date it remains unknown how a transient episode of delirium can contribute to the development of Alzheimer s Disease and related dementia (ADRD). We have established and validated a clinically relevant mouse model to study the acute impact of surgery on delirium-like pathology in rodents. With this model we found significant changes in blood-brain barrier (BBB) function and neuroinflammatory markers. Our Preliminary Results indicate that surgery induces vascular dysfunction in the central nervous system (CNS), with a rapid loss of ~58% of pericytes in the hippocampal microvasculature. Pericytes in the CNS play key roles in neurovascular integrity and supporting communication and signaling with other cell types. Recent studies from Alzheimer s disease (AD) samples demonstrated that pericyte dysfunction can promote neurodegeneration. The role of pericytes in delirium and their putative contribution to long-lasting cognitive decline and ADRD remain unknown This proposal will begin to investigate whether protracted loss of pericytes after surgery in aged mice predisposes to long-term cognitive decline and neurodegeneration. The Objective is to define the role of pericytes in postoperative neurocognitive disorders. Our Central Hypothesis is that aging prolongs pericytes dysfunction after surgery leading to enduring neurovascular disorders and dementia. The hypothesis will be tested in 2 aims: 1) Identify the effects of surgery- induced pericyte loss on acute and long-term neuroinflammation and neuronal loss; and 2) Determine the role of pericytes in postoperative neurocognitive disorder. We will subject adult (3-months) and aged (18-mo-old) male and female mice to orthopedic surgery, and evaluate changes in pericytes, neuronal loss, and neurodegenerative markers at 24 hr and 3 months after surgery. We will also treat aged mice with PDGF-BB to boost PDGFRb signaling and promote pericytes recruitment to possibly prevent long-lasting cognitive pathology sequalae, focusing on PNDs behaviors and neurodegenerative biomarkers 3 months after surgery. Overall, results from this project will provide a foundation to identify novel and specific targets to prevent PNDs and curtail the effects of surgery on vulnerable older adults with AD or other forms of dementia and neurodegeneration.
 
18. Project Title: The Role of the Aging Brain-Heart-Immune Axis in Postoperative Delirium
  Leader(s): ACKER, LEAH
    DUKE UNIVERSITY
    NIH R03AG078891 / ( 2022 - 2024 )
  Core(s):
  ABSTRACT Postoperative delirium (POD) is a syndrome of acute fluctuating changes in attention and consciousness that affects up to 50% of surgery patients 65 and older, increases the risk for Alzheimer's disease (AD) and AD-related dementias (ADRD), and accelerates dementia progression. Yet, interventions for POD are limited because its pathophysiologic mechanisms are poorly understood. The vagus nerve mediates the brain-heart-immune axis, which allows the brain to suppress systemic inflammation via the cholinergic anti-inflammatory reflex. Advanced age, preoperative stressors, the condition requiring surgery, and surgery and anesthesia themselves all decrease vagal tone. Without sufficient vagal tone to keep inflammation in check, excessive inflammation will result, including neuroinflammation. Excessive postoperative inflammation is thought to play a role in POD pathogenesis. Furthermore, excessive postoperative inflammation can injure neurons, providing a plausible mechanistic link between POD and AD+ADRD. Thus, there is a critical need to evaluate the role of the brain-heart-immune axis in POD among older adults. To interrogate the aging brain-heart-immune axis as a possible contributor to POD pathogenesis, heart rate variability (HRV), the standard measure of vagal tone, will be measured before general surgery in 100 patients 65 and older. Specifically, the prospective, observational HIPPIE - HRV In POD and Postoperative Inflammatory Endpoints - study will quantify the relationship between preoperative vagal tone and (1) POD incidence and (2) postoperative increase in serum biomarkers of inflammation and neuronal injury. Successful completion of the HIPPIE study will demonstrate the involvement of the brain-heart-immune axis in POD pathogenesis and will provide novel biomarker(s) of POD risk. Furthermore, a mechanistic link between POD and the brain-heart-immune axis is anticipated to provide strong scientific justification for future trials of vagal tone enhancement as an intervention for POD. Finally, this work will provide a rich new perioperative geriatric data set including measurements of the previously unexplored perioperative brain-heart-immune axis. The data, experience, and training from this proposal will lay the foundation of a successful career in geriatrics research.
 
19. Project Title: Feasibility Trial of a Novel Integrated Mindfulness and Acupuncture Program to Improve Outcomes after Spine Surgery (I-MASS)
  Leader(s): LENTZ, TREVOR ; GOERTZ, CHRISTINE MARIE;
    DUKE UNIVERSITY
    NIH R34AT012082 / ( 2023 - 2025 )
  Core(s):
  ABSTRACT Spine pain consistently ranks first or near the top in global rankings of disease burden, and epidemiological data suggest the burden is worsening. The number of low back surgeries has increased by 300% over the past 2 decades, accounting for approximately 30% of spine-related costs in the US. While it can provide cost- effective pain relief to some patients, up to 25% of those who undergo spine surgery will develop persistent pain requiring additional surgery, imaging, or other invasive interventions. Moreover, many patients will experience persistent opioid use, which carries significant risks of misuse, addiction, and overdose. Clinical practice guidelines strongly recommend the use of multimodal or mind and body treatments for effective pain management after surgery. This approach combines interventions with analgesic or physical therapeutic inputs alongside interventions with psychological or behavioral inputs to better address the multifaceted risk factors for persistent pain and opioid use following surgery. Integration of Mindfulness delivered via mobile app (mHealth) with auricular Acupuncture (AA) in individuals undergoing Spine Surgery (I-MASS) is a highly promising multimodal treatment approach given the distinct yet complementary mechanisms by which mindfulness and AA influence pain after surgery. Establishing the effectiveness of I-MASS requires a rigorously designed pragmatic trial comparing it to usual medical care in adults who undergo spine surgery. However, trials of this size and scope require careful preparation. This proposed mixed methods R34 project is designed to answer important preparatory questions regarding the feasibility and acceptability of I-MASS through the following Specific Aims: 1) Conduct interviews with patient and care delivery stakeholders to refine and finalize the I-MASS intervention protocol by integrating mHealth mindfulness training and AA for use in patients age 18-80 undergoing spine surgery; 2) Conduct a single-site, exploratory randomized controlled clinical trial to assess the feasibility and acceptability of I-MASS in patients undergoing single-level laminectomy, discectomy or fusion; and 3) Use feasibility trial results to develop and submit a competitive research proposal to NIH for a multi-site, pragmatic, randomized comparative effectiveness clinical trial designed to rigorously evaluate I-MASS compared to mHealth mindfulness, AA, and usual care augmented with standard education. The results of this R34 project will provide the information needed to successfully execute on such a study and create new knowledge regarding the feasibility and acceptability of a highly innovative non-pharmacological multimodal approach designed to improve the lives of patients undergoing spine surgery.
 
20. Project Title: Improving physical function and quality of life in older adults with prediabetes utilizing interactive small-group resistance training through video conference technology
  Leader(s): LEVITAN, ERIC ; STARR, KATHRYN N;
    IMPACTIV, INC.
    NIH R44AG076087 / ( 2022 - 2023 )
  Core(s):
  Vivo is a virtual small group exercise program designed for adults 55 and over that is unique in the increasingly popular digital fitness market. Vivo offers 3 key market differentiators: 1) a personalized and individualized live training experience with feedback from a certified trainer, 2) a community of older adult exercisers which enhances motivation and social support, and increase accountability and fun, and 3) the Vivo training experience focuses on improving physical function using performance feedback, goal setting, and a system to measure perceived exertion. Most older adults experience a 30% loss in muscle mass between ages 50 70. Resistance training is the most effective strategy for improving both muscle mass and function and managing sarcopenia. Vivo s programming is based on the scientific evidence that even in the absence of chronic disease, resistance training that is customized to meet the individual s needs and level of functioning is a feasible and evidence-based approach to improve physical function, regulate glucose handling, reduce the risk for falls, and prolong independent living and aging in place. To date 92 people have participated in Vivo (age range 44-93). In our pilot study of 34 older adults (74% women; mean age 70.9 y; range 60-84y) after 8 weeks of participating in Vivo with a certified trainer (average of 12 hours of training per person) we observed +25.8% improvement in upper body strength as measured by the 30 second arm curl test; +25.9% improvement in lower body strength as measured by the 30 second chair stand test; and +28% improvement in endurance as measured by the 2-minute knee raise test. The aims for this SBIR FastTrack are as follows: Phase I Aim 1: Evaluate the acceptability, feasibility, and fidelity of current Vivo prototype in sedentary older adults with prediabetes Milestone 1: Assess a) attendance, benefits and barriers/facilitators of participation; b) ease of use; and c) overall satisfaction. Milestone 2: Assess trainer fidelity. Aim 2 : Design and develop a multifunctional platform prototype for Vivo 2.0 Milestone 1: Create functional specifications of the client-centered approach (results, goals, adherence, upcoming workouts), and social engagement and support. Milestone 2: Develop a clickable prototype of the platform. Phase II Aim 1: Design and build the Vivo 2.0 platform a unified web/mobile application. Milestone 1: Assess prototype usability. Milestone 2: Iterate the design on the software and hardware to increase usage, accuracy and usability. Milestone 3: Develop and test a minimum viable software product based on the new prototype and functional design to include a mobile front-end and web front-end app and a backend database. Aim 2: Conduct a RCT to determine effectiveness of Vivo 2.0 v. wait list control. Primary outcomes will be change in lower extremity strength after 12 weeks measured by the number of chair stands in 30 seconds and average glycemic level (HgA1c). Secondary outcomes will include improvements in quality of life, and effect of adherence and social engagement on physical function outcomes.
 
21. Project Title: Trajectories of blood-based biomarkers of AD, their determinants, and ability to predict cognitive impairment
  Leader(s): LIU, YONGMEI ; LUO, SHENG ;
    DUKE UNIVERSITY
    NIH R56AG076622 / ( 2022 - 2023 )
  Core(s):
  The AT(N) framework uses PET and/or CSF biomarkers to define Alzheimer s Disease (AD) pathology and continuum; however, its broad implementation is restricted by high cost and limited accessibility. Recent advances in primarily Caucasian samples have identified plasma AD biomarkers namely, the ratio of A 42/A 40 and phosphorylated tau (p-tau, e.g. p-tau181, p-tau217) that are highly sensitive and specific for detecting abnormal A and Tau. Plasma p- tau is particularly promising for AD diagnosis and prediction of conversion to AD; yet, their potential as markers of disease progression and risk predictors for mild cognitive impairment (MCI)/AD, especially among racial/ethnic minorities who are disproportionately affected by AD, remains largely unexplored. Here, our objective is to use trajectories of promising plasma AD biomarkers to 1) define their natural history, 2) their ability to predict the risk of developing AD- specific cognitive impairment, and 3) to identify their molecular determinants. We propose to measure A 42/A 40 and p-tau217 in 3,810 MESA participants, across five time points (Exam 1, 4, 5, 6 & 7) spanning 22 years, and human neuronal cell lines to achieve the following specific aims: Aim 1. To quantify two plasma AD biomarkers (p-tau217 and A 42/A 40) and determine their changes with age starting from age 45 to 100+. Aim 2. To determine the ability of baseline and longitudinal changes in plasma AD biomarkers to predict future cognitive impairment. Aim 3. To examine effects of vascular aging and cognitive decline-associated genomic features, that we have previously identified, on AD biomarkers. The proposed MESA longitudinal study combining plasma AD biomarkers with multi-omics data, cardiometabolic measures, brain imaging, cognitive testing, and clinical MCI/AD data across the mid- to late-life transition period is a critical next step to evaluate the utility of plasma AD biomarkers to predict future risk of cognitive impairment in a racially and ethnically diverse population, and to identify candidate causal molecular processes in early AD pathogenesis that could serve as targets for disease- modifying interventions.
 
22. Project Title: PRAGMATIC EVALUATION OF EVENTS AND BENEFITS OF LIPID-LOWERING IN OLDER ADULTS (PREVENTABLE)
  Leader(s): ALEXANDER, KAREN P; AMBROSIUS, WALTER T ; HERNANDEZ, ADRIAN ; WILLIAMSON, JEFF DOUGLAS ;
    DUKE UNIVERSITY
    NIH U19AG065188 / ( 2019 - 2026 )
  Core(s):
  There is an urgent need for evidence to guide clinical care of older adults due to demographic shifts, includinglonger life expectancy and a recent doubling of the older adult population. Statins reduce recurrent CVD eventsand prevent initial events in patients younger than 75 years. However, clinical research has often excludedpersons older than 75 years due to a higher prevalence of comorbidity and frailty so little to no evidence isavailable to guide care in this population. For older adults living longer, the promise of preventing cognitiveimpairment is as compelling as preventing a CVD event, but some evidence suggests statins maycontribute to memory difficulty or muscle symptoms. There is equipoise regarding the usefulness of statinsfor primary CVD, dementia, and disability prevention in adults older than 75 years, especially in the settingof multiple chronic conditions, advanced age, or frailty. Evidence to improve cognitive and functionaloutcomes in older populations with diverse race/ethnicity and health status will require new clinical trialapproaches with sustainable methodology and infrastructure. We propose PREVENTABLE (PRagmaticEValuation of evENTs And Benefits of Lipid-lowering in oldEr adults), the first statin trial with a non-CVDprimary outcome survival free of dementia or persisting disability. Using a placebo-controlled pragmaticclinical trial (PCT) design across PCORnet and VA network, the trial will be under the leadership of Dr. KarenAlexander at DCRI, Dr. Jeff Williamson at WFSM, Dr. Adrian Hernandez at DCRI, and Dr. Walter Ambrosius atWFSM. This team has established experience and track-record of accomplishment in the design and conductof PCTs, trial expertise in ascertaining cognitive and disability outcomes in older adults, and is supported by arobust administrative infrastructure for coordinating these shared responsibilities for success. The overarchinggoal of PREVENTABLE is to generate knowledge about the role of statins in older adults, a population in whichrisk/benefit for primary prevention has been under studied. The hypothesis is that a large trial conducted in anolder adult population will demonstrate the benefit of statins for reducing dementia, disability, and CV events.We further hypothesize that extensive genomic, biochemical and imaging ancillary studies will offer uniqueinsights into these key outcomes. PREVENTABLE has the following specific aims: AIM 1: Determine the roleof a moderate-intensity statin in preventing dementia and prolonging disability-free survival in patients 75 yearsand older without clinically evident coronary heart disease, including those with frailty, impaired physicalfunction, mild cognitive impairment, polypharmacy, and multi-morbidity. AIM 2: Determine the role of moderate-intensity statin in preventing hospitalization for myocardial infarction/acute coronary syndrome, stroke, heartfailure, revascularization or cardiovascular-related death, and preventing either mild cognitive impairment ordementia. AIM 3: Test the safety and tolerability of statins in older adults and collect 17,000 bio-specimens toadvance precision health.
 
PUBLICATIONS
2023
  1. Beyond implementation: Uncovering the parallels between de-implementation and antimicrobial stewardship.
    Advani SD, McKay V
    Antimicrob Steward Healthc Epidemiol, 2023, 3(1): e73
    https://doi.org/10.1017/ash.2023.150 | PMID: 37113202 | PMCID: PMC10127237
    Citations: 2 | AltScore: NA
  2. Remotely Supervised Weight Loss and Exercise Training to Improve Rheumatoid Arthritis Cardiovascular Risk: Rationale and Design of the Supervised Weight Loss Plus Exercise Training-Rheumatoid Arthritis Trial.
    Andonian B, Ross LM, Zidek AM, Fos LB, Piner LW, Johnson JL, Belski KB, Counts JD, Pieper CF, Siegler IC, Bales CW, Porter Starr KN, Kraus WE, Huffman KM
    ACR Open Rheumatol, 2023 May, 5(5): 252-263
    https://doi.org/10.1002/acr2.11536 | PMID: 36992545 | PMCID: PMC10184018
    Citations: NA | AltScore: NA
  3. Editorial: The immune system and inflammation in musculoskeletal health, aging, and disease.
    Baht GS, Grol MW
    Front Immunol, 2023, 14: 1218118
    https://doi.org/10.3389/fimmu.2023.1218118 | PMID: 37275852 | PMCID: PMC10233133
    Citations: NA | AltScore: NA
  4. Which types of stress are associated with accelerated biological aging? Comparing perceived stress, stressful life events, childhood adversity, and posttraumatic stress disorder.
    Bourassa KJ, Caspi A, Brennan GM, Hall KS, Harrington H, Houts R, Kimbrel NA, Poulton R, Ramrakha S, Taylor GA, Moffitt TE
    Psychosom Med, 2023 Apr 6, 85(5): 389-396
    https://doi.org/10.1097/PSY.0000000000001197 | PMID: 37053097 | PMCID: PMC10239326
    Citations: NA | AltScore: 18.35
  5. Physical Function Assessment of Older Veterans With Serious Mental Illness.
    Browne J, Elbogen EB, Mueser KT, Rudolph JL, Wu WC, Philip NS, Mills WL, Sloane R, Hall KS
    Am J Geriatr Psychiatry, 2023 Sep, 31(9): 657-666
    https://doi.org/10.1016/j.jagp.2023.02.048 | PMID: 36941144 | PMCID: PMC10474249
    Citations: 2 | AltScore: NA
  6. Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study.
    Carroll JE, Nakamura ZM, Small BJ, Zhou X, Cohen HJ, Ahles TA, Ahn J, Bethea TN, Extermann M, Graham D, Isaacs C, Jim HSL, Jacobsen PB, McDonald BC, Patel SK, Rentscher K, Root J, Saykin AJ, Tometich DB, Van Dyk K, Zhai W, Breen EC, Mandelblatt JS
    J Clin Oncol, 2023 Jan 10, 41(2): 295-306
    https://doi.org/10.1200/JCO.22.00406 | PMID: 36179271 | PMCID: PMC9839283
    Citations: 10 | AltScore: 248.012
  7. Synergistic roles of CBX4 chromo and SIM domains in regulating senescence of primary human osteoarthritic chondrocytes.
    Chen YH, Zhang X, Attarian D, Kraus VB
    Arthritis Res Ther, 2023 Oct 12, 25(1): 197
    https://doi.org/10.1186/s13075-023-03183-8 | PMID: 37828576 | PMCID: PMC10568837
    Citations: NA | AltScore: NA
  8. Association of Dipeptidylpeptidase 4 (CD26) With Chondrocyte Senescence and Radiographic Progression in Knee Osteoarthritis.
    Chen YH, Zhang X, Chou CH, Hsueh MF, Attarian D, Li YJ, Kraus VB
    Arthritis Rheumatol, 2023 Jan 27, 75(7): 1120-1131
    https://doi.org/10.1002/art.42455 | PMID: 36704903 | PMCID: PMC10313751
    Citations: 1 | AltScore: NA
  9. Reply.
    Chen YH, Zhang X, Kraus VB
    Arthritis Rheumatol, 2023 Mar 12, 75(9): 1679-1680
    https://doi.org/10.1002/art.42500 | PMID: 36908027
    Citations: NA | AltScore: NA
  10. RELATIONSHIP BETWEEN REPRODUCTIVE AND BONE BIOMARKERS AND OSTEOARTHRITIS IN ZOO ASIAN (ELEPHAS MAXIMUS) AND AFRICAN (LOXODONTA AFRICANA) ELEPHANTS.
    Chusyd DE, Brown JL, Golzarri-Arroyo L, Dickinson SL, Kraus VB, Siegal-Willott J, Griffin TM, Huebner JL, Edwards KL, Allison DB, Austad SN
    J Zoo Wildl Med, 2023 Jan, 53(4): 801-810
    https://doi.org/10.1638/2021-0080 | PMID: 36640083 | PMCID: PMC10150656
    Citations: NA | AltScore: NA
  11. Ageing and physical resilience after health stressors.
    Colon-Emeric C, Schmader K, Cohen HJ, Morey M, Whitson H
    Stress Health, 2023 Mar 6, 39(S1): 48-54
    https://doi.org/10.1002/smi.3241 | PMID: 36879359 | PMCID: PMC10480330
    Citations: 2 | AltScore: 1.85
  12. Calorie restriction modulates the transcription of genes related to stress response and longevity in human muscle: The?CALERIE study.
    Das JK, Banskota N, Candia J, Griswold ME, Orenduff M, de Cabo R, Corcoran DL, Das SK, De S, Huffman KM, Kraus VB, Kraus WE, Martin CK, Racette SB, Redman LM, Schilling B, Belsky DW, Ferrucci L
    Aging Cell, 2023 Oct 12 e13963
    https://doi.org/10.1111/acel.13963 | PMID: 37823711
    Citations: NA | AltScore: 281.588
  13. A Role for Blood-brain Barrier Dysfunction in Delirium following Non-Cardiac Surgery in Older adults.
    Devinney MJ, Wong MK, Wright MC, Marcantonio ER, Terrando N, Browndyke JN, Whitson HE, Cohen HJ, Nackley AG, Klein ME, Ely EW, Mathew JP, Berger M, MADCO-PC & INTUIT Study Groups
    medRxiv, 2023 May 10
    pii: 2023.04.07.23288303. https://doi.org/10.1101/2023.04.07.23288303 | PMID: 37214925 | PMCID: PMC10197714
    Citations: 1 | AltScore: 4.5
  14. Role of Blood-Brain Barrier Dysfunction in Delirium following Non-cardiac Surgery in Older Adults.
    Devinney MJ, Wong MK, Wright MC, Marcantonio ER, Terrando N, Browndyke JN, Whitson HE, Cohen HJ, Nackley AG, Klein ME, Ely EW, Mathew JP, Berger M, MADCO-PC and INTUIT Study Teams
    Ann Neurol, 2023 Aug 24
    https://doi.org/10.1002/ana.26771 | PMID: 37615660
    Citations: NA | AltScore: 145.03
  15. A prospective randomized study examining the impact of intravenous versus inhalational anesthesia on postoperative cognitive decline and delirium.
    Farrer TJ, Monk TG, McDonagh DL, Martin G, Pieper CF, Koltai D
    Appl Neuropsychol Adult, 2023 Aug 12 7-Jan
    https://doi.org/10.1080/23279095.2023.2246612 | PMID: 37572422
    Citations: NA | AltScore: NA
  16. CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting.
    Fillenbaum GG, Mohs R
    J Alzheimers Dis, 2023, 93(1): 27-Jan
    https://doi.org/10.3233/JAD-230026 | PMID: 36938738 | PMCID: PMC10175144
    Citations: 2 | AltScore: 7
  17. Effects of Leptin and Body Weight on Inflammation and Knee Osteoarthritis Phenotypes in Female Rats.
    Fu Y, Batushansky A, Kinter M, Huebner JL, Kraus VB, Griffin TM
    JBMR Plus, 2023 Jul, 7(7): e10754
    https://doi.org/10.1002/jbm4.10754 | PMID: 37457883 | PMCID: PMC10339097
    Citations: NA | AltScore: NA
  18. Emergency Department-to-Community Transitions of Care: Best Practices for the Older Adult Population.
    Gettel CJ, Hastings SN, Biese KJ, Goldberg EM
    Clin Geriatr Med, 2023 Nov, 39(4): 659-672
    https://doi.org/10.1016/j.cger.2023.05.009 | PMID: 37798071
    Citations: NA | AltScore: NA
  19. SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022.
    Gigot C, Pisanic N, Kruczynski K, Gregory Rivera M, Spicer K, Kurowski KM, Randad P, Koehler K, Clarke WA, Holmes P, Hall DJ Jr, Hall DJ, Heaney CD
    mSphere, 2023 Feb 21, 8(1): e0052222
    https://doi.org/10.1128/msphere.00522-22 | PMID: 36656002 | PMCID: PMC9942583
    Citations: 2 | AltScore: NA
  20. Reply to: Comment on \Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice\"."
    Goetz CG, Zou H, Stebbins GT, Schrag A, Mestre TA, Luo S
    Mov Disord, 2023 Aug, 38(8): 1564
    https://doi.org/10.1002/mds.29513 | PMID: 37565401
    Citations: NA | AltScore: NA
  21. Biomarkers and longitudinal changes in lumbar spine degeneration and low back pain: the Johnston County Osteoarthritis Project.
    Goode AP, Cleveland RJ, Kraus VB, Taylor KA, George SZ, Schwartz TA, Renner J, Huebner JL, Jordan JM, Golightly YM
    Osteoarthritis Cartilage, 2023 Jun, 31(6): 809-818
    https://doi.org/10.1016/j.joca.2023.02.005 | PMID: 36804589 | PMCID: PMC10200763
    Citations: 1 | AltScore: 15.6
  22. Branched-chain a-keto acids and glutamate/glutamine: Biomarkers of insulin resistance in childhood obesity.
    Gumus Balikcioglu P, Jachthuber Trub C, Balikcioglu M, Ilkayeva O, White PJ, Muehlbauer M, Bain JR, Armstrong S, Freemark M
    Endocrinol Diabetes Metab, 2023 Jan, 6(1): e388
    https://doi.org/10.1002/edm2.388 | PMID: 36415168 | PMCID: PMC9836245
    Citations: 2 | AltScore: NA
  23. Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.
    Guo Y, Goetz CG, Stebbins GT, Mestre TA, Luo S
    Mov Disord, 2023 Jan 9, 38(3): 453-463
    https://doi.org/10.1002/mds.29308 | PMID: 36621935 | PMCID: PMC10033355
    Citations: 2 | AltScore: 0.5
  24. Stakeholder Perspectives on Factors Related to Deprescribing Potentially Inappropriate Medications in Older Adults Receiving Dialysis.
    Hall RK, Rutledge J, Lucas A, Liu CK, Clair Russell JS, Peter WS, Fish LJ, Col?n-Emeric C
    Clin J Am Soc Nephrol, 2023 Jul 27, 18(10): 1310-1320
    https://doi.org/10.2215/CJN.0000000000000229 | PMID: 37499693 | PMCID: PMC10578639
    Citations: NA | AltScore: NA
  25. Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.
    Hemmersbach-Miller M, Balevic SJ, Winokur PL, Landersdorfer CB, Gu K, Chan AW, Cohen-Wolkowiez M, Conrad T, An G, Kirkpatrick CMJ, Swamy GK, Walter EB, Schmader KE
    Clin Pharmacokinet, 2023 Jan 12, 62(1): 127-139
    https://doi.org/10.1007/s40262-022-01198-z | PMID: 36633812 | PMCID: PMC9969806
    Citations: NA | AltScore: 1
  26. Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study.
    Ji J, Sun CL, Cohen HJ, Synold T, Muss H, Sedrak MS
    J Clin Oncol, 2023 Jan 10, 41(2): 307-315
    https://doi.org/10.1200/JCO.22.01217 | PMID: 36126235 | PMCID: PMC9839275
    Citations: 3 | AltScore: 62.086
  27. Dysphagia in Older Adults is Associated With Food Insecurity and Being Homebound.
    Jones HN, Leiman DA, Porter Starr KN, North R, Pieper CF, Robison RD, Cohen SM
    J Appl Gerontol, 2023 Sep, 42(9): 1993-2002
    https://doi.org/10.1177/07334648231177568 | PMID: 37249305
    Citations: NA | AltScore: NA
  28. Chondroprotection of leptin deficiency demystified?
    Kraus VB, Nelson AE, Huang Z
    Osteoarthritis Cartilage, 2023 Jan, 31(1): 18-20
    https://doi.org/10.1016/j.joca.2022.10.006 | PMID: 36244625 | PMCID: PMC9772286
    Citations: 1 | AltScore: 4.2
  29. Metabolic factors associated with incident fracture among older adults with type 2 diabetes mellitus: a nested case-control study.
    Lee RH, Bain J, Muehlbauer M, Ilkayeva O, Pieper C, Wixted D, Col?n-Emeric C
    Osteoporos Int, 2023 Apr 26, 34(7): 1263-1268
    https://doi.org/10.1007/s00198-023-06763-1 | PMID: 37100949 | PMCID: PMC10443052
    Citations: NA | AltScore: 3.6
  30. Type-2 Diabetes, Pancreatic Amylin, and Neuronal Metabolic Remodeling in Alzheimer's Disease.
    Leibold N, Bain JR, Despa F
    Mol Nutr Food Res, 2023 Jan 28 e2200405
    https://doi.org/10.1002/mnfr.202200405 | PMID: 36708219 | PMCID: PMC10374875
    Citations: NA | AltScore: 10
  31. Self-Reported Dysphagia and Psychosocial Health Among Community-Dwelling Older Adults: Results of a National Study.
    Leiman DA, Jones HN, North R, Porter Starr KN, Pieper CF, Cohen SM
    J Gen Intern Med, 2023 May 30
    https://doi.org/10.1007/s11606-023-08232-1 | PMID: 37254012
    Citations: NA | AltScore: 4.95
  32. Novel Genetic Variants in TP37, PIK3R1, CALM1, and PLCG2 of the Neurotrophin Signaling Pathway Are Associated with the Progression from Mild Cognitive Impairment to Alzheimer's Disease.
    Li H, Liu H, Lutz MW, Luo S, Alzheimer?s Disease Neuroimaging Initiative
    J Alzheimers Dis, 2023, 91(3): 977-987
    https://doi.org/10.3233/JAD-220680 | PMID: 36530083 | PMCID: PMC9905310
    Citations: 2 | AltScore: 1
  33. Plasma levels of interleukin-6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study.
    Mandelblatt JS, Small BJ, Zhou X, Nakamura ZM, Cohen HJ, Ahles TA, Ahn J, Bethea TN, Extermann M, Graham D, Isaacs C, Jacobsen PB, Jim HSL, McDonald BC, Patel SK, Rentscher KE, Root JC, Saykin AJ, Tometich DB, Van Dyk K, Zhai W, Breen EC, Carroll JE
    Cancer, 2023 Aug 1, 129(15): 2409-2421
    https://doi.org/10.1002/cncr.34784 | PMID: 37096888
    Citations: NA | AltScore: 8.2
  34. Longitudinal analysis of physical function in older adults: The effects of physical inactivity and exercise training.
    Manning KM, Hall KS, Sloane R, Magistro D, Rabaglietti E, Lee CC, Castle S, Kopp T, Giffuni J, Katzel L, McDonald M, Miyamoto M, Pearson M, Jennings SC, Bettger JP, Morey MC
    Aging Cell, 2023 Sep 8 e13987
    https://doi.org/10.1111/acel.13987 | PMID: 37681737
    Citations: NA | AltScore: NA
  35. Demographically-adjusted normative data among Latinos for the version 3 of the Alzheimer's Disease Centers' Neuropsychological Test Battery in the Uniform Data Set.
    Marquine MJ, Parks A, Perales-Puchalt J, Gonz?lez DA, Rosado-Bruno M, North R, Pieper C, Werry AE, Kiselica A, Chapman S, Dodge H, Gauthreaux K, Kukull WA, Rascovsky K
    Alzheimers Dement, 2023 Sep, 19(9): 4174-4186
    https://doi.org/10.1002/alz.13313 | PMID: 37356069
    Citations: NA | AltScore: NA
  36. Comparison of Postoperative Outcomes of Laparoscopic vs Open Inguinal Hernia Repair.
    Meier J, Stevens A, Berger M, Makris KI, Bramos A, Reisch J, Cullum CM, Lee SC, Sugg Skinner C, Zeh H, Brown CJ, Balentine CJ
    JAMA Surg, 2023 Feb 1, 158(2): 172-180
    https://doi.org/10.1001/jamasurg.2022.6616 | PMID: 36542394 | PMCID: PMC9857280
    Citations: 1 | AltScore: 40.8
  37. Exploration of model misspecification in latent class methods for longitudinal data: Correlation structure matters.
    Neely ML, Pieper CF, Gu B, Dmitrieva NO, Pendergast JF
    Stat Med, 2023 Jun 30, 42(14): 2420-2438
    https://doi.org/10.1002/sim.9730 | PMID: 37019876
    Citations: NA | AltScore: NA
  38. Mitigation behavior prior to COVID-19 vaccination availability is associated with COVID-19 infection and time to vaccination.
    Neighbors CE, Sloane R, Pieper CF, Wixted D, Woods CW, Newby LK
    PLoS One, 2023, 18(3): e0283381
    https://doi.org/10.1371/journal.pone.0283381 | PMID: 36961840 | PMCID: PMC10038251
    Citations: NA | AltScore: NA
  39. Physical activity and relationship to physical function, quality of life, and cognitive function in older patients with acute decompensated heart failure.
    Nelson MB, Shiroma EJ, Kitzman DW, Duncan PW, Reeves GR, Whellan DJ, Mentz RJ, Chen H, Pastva AM
    Am Heart J, 2023 Feb, 256: 85-94
    https://doi.org/10.1016/j.ahj.2022.11.002 | PMID: 36372251 | PMCID: PMC9840656
    Citations: NA | AltScore: 21.3
  40. Genetic Variants Associated with Longitudinal Cognitive Performance in Older Breast Cancer Patients and Controls.
    Nudelman K, Nho K, Zhang M, McDonald BC, Zhai W, Small BJ, Wegel CE, Jacobsen PB, Jim HSL, Patel SK, Graham DMA, Ahles TA, Root JC, Foroud T, Breen EC, Carroll JE, Mandelblatt JS, Saykin AJ
    Cancers (Basel), 2023 May 23, 15(11):
    https://doi.org/10.3390/cancers15112877 | PMID: 37296840 | PMCID: PMC10252108
    Citations: 1 | AltScore: 0.5
  41. Frailty and Effects of a Multidomain Physical Rehabilitation Intervention Among Older Patients Hospitalized for Acute Heart Failure: A Secondary Analysis of a Randomized Clinical Trial.
    Pandey A, Kitzman DW, Nelson MB, Pastva AM, Duncan P, Whellan DJ, Mentz RJ, Chen H, Upadhya B, Reeves GR
    JAMA Cardiol, 2023 Feb 1, 8(2): 167-176
    https://doi.org/10.1001/jamacardio.2022.4903 | PMID: 36598761 | PMCID: PMC9857661
    Citations: 7 | AltScore: 89.1
  42. Tryptophan Metabolism and Neurodegeneration: Longitudinal Associations of Kynurenine Pathway Metabolites with Cognitive Performance and Plasma Alzheimer's Disease and Related Dementias Biomarkers in the Duke Physical Performance Across the LifeSpan Study.
    Parker DC, Kraus WE, Whitson HE, Kraus VB, Smith PJ, Cohen HJ, Pieper CF, Faldowski RA, Hall KS, Huebner JL, Ilkayeva OR, Bain JR, Newby LK, Huffman KM
    J Alzheimers Dis, 2023, 91(3): 1141-1150
    https://doi.org/10.3233/JAD-220906 | PMID: 36565121 | PMCID: PMC10074831
    Citations: 1 | AltScore: 7.35
  43. Machine learning functional impairment classification with electronic health record data.
    Pavon JM, Previll L, Woo M, Henao R, Solomon M, Rogers U, Olson A, Fischer J, Leo C, Fillenbaum G, Hoenig H, Casarett D
    J Am Geriatr Soc, 2023 May 17, 71(9): 2822-2833
    https://doi.org/10.1111/jgs.18383 | PMID: 37195174 | PMCID: PMC10524844
    Citations: NA | AltScore: 1.25
  44. Epigenetic aging in older breast cancer survivors and non-cancer controls: preliminary findings from the Thinking and Living with Cancer (TLC) Study.
    Rentscher KE, Bethea TN, Zhai W, Small BJ, Zhou X, Ahles TA, Ahn J, Breen EC, Cohen HJ, Extermann M, Graham DMA, Jim HSL, McDonald BC, Nakamura ZM, Patel SK, Root JC, Saykin AJ, Van Dyk K, Mandelblatt JS, Carroll JE
    Cancer, 2023 Jun 1, 129(17): 2741-2753
    https://doi.org/10.1002/cncr.34818 | PMID: 37259669
    Citations: NA | AltScore: 39.88
  45. The Aging-Cancer Cycle: Mechanisms and Opportunities for Intervention.
    Sedrak MS, Cohen HJ
    J Gerontol A Biol Sci Med Sci, 2023 Jul 8, 78(7): 1234-1238
    https://doi.org/10.1093/gerona/glac247 | PMID: 36512079 | PMCID: PMC10329223
    Citations: NA | AltScore: 1.1
  46. Circulating Inflammatory Biomarkers Predict Pain Change Following Exercise-Induced Shoulder Injury: Findings From the Biopsychosocial Influence on Shoulder Pain Preclinical Trial.
    Simon CB, Bishop MD, Wallace MR, Staud R, DelRocco N, Wu SS, Dai Y, Borsa PA, Greenfield WH 3rd, Fillingim RB, George SZ
    J Pain, 2023 May 12, 24(8): 1465-1477
    pii: S1526-5900(23)00392-9. https://doi.org/10.1016/j.jpain.2023.04.001 | PMID: 37178095 | PMCID: PMC10523877
    Citations: NA | AltScore: 4.75
  47. A Novel Movement-Evoked Pain Provocation Test for Older Adults With Persistent Low Back Pain: Safety, Feasibility, and Associations With Self-reported Physical Function and Usual Gait Speed.
    Simon CB, Hicks GE, Pieper CF, Byers Kraus V, Keefe FJ, Col?n-Emeric C
    Clin J Pain, 2023 Apr 1, 39(4): 166-174
    https://doi.org/10.1097/AJP.0000000000001101 | PMID: 36943160 | PMCID: PMC10034602
    Citations: NA | AltScore: NA
  48. Cognitive-motor dual-task interference in adults with sickle cell disease.
    Subramaniam AP, Oyedeji CI, Parikh JS, Feld JA, Strouse JJ
    Gait Posture, 2023 May, 102: 164-170
    https://doi.org/10.1016/j.gaitpost.2023.03.009 | PMID: 37023564
    Citations: NA | AltScore: 0.25
  49. Recommendations for using the 5Ts Framework to support research inclusion across the lifespan.
    Thomas J, Eckstrom E, Lam WKK, Sullivan S, Bentley-Edwards K, Gierisch JM, Bowling CB
    J Am Geriatr Soc, 2023 Apr 10, 71(8): 2664-2669
    https://doi.org/10.1111/jgs.18359 | PMID: 37036034 | PMCID: PMC10495931
    Citations: NA | AltScore: NA
  50. Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate?
    Werbel WA, Weld ED, Advani SD, Patel PK, Sundaram ME, Phadke VK
    Clin Infect Dis, 2023 Jul 5, 77(1): 32-37
    https://doi.org/10.1093/cid/ciad178 | PMID: 36999905 | PMCID: PMC10320072
    Citations: NA | AltScore: 20.25
  51. Aging and obesity prime the methylome and transcriptome of adipose stem cells for disease and dysfunction.
    Xie S, Choudhari S, Wu CL, Abramson K, Corcoran D, Gregory SG, Thimmapuram J, Guilak F, Little D
    FASEB J, 2023 Mar, 37(3): e22785
    https://doi.org/10.1096/fj.202201413R | PMID: 36794668 | PMCID: PMC10561192
    Citations: 1 | AltScore: 12.85
  52. An enhancer-based gene-therapy strategy for spatiotemporal control of cargoes during tissue repair.
    Yan R, Cigliola V, Oonk KA, Petrover Z, DeLuca S, Wolfson DW, Vekstein A, Mendiola MA, Devlin G, Bishawi M, Gemberling MP, Sinha T, Sargent MA, York AJ, Shakked A, DeBenedittis P, Wendell DC, Ou J, Kang J, Goldman JA, Baht GS, Karra R, Williams AR, Bowles DE, Asokan A, Tzahor E, Gersbach CA, Molkentin JD, Bursac N, Black BL, Poss KD
    Cell Stem Cell, 2023 Jan 5, 30(1): 96-111.e6
    https://doi.org/10.1016/j.stem.2022.11.012 | PMID: 36516837 | PMCID: PMC9830588
    Citations: 11 | AltScore: 263.51
  53. Dietary Diversity Changes and Cognitive Frailty in Chinese Older Adults: A Prospective Community-Based Cohort Study.
    Zhong WF, Song WQ, Wang XM, Li ZH, Shen D, Liu D, Zhang PD, Shen QQ, Liang F, Nan Y, Xiang JX, Chen ZT, Li C, Li ST, Lv XG, Lin XR, Lv YB, Gao X, Kraus VB, Shi XM, Mao C
    Nutrients, 2023 Aug 30, 15(17):
    https://doi.org/10.3390/nu15173784 | PMID: 37686817 | PMCID: PMC10490160
    Citations: NA | AltScore: NA
  54. Development and Validation of a Lifespan Prediction Model in Chinese Adults Aged 65?Years or Older.
    Zhou J, Chen C, Wang J, Liu S, Li X, Wei Y, Ye L, Ye J, Kraus VB, Lv Y, Shi X
    J Am Med Dir Assoc, 2023 Mar 22, 24(7): 1068-1073.e6
    pii: S1525-8610(23)00135-4. https://doi.org/10.1016/j.jamda.2023.02.016 | PMID: 36965505 | PMCID: PMC10335838
    Citations: NA | AltScore: NA
  55. Leisure Activities, Genetic Risk, and Frailty: Evidence from the Chinese Adults Aged 80 Years or Older.
    Zhou J, Li X, Gao X, Wei Y, Ye L, Liu S, Ye J, Qiu Y, Zheng X, Chen C, Wang J, Kraus VB, Lv Y, Mao C, Shi X
    Gerontology, 2023, 69(8): 961-971
    https://doi.org/10.1159/000530665 | PMID: 37075711
    Citations: NA | AltScore: 2
  56. Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice.
    Zou H, Goetz CG, Stebbins GT, Schrag A, Mestre TA, Luo S
    Mov Disord, 2023 Apr 23, 38(7): 1363-1364
    https://doi.org/10.1002/mds.29417 | PMID: 37087725
    Citations: 1 | AltScore: NA
  57. Multivariate functional mixed model with MRI data: An?application to Alzheimer's disease.
    Zou H, Xiao L, Zeng D, Luo S, Alzheimer's Disease Neuroimaging Initiative
    Stat Med, 2023 May 10, 42(10): 1492-1511
    https://doi.org/10.1002/sim.9683 | PMID: 36805635 | PMCID: PMC10133011
    Citations: NA | AltScore: 9.5
  58. BAYESIAN INFERENCE AND DYNAMIC PREDICTION FOR MULTIVARIATE LONGITUDINAL AND SURVIVAL DATA.
    Zou H, Zeng D, Xiao L, Luo S
    Ann Appl Stat, 2023 Sep, 17(3): 2574-2595
    https://doi.org/10.1214/23-aoas1733 | PMID: 37719893 | PMCID: PMC10500582
    Citations: NA | AltScore: 7
 
2022
  1. Clin-Star corner: What's new at the interface of geriatrics, infectious diseases, and antimicrobial stewardship.
    Advani SD, Schmader KE, Mody L
    J Am Geriatr Soc, 2022 Aug, 70(8): 2214-2218
    https://doi.org/10.1111/jgs.17907 | PMID: 35704918 | PMCID: PMC9378540
    Citations: 1 | AltScore: 26.34
  2. Tibiofemoral knee osteoarthritis progresses symmetrically by knee compartment in the GOGO cohort.
    Alexander LC Jr, Huebner JL, Cicconetti G, Jordan JM, Renner JB, Doherty M, Wilson AG, Hochberg MC, Loeser R, Kraus VB
    Osteoarthr Cartil Open, 2022 Sep, 4(3):
    pii: 100288. https://doi.org/10.1016/j.ocarto.2022.100288 | PMID: 36081777 | PMCID: PMC9451142
    Citations: 1 | AltScore: NA
  3. Rheumatoid arthritis T cell and muscle oxidative metabolism associate with exercise-induced changes in cardiorespiratory fitness.
    Andonian BJ, Koss A, Koves TR, Hauser ER, Hubal MJ, Pober DM, Lord JM, MacIver NJ, St Clair EW, Muoio DM, Kraus WE, Bartlett DB, Huffman KM
    Sci Rep, 2022 May 6, 12(1): 7450
    https://doi.org/10.1038/s41598-022-11458-4 | PMID: 35523821 | PMCID: PMC9076829
    Citations: 1 | AltScore: 26.35
  4. Blood and urine biomarkers in osteoarthritis - an update on cartilage associated type II collagen and aggrecan markers.
    Bay-Jensen AC, Mobasheri A, Thudium CS, Kraus VB, Karsdal MA
    Curr Opin Rheumatol, 2022 Jan 1, 34(1): 54-60
    https://doi.org/10.1097/BOR.0000000000000845 | PMID: 34652292 | PMCID: PMC8635261
    Citations: 17 | AltScore: NA
  5. Implementation of a telehealth videoconference to improve hospital-to-skilled nursing care transitions: Preliminary data.
    Bellantoni J, Clark E, Wilson J, Pendergast J, Pavon JM, White HK, Malone D, Knechtle W, Jolly Graham A
    J Am Geriatr Soc, 2022 Mar 25, 70(6): 1828-1837
    https://doi.org/10.1111/jgs.17751 | PMID: 35332931
    Citations: 2 | AltScore: 9.2
  6. Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers.
    Berger M, Browndyke JN, Cooter Wright M, Nobuhara C, Reese M, Acker L, Bullock WM, Colin BJ, Devinney MJ, Moretti EW, Moul JW, Ohlendorf B, Laskowitz DT, Waligorska T, Shaw LM, Whitson HE, Cohen HJ, Mathew JP, MADCO-PC Investigators.
    Ann Clin Transl Neurol, 2022 Feb 1, 9(2): 155-170
    https://doi.org/10.1002/acn3.51499 | PMID: 35104057 | PMCID: PMC8862419
    Citations: 11 | AltScore: 34.2
  7. Developing a Real-Time Electroencephalogram-Guided Anesthesia-Management Curriculum for Educating Residents: A Single-Center Randomized Controlled Trial.
    Berger M, Eleswarpu SS, Cooter Wright M, Ray AM, Wingfield SA, Heflin MT, Bengali S, Udani AD
    Anesth Analg, 2022 Jan 1, 134(1): 159-170
    https://doi.org/10.1213/ANE.0000000000005677 | PMID: 34709008 | PMCID: PMC8678191
    Citations: 6 | AltScore: 18.65
  8. Associations between longitudinal changes in sleep disturbance and depressive and anxiety symptoms during the COVID-19 virus pandemic among older women with and without breast cancer in the thinking and living with breast cancer study.
    Bethea TN, Zhai W, Zhou X, Ahles TA, Ahn J, Cohen HJ, Dilawari AA, Graham DMA, Jim HSL, McDonald BC, Nakamura ZM, Patel SK, Rentscher KE, Root J, Saykin AJ, Small BJ, Van Dyk KM, Mandelblatt JS, Carroll JE
    Cancer Med, 2022 Mar 22, 11(17): 3352-3363
    https://doi.org/10.1002/cam4.4682 | PMID: 35315588 | PMCID: PMC9110906
    Citations: 9 | AltScore: 15.5
  9. Reserve and resilience in CKD: concept introduction and baseline results from the Physical REsilience Prediction in Advanced REnal Disease (PREPARED) study.
    Bowling CB, Olsen MK, Berkowitz TSZ, Smith B, Floyd B, Majette N, Miles AL, Crowley SD, Wang V, Maciejewski ML, Whitson HE
    BMC Nephrol, 2022 Dec 31, 23(1): 418
    https://doi.org/10.1186/s12882-022-03033-w | PMID: 36585609 | PMCID: PMC9803898
    Citations: 1 | AltScore: 0.5
  10. Preoperative dysphagia risk in community-dwelling adults aged =50 years: Prevalence and risk factors.
    Canick J, Campbell JC, Cohen SM, Jones HN, Leiman DA, Raman S, Porter Starr KN
    Nutr Clin Pract, 2022 Jul 5, 38(1): 157-166
    https://doi.org/10.1002/ncp.10889 | PMID: 35788985 | PMCID: PMC10026185
    Citations: 2 | AltScore: 1
  11. Hevin/Sparcl1 drives pathological pain through spinal cord astrocyte and NMDA receptor signaling.
    Chen G, Xu J, Luo H, Luo X, Singh SK, Ramirez JJ, James ML, Mathew JP, Berger M, Eroglu C, Ji RR
    JCI Insight, 2022 Dec 8, 7(23):
    https://doi.org/10.1172/jci.insight.161028 | PMID: 36256481 | PMCID: PMC9746899
    Citations: 1 | AltScore: NA
  12. CBX4 Regulates Replicative Senescence of WI-38 Fibroblasts.
    Chen YH, Zhang X, Ko KY, Hsueh MF, Kraus VB
    Oxid Med Cell Longev, 2022, 2022: 5503575
    https://doi.org/10.1155/2022/5503575 | PMID: 35251476 | PMCID: PMC8890863
    Citations: 2 | AltScore: 1
  13. Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial: A Secondary Analysis of a Randomized Clinical Trial.
    Chew DS, Li Y, Zeitouni M, Whellan DJ, Kitzman D, Mentz RJ, Duncan P, Pastva AM, Reeves GR, Nelson MB, Chen H, Reed SD
    JAMA Cardiol, 2022 Feb 1, 7(2): 140-148
    https://doi.org/10.1001/jamacardio.2021.4836 | PMID: 34817542 | PMCID: PMC8613698
    Citations: 5 | AltScore: 33
  14. A Processed Electroencephalogram-Based Brain Anesthetic Resistance Index Is Associated With Postoperative Delirium in Older Adults: A Dual Center Study.
    Cooter Wright M, Bunning T, Eleswarpu SS, Heflin MT, McDonald SR, Lagoo-Deenadalayan S, Whitson HE, Martinez-Camblor P, Deiner SG, Berger M
    Anesth Analg, 2022 Jan 1, 134(1): 149-158
    https://doi.org/10.1213/ANE.0000000000005660 | PMID: 34252066 | PMCID: PMC8678136
    Citations: 7 | AltScore: 18.2
  15. \I know that my role is going to change\": a mixed-methods study of the relationship between amyloid-? PET scan results and caregiver burden."
    Couch E, Belanger E, Gadbois EA, DePasquale N, Zhang W, Wetle T
    Aging Clin Exp Res, 2022 Dec 9, 35(2): 387-397
    https://doi.org/10.1007/s40520-022-02314-6 | PMID: 36484946 | PMCID: PMC9735001
    Citations: 1 | AltScore: 2.85
  16. The potential link between obstructive sleep apnea and postoperative neurocognitive disorders: current knowledge and possible mechanisms.
    Devinney MJ, VanDusen KW, Kfouri JM, Avasarala P, Spector AR, Mathew JP, Berger M
    Can J Anaesth, 2022 Oct, 69(10): 1272-1287
    https://doi.org/10.1007/s12630-022-02302-4 | PMID: 35982354 | PMCID: PMC9924301
    Citations: 1 | AltScore: 17.55
  17. A Multidimensional Bioinformatic Platform for the Study of Human Response to Surgery.
    Eckhoff AM, Connor AA, Thacker JKM, Blazer DG, Moore HG, Scheri RP, Lagoo-Deenadayalan SA, Harpole DH, Seymour KA, Purves JT, Ravindra KV, Southerland KW, Rocke DJ, Gilner JB, Parker DC, Bain JR, Muehlbauer MJ, Ilkayeva OR, Corcoran DL, Modliszewski JL, Devos N, Foster MW, Moseley MA, Dressman HK, Chan C, Huebner JL, Chasse S, Stempora L, Aschenbrenner ME, Joshi MB, Hollister B, Henao R, Barfield RT, Ellison MA, Bailey S, Woody S, Huang ES, Kirk A, Hwang ES
    Ann Surg, 2022 Mar 3, 275(6): 1094-1102
    https://doi.org/10.1097/SLA.0000000000005429 | PMID: 35258509
    Citations: 1 | AltScore: 7.5
  18. It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum.
    Goetz CG, Choi D, Guo Y, Stebbins GT, Mestre TA, Luo S
    Mov Disord, 2022 Dec 8, 38(2): 342-347
    https://doi.org/10.1002/mds.29279 | PMID: 36480107 | PMCID: PMC9974855
    Citations: 2 | AltScore: 6
  19. Biomarker clusters differentiate phenotypes of lumbar spine degeneration and low back pain: The Johnston County Osteoarthritis Project.
    Goode AP, Hu D, George SZ, Schwartz TA, Kraus VB, Huebner JL, Cleveland RJ, Taylor KA, Jordan JM, Golightly YM
    Osteoarthr Cartil Open, 2022 Sep, 4(3):
    pii: 100270. https://doi.org/10.1016/j.ocarto.2022.100270 | PMID: 35991624 | PMCID: PMC9387345
    Citations: 3 | AltScore: 6.05
  20. The role of Meteorin-like in skeletal development and bone fracture healing.
    Huang R, Balu AR, Molitoris KH, White JP, Robling AG, Ayturk UM, Baht GS
    J Orthop Res, 2022 Jan 25, 40(11): 2510-2521
    https://doi.org/10.1002/jor.25286 | PMID: 35076116 | PMCID: PMC9309188
    Citations: 6 | AltScore: NA
  21. Single cell transcriptomics in human osteoarthritis synovium and in silico deconvoluted bulk RNA sequencing.
    Huang ZY, Luo ZY, Cai YR, Chou CH, Yao ML, Pei FX, Kraus VB, Zhou ZK
    Osteoarthritis Cartilage, 2022 Mar, 30(3): 475-480
    https://doi.org/10.1016/j.joca.2021.12.007 | PMID: 34971754 | PMCID: PMC10097426
    Citations: 13 | AltScore: 2.85
  22. The association of accelerated epigenetic age with all-cause mortality in cardiac catheterization patients as mediated by vascular and cardiometabolic outcomes.
    Jiang R, Hauser ER, Kwee LC, Shah SH, Regan JA, Huebner JL, Kraus VB, Kraus WE, Ward-Caviness CK
    Clin Epigenetics, 2022 Dec 3, 14(1): 165
    https://doi.org/10.1186/s13148-022-01380-x | PMID: 36461124 | PMCID: PMC9719253
    Citations: 1 | AltScore: 16.358
  23. Causal analysis identifies small HDL particles and physical activity as key determinants of longevity of older adults.
    Kraus VB, Ma S, Tourani R, Fillenbaum GG, Burchett BM, Parker DC, Kraus WE, Connelly MA, Otvos JD, Cohen HJ, Orenduff MC, Pieper CF, Zhang X, Aliferis CF
    EBioMedicine, 2022 Nov, 85: 104292
    https://doi.org/10.1016/j.ebiom.2022.104292 | PMID: 36182774 | PMCID: PMC9526168
    Citations: 4 | AltScore: 223.068
  24. Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years.
    Lew MV, Ren Y, Lowder YP, Siamakpour-Reihani S, Ramalingam S, Romero KM, Thompson JC, Bohannon LM, McIntyre J, Tang H, Van Opstal J, Johnson E, Cohen HJ, Bartlett DB, Pastva AM, Morey M, Hall KS, Smith P, Peters KB, Somers TJ, Kelleher S, Smith SK, Wischmeyer PE, Lin PH, Wood WA, Thorpe G, Minor K, Wiggins K, Hennig T, Helms T, Welch R, Matthews B, Liu J, Burleson J, Aberant T, Engemann AK, Henshall B, Darby M, Proch C, Dellascio M, Pittman A, Suminguit J, Choi T, Gasparetto C, Long GD, Lopez RD, Sarantopoulos S, Horwitz ME, Chao NJ, Sung AD
    Transplant Cell Ther, 2022 Aug, 28(8): 498.e1-498.e9
    https://doi.org/10.1016/j.jtct.2022.05.018 | PMID: 35595226 | PMCID: PMC10042624
    Citations: 3 | AltScore: NA
  25. Deep learning for the dynamic prediction of multivariate longitudinal and survival data.
    Lin J, Luo S
    Stat Med, 2022 Mar 28, 41(15): 2894-2907
    https://doi.org/10.1002/sim.9392 | PMID: 35347750 | PMCID: PMC9232978
    Citations: NA | AltScore: NA
  26. Genetic Association Between Epigenetic Aging-Acceleration and the Progression of Mild Cognitive Impairment to Alzheimer's Disease.
    Liu H, Lutz M, Luo S, Alzheimer?s Disease Neuroimaging Initiative
    J Gerontol A Biol Sci Med Sci, 2022 Sep 1, 77(9): 1734-1742
    https://doi.org/10.1093/gerona/glac138 | PMID: 35797594 | PMCID: PMC9434458
    Citations: 3 | AltScore: 13.25
  27. Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine.
    Luo S, Goetz CG, Choi D, Aggarwal S, Mestre TA, Stebbins GT
    Mov Disord, 2022 Jun 18, 37(8): 1749-1755
    https://doi.org/10.1002/mds.29129 | PMID: 35716143 | PMCID: PMC9391277
    Citations: 1 | AltScore: 1.25
  28. Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling.
    Luo S, Zou H, Stebbins GT, Schwarzschild MA, Macklin EA, Chan J, Oakes D, Simuni T, Goetz CG, Parkinson Study Group SURE-PD3 Investigators.
    Mov Disord, 2022 Jul 16, 37(9): 1904-1914
    https://doi.org/10.1002/mds.29154 | PMID: 35841312 | PMCID: PMC9897939
    Citations: 3 | AltScore: 3
  29. Aging reduces liver resiliency by dysregulating Hedgehog signaling.
    Maeso-D?az R, Dalton GD, Oh S, Du K, Tang L, Chen T, Dutta RK, Hartman JH, Meyer JN, Diehl AM
    Aging Cell, 2022 Jan 4, 21(2): e13530
    https://doi.org/10.1111/acel.13530 | PMID: 34984806 | PMCID: PMC8844109
    Citations: 8 | AltScore: 2.5
  30. Physical Rehabilitation in Older Patients Hospitalized with Acute Heart Failure and Diabetes: Insights from REHAB-HF.
    Murray EM, Whellan DJ, Chen H, Bertoni AG, Duncan P, Pastva AM, Kitzman DW, Mentz RJ
    Am J Med, 2022 Jan, 135(1): 82-90
    https://doi.org/10.1016/j.amjmed.2021.08.001 | PMID: 34516959 | PMCID: PMC8688185
    Citations: 7 | AltScore: 7.85
  31. Intervention Adherence in REHAB-HF: Predictors and Relationship With Physical Function, Quality of Life, and Clinical Events.
    Nelson MB, Gilbert ON, Duncan PW, Kitzman DW, Reeves GR, Whellan DJ, Mentz RJ, Chen H, Hewston LA, Taylor KM, Pastva AM
    J Am Heart Assoc, 2022 Jun 7, 11(11): e024246
    https://doi.org/10.1161/JAHA.121.024246 | PMID: 35656973 | PMCID: PMC9238741
    Citations: 3 | AltScore: 10.75
  32. The Sickle Cell Disease Functional Assessment (SCD-FA) tool: a feasibility pilot study.
    Oyedeji CI, Hall K, Luciano A, Morey MC, Strouse JJ
    Pilot Feasibility Stud, 2022 Mar 4, 8(1): 53
    https://doi.org/10.1186/s40814-022-01005-3 | PMID: 35246265 | PMCID: PMC8895638
    Citations: 4 | AltScore: 9.35
  33. \Death is as Much Part of Life as Living\": Attitudes and Experiences Preparing for Death from Older Adults with Sickle Cell Disease."
    Oyedeji CI, Strouse JJ, Masese R, Gray N, Oyesanya TO
    Omega (Westport), 2022 Jul 20 3.02228E+14
    https://doi.org/10.1177/00302228221116513 | PMID: 35857485 | PMCID: PMC10082645
    Citations: NA | AltScore: 8.45
  34. Obesity Status and Physical Rehabilitation in Older Patients Hospitalized With Acute HF: Insights From REHAB-HF.
    Peters AE, Kitzman DW, Chen H, Nelson MB, Pastva AM, Duncan PW, Reeves GR, Upadhya B, Whellan DJ, Mentz RJ
    JACC Heart Fail, 2022 Dec, 10(12): 918-927
    https://doi.org/10.1016/j.jchf.2022.07.008 | PMID: 36164731 | PMCID: PMC10234458
    Citations: NA | AltScore: 22.95
  35. Partnering to cope with pain: A pilot study of a caregiver-assisted pain coping skills intervention for patients with cognitive impairment and dementia.
    Porter LS, Weiner DK, Ramos K, Barnes DE, Schmader KE, Gwyther L, Ritchie CS, Keefe FJ
    Palliat Support Care, 2022 Dec, 20(6): 785-793
    https://doi.org/10.1017/S1478951521001747 | PMID: 36942584 | PMCID: PMC10032330
    Citations: NA | AltScore: 1.5
  36. Epigenome-wide Association Study Analysis of Calorie Restriction in Humans, CALERIETM Trial Analysis.
    Ramaker ME, Corcoran DL, Apsley AT, Kobor MS, Kraus VB, Kraus WE, Lin DTS, Orenduff MC, Pieper CF, Waziry R, Huffman KM, Belsky DW
    J Gerontol A Biol Sci Med Sci, 2022 Dec 29, 77(12): 2395-2401
    https://doi.org/10.1093/gerona/glac168 | PMID: 35965483 | PMCID: PMC9799188
    Citations: 3 | AltScore: 23.05
  37. Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study.
    Root JC, Zhou X, Ahn J, Small BJ, Zhai W, Bethea T, Carroll JE, Cohen HJ, Dilawari A, Extermann M, Graham D, Isaacs C, Jacobsen PB, Jim H, McDonald BC, Nakamura ZM, Patel SK, Rentscher K, Saykin AJ, Van Dyk K, Mandelblatt JS, Ahles TA
    Breast Cancer Res Treat, 2022 May 19, 194(2): 413-422
    https://doi.org/10.1007/s10549-022-06623-2 | PMID: 35587324 | PMCID: PMC9392482
    Citations: 3 | AltScore: 1.25
  38. Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia.
    Siamakpour-Reihani S, Cao F, Lyu J, Ren Y, Nixon AB, Xie J, Bush AT, Starr MD, Bain JR, Muehlbauer MJ, Ilkayeva O, Byers Kraus V, Huebner JL, Chao NJ, Sung AD
    PLoS One, 2022, 17(6): e0268963
    https://doi.org/10.1371/journal.pone.0268963 | PMID: 35700185 | PMCID: PMC9197059
    Citations: NA | AltScore: 11.5
  39. Change in four measures of physical function among older adults during lung cancer treatment: A mixed methods cohort study.
    Singhal S, Walter LC, Smith AK, Loh KP, Cohen HJ, Zeng S, Shi Y, Boscardin WJ, Presley CJ, Williams GR, Magnuson A, Mohile SG, Wong ML
    J Geriatr Oncol, 2022 Sep 1, 14(2): 101366
    pii: S1879-4068(22)00206-5. https://doi.org/10.1016/j.jgo.2022.08.015 | PMID: 36058839 | PMCID: PMC9974579
    Citations: NA | AltScore: 9.95
  40. Home-Based Hematopoietic Cell Transplantation in the United States.
    Sung AD, Giri VK, Tang H, Nichols KR, Lew MV, Bohannon L, Ren Y, Jung SH, Dalton T, Bush A, Van Opstal J, Artica A, Messina J, Shelby R, Frith J, Lassiter M, Burleson J, Leonard K, Potter AS, Choi T, Gasparetto CJ, Horwitz ME, Long GD, Lopez RD, Sarantopoulos S, Chao NJ
    Transplant Cell Ther, 2022 Jan 20, 28(4): 207.e1-207.e8
    pii: S2666-6367(22)00034-3. https://doi.org/10.1016/j.jtct.2022.01.015 | PMID: 35066211 | PMCID: PMC8977260
    Citations: 3 | AltScore: NA
  41. Financial incentives to increase stool collection rates for microbiome studies in adult bone marrow transplant patients.
    Thompson JC, Ren Y, Romero K, Lew M, Bush AT, Messina JA, Jung SH, Siamakpour-Reihani S, Miller J, Jenq RR, Peled JU, van den Brink MRM, Chao NJ, Shrime MG, Sung AD
    PLoS One, 2022, 17(5): e0267974
    https://doi.org/10.1371/journal.pone.0267974 | PMID: 35507633 | PMCID: PMC9067695
    Citations: NA | AltScore: 16.83
  42. Associating persistent self-reported cognitive decline with neurocognitive decline in older breast cancer survivors using machine learning: The Thinking and Living with Cancer study.
    Van Dyk K, Ahn J, Zhou X, Zhai W, Ahles TA, Bethea TN, Carroll JE, Cohen HJ, Dilawari AA, Graham D, Jacobsen PB, Jim H, McDonald BC, Nakamura ZM, Patel SK, Rentscher KE, Saykin AJ, Small BJ, Mandelblatt JS, Root JC
    J Geriatr Oncol, 2022 Nov, 13(8): 1132-1140
    https://doi.org/10.1016/j.jgo.2022.08.005 | PMID: 36030173 | PMCID: PMC10016202
    Citations: 1 | AltScore: 5.35
  43. Differential microRNA profiles of intramuscular and secreted extracellular vesicles in human tissue-engineered muscle.
    Vann CG, Zhang X, Khodabukus A, Orenduff MC, Chen YH, Corcoran DL, Truskey GA, Bursac N, Kraus VB
    Front Physiol, 2022, 13: 937899
    https://doi.org/10.3389/fphys.2022.937899 | PMID: 36091396 | PMCID: PMC9452896
    Citations: NA | AltScore: NA
  44. Comparison of a Blood Self-Collection System with Routine Phlebotomy for SARS-CoV-2 Antibody Testing.
    Wixted D, Neighbors CE, Pieper CF, Wu A, Kingsbury C, Register H, Petzold E, Newby LK, Woods CW
    Diagnostics (Basel), 2022 Jul 31, 12(8):
    https://doi.org/10.3390/diagnostics12081857 | PMID: 36010206 | PMCID: PMC9406345
    Citations: 3 | AltScore: NA
  45. Impact of a Novel Training Approach on Hemodynamic and Vascular Profiles in Older Adults.
    Woessner MN, Welsch MA, VanBruggen MD, Johannsen NM, Credeur DP, Pieper CF, Sloane R, Earnest CP, Ortiz De Zevallos Munoz J, Church TS, Ravussin E, Kraus WE, Allen JD
    J Aging Phys Act, 2022 Apr 1, 30(2): 196-203
    https://doi.org/10.1123/japa.2020-0509 | PMID: 34348230 | PMCID: PMC9182940
    Citations: NA | AltScore: 2.85
  46. Severity of functional impairments by race and sex in older patients hospitalized with acute decompensated heart failure.
    Ye F, Nelson MB, Bertoni AG, Ditzenberger GL, Duncan P, Mentz RJ, Reeves G, Whellan D, Chen H, Upadhya B, Kitzman DW, Pastva AM
    J Am Geriatr Soc, 2022 Dec, 70(12): 3447-3457
    https://doi.org/10.1111/jgs.18006 | PMID: 36527410 | PMCID: PMC9759671
    Citations: 3 | AltScore: 1.5
  47. Rejuvenation of neutrophils and their extracellular vesicles is associated with enhanced aged fracture healing.
    Zhang X, Baht GS, Huang R, Chen YH, Molitoris KH, Miller SE, Kraus VB
    Aging Cell, 2022 Jun 3, 21(7): e13651
    https://doi.org/10.1111/acel.13651 | PMID: 35657721 | PMCID: PMC9282841
    Citations: 5 | AltScore: 3.35
  48. Glucosamine use, smoking and risk of incident chronic obstructive pulmonary disease: a large prospective cohort study.
    Zhang XR, Zhang PD, Li ZH, Yang P, Wang XM, Liu HM, Liang F, Wang JD, Sun Y, Shen D, Chen PL, Zhong WF, Huang QM, Liu D, Wang ZH, Kraus VB, Mao C
    Br J Nutr, 2022 Aug 28, 128(4): 721-732
    https://doi.org/10.1017/S000711452100372X | PMID: 34526168 | PMCID: PMC9892851
    Citations: 4 | AltScore: 9.2
  49. Albumin-Corrected Fructosamine Predicts All-Cause and Non-CVD Mortality Among the Very Elderly Aged 80 Years or Older Without Diabetes.
    Zhou J, Lv Y, Zhao F, Wei Y, Gao X, Chen C, Lu F, Liu Y, Li C, Wang J, Zhang X, Gu H, Yin Z, Cao Z, Kraus VB, Mao C, Shi X
    J Gerontol A Biol Sci Med Sci, 2022 Aug 12, 77(8): 1673-1682
    https://doi.org/10.1093/gerona/glab339 | PMID: 34758092 | PMCID: PMC9373969
    Citations: 2 | AltScore: 1.25
  50. Geriatric Preoperative Optimization: A Review.
    Zietlow KE, Wong S, Heflin MT, McDonald SR, Sickeler R, Devinney M, Blitz J, Lagoo-Deenadayalan S, Berger M
    Am J Med, 2022 Jan, 135(1): 39-48
    https://doi.org/10.1016/j.amjmed.2021.07.028 | PMID: 34416164 | PMCID: PMC8688225
    Citations: 15 | AltScore: 104.75
  51. Application of longitudinal item response theory models to modeling Parkinson's disease progression.
    Zou H, Aggarwal V, Stebbins GT, M?ller MLTM, Cedarbaum JM, Pedata A, Stephenson D, Simuni T, Luo S
    CPT Pharmacometrics Syst Pharmacol, 2022 Oct, 11(10): 1382-1392
    https://doi.org/10.1002/psp4.12853 | PMID: 35895005 | PMCID: PMC9574723
    Citations: 3 | AltScore: 3.75


EXTERNAL ADVISORY BOARD MEMBERS

Karen Bandeen Roche, PhD
John Hopkins University
Serving since 2010 (13 years)

George Kuchel, MD
University of Connecticut, Geriatrics and Gerontology
Serving since 2016 (7 years)

Neil Alexander, MD
University of Michigan
Serving since 2016 (7 years)


RECOGNITION AND AWARDS (2022-2023)
Harvey J. Cohen, MD (2022)
  • Inaugural winner of Duke Department of Medicine Career Achievement Award
Heather Whitson, MD, MHS (2023)
  • Neil Spector Humanism in Medicine Award, Duke Department of Medicine
  • Translation Research Mentor Award, Duke School of Medicine
Heather Whitson, MD, MHS (2022)
  • Outstanding Committee Service Award, Research Committee, American Geriatrics Society
James R. Bain, PhD (2022)
  • Visiting Professor in the Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington
Katherine Hall, PhD (2022)
  • Inducted as a Fellow to the Society of Behavioral Medicine
Kenneth Schmader, MD (2022)
  • Appointed to CDC ACIP Work Group on Respiratory Syncytial Virus vaccines
Leah Acker, MD, PhD (2023)
  • American Delirium Society New Investigator Award
  • Duke University LEADER Program Award
Leah Acker, MD, PhD (2022)
  • AGS-NIA R13 Bench-to-Bedside Resilience "Rising Star" Award
  • Society for Neuroscience in Anesthesia and Critical Care, John D. Michenfelder New Investigator Award
Susan N. Hastings, MD (2022)
  • National VHA Diffusion Award
Virginia Byers Kraus, MD, PhD (2023)
  • Elected to The American Clinical and Climatological Association

MINORITY RESEARCH

General Brief Description of Minority Activities:

Physical Rehabilitation for Older Patients with Acute HFpEF-The REHAB-HFpEF Trial (1R01AG078153-01) NIA

Dalane W. Kitzman, MD, PI, Amy Pastva, Intervention Coordinator 

The REHAB-HFpEF trial will determine whether a novel physical rehabilitation intervention will improve the primary outcome of combined all-cause rehospitalizations and mortality and the secondary outcome of major mobility disability during 6-month follow-up in patients hospitalized for heart failure and preserved ejection fraction (HFpEF), which is nearly unique to older persons, particularly women and Black persons, and for which there are few treatment options.

----------------------------------------------

Access to and effectiveness of community-based rehabilitation after stroke (5R01HD101493-02) NICHD 

Janet Freburger, PI, Sara Bingham Jones, PI, Amy Pastva, PI

This study will fill gaps in our understanding of access to and effectiveness of rehabilitation care for patients discharged home following stroke. It will also determine the potential effectiveness of a transitional care model in improving access to and appropriate delivery of rehabilitation care. Findings from this study will inform care delivery at the patient-, provider-, health system-, and policy-levels and may have a significant impact on the health of the nearly 800,000 persons per year who experience a stroke.

----------------------------------------------

Duke/UNC Alzheimer's Disease Research Center (5P30AG072958-02) NIA

Heather Whitson, MD, PI and Gwenn Garden, MD, PhD, PI

The Duke/University of North Carolina (UNC) Alzheimer’s Disease Research Center (Duke/UNC ADRC) is a collaboration of leading researchers in aging and Alzheimer’s disease. The Center’s primary objective is to catalyze and support research and innovation that will ultimately reduce the prevalence and impact of Alzheimer’s disease and related dementias. Leveraging the diversity of Eastern North Carolina and our strong scientific environment, we will enable novel research to identify opportunities to intervene in the years before Alzheimer’s disease symptoms arise and to reduce racial and urban/rural disparities associated with dementia.

----------------------------------------------

Duke Center for REsearch to AdvanCe Healhcare Equity (REACH EQUITY) (3U54MD012530-05S2) NIHMD

Kimberly S. Johnson, MD, MHS, PI

African Americans, Hispanics and other minorities receive lower quality healthcare and have poorer health than Whites. The Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity) will test interventions to improve the quality of care that minorities receive in the healthcare setting.




Minority Trainee(s):
  • Charity Oyedeji, MD, PESC Scholar, Assistant Professor of Medicine (Hematology)
    Dr. Charity Oyedeji's research focuses on implementing a geriatric assessment into clinical assessments of older adults with sickle cell disease. Due to advances in care and access, patients with sickle cell disease (SCD) are living longer than they have in previous generations. SCD is recognized as a condition that mimics accelerated aging, but little is known about aging with SCD. In particular, SCD patients face frequent health stressors including hypoxia, pain crises, and frequent hospitalizations, but little is known about how aging with SCD affects one’s resilience to these stressors. The objective of this study is to test the feasibility and safety of focused geriatric assessment and provocative tests that measure physiological reserve in SCD patients over age 50 and to determine the feasibility of a protocol to assess resilience to the stressor of hospitalization in older SCD patients. In addition, biomarkers of inflammation, coagulation, and longevity will be compared in 20 older (age 50-70) people with SCD and 20 younger (age 18-49) people with SCD. Thus far, the study has demonstrated that focused geriatric assessment, including provocative performance measures was safe and well-tolerated by older SCD patients. 50% of the older participants experienced a hospitalization within 12 months of a baseline assessment, indicating the feasibility of a future study to prospectively measure resilience after hospitalization by following a cohort of well-characterized participants for 2 years. Measures of physiological reserve in older SCD patients, on average, were consistent with normative measures from healthy seniors 20-30 years older. In 2020, Dr. Oyedeji used these findings to support a successful application for funding from the American Society of Hematology. She was also the recipient of 3 outstanding abstract awards at national meetings, and the recipient of the 2019 Duke Maddox Award for Aging Research. In 2021, Dr. Oyedeji received a Duke REACH Equity Career Development Award, an invitation to present at the American Society of Hematology Annual Meeting in December, and submitted a manuscript to the ASH Education Program.
  • Gentzon Hall, MD, PhD, Assistant Professor of Medicine (Nephrology)
    Dr. Hall is an Assistant Professor of Medicine (Nephrology) whose lab utilizes sophisticated genetic studies to better understand contributors to glomerulosclerosis (AAGS), a common cause of chronic kidney disease (CKD) in older adults. His ultimate goal is to identify targets for pharmacological intervention that will protect kidney function, especially in populations at highest risk for AAGS. Progressive loss of glomerular visceral epithelial cells (i.e. podocytes) with age is thought to be the principal driver of AAGS. Based on his own previous findings, Dr. Hall hypothesizes that impaired IL-15/IL-15R axis signaling reduces podocyte resiliency to proapototic stimuli, increasing risk of AAGS across the lifespan. In Aim 1 of his pilot study, he utilizes immortalized human podocyte lines to quantify podocyte apoptosis in gene knockdown and controls after exposure to two well-validated proapototic stimuli. In Aim 2, he will utilize targeted gene deletion in zebrafish embryos to understand the role of the IL-15 signaling in vivo. A validated surrogate model for albuminuria in humans will be used to detect and quantify proteinuria in knockdown IL-15 and IL-15R zebrafish compared to controls. If these experiments confirm the role ofIL-15 signaling in podocyte survival and function after nephrotoxic stressors, it will justify future research to develop IL-15 signaling agents to enhance kidney resilience and protect against AAGS.
  • Katherine Ramos, PhD, Assistant Professor of Medicine, Psychiatry and Behavioral Sciences
    Dr. Ramos' research focuses on developing and implementing behavioral interventions for older adults to enhance both their psychological and physical well-being in the context of medical complexity and/ or metastatic cancer. Despite the availability of interventions to improve functioning and quality of life in older adults by targeting their behaviors and mental health, there is a scarcity of research that focuses exclusively on older adults living with serious, life-limiting illness such as late-stage lung cancer. The objective of the Roybal study was to provide 8-12 sessions of Self-System Therapy (an evidenced-based psychotherapy treatment for depression) adapted and implemented for older adults over 65 years of age with Stage III or Stage IV lung cancer. The intervention primarily focuses on teaching older adults how to integrate promotion-focused and prevention-focused goal setting to improve self-regulation and increase behaviors that promote mental health and physical well-being. The study was recently completed with a sample of 12 focus group members, 5 user testers, 5 advisory members, and 30 participants enrolled in the pilot. Analyses are underway. An extension of this work has been recently funding by the NIA Research Centers Collaborative Network (RCCN) via Wake Forest School of Medicine. This study is currently underway with a focus on piloting measures targeting physical and psychological resilience(including accelerometry data collection) as older adults with late-stage lung cancer participate in the Self-System Therapy for Lung Cancer Intervention. Study completion is anticipated by March 2022. Thus far, from this work Dr. Ramos has presented her findings in national and international conferences, these include the: Association for Behavioral and Cognitive Therapies (ABCT), the American Psychological Association (APA), and the International Society for Psychotherapy Research in Heidelberg, Germany. A special issue paper abstract has been submitted for a full manuscript submission and an NIH R21 grant submission is currently underway to test the initial efficacy of the intervention in a larger randomized control trial.
  • Nicole DePasquale, PhD, Assistant Professor, Dept. of Medicine
    Nicole DePasquale's research addresses questions about health, well-being, and multiple role management in the context of middle and late adulthood, with the ultimate aim of informing intervention efforts. She addresses these questions through two lines of research that utilize quantitative and qualitative methodology. One line examines the ways in which patients with chronic kidney disease and their family care partners work together to self-manage the disease and the impact dyadic self-management has on their health both as individuals and as a unit. The second line examines the work/nonwork interface of long-term care employees with family caregiving roles, or double- and triple-duty caregivers. Recent research includes patient-family discussions about living-donor kidney transplantation, decisional conflict regarding kidney failure treatment modalities, and the work and nonwork benefits of family-supportive supervisor behavior among double- and triple-duty caregiving men. Dr. DePasquale has self-identified as an Individual from a disadvantaged background, as defined by the Notice of NIH’s Interest in Diversity (NOT-OD-20-031) released in 2019 regarding Underrepresented Populations in the U.S. Biomedical, Clinical, Behavioral and Social Sciences Research Enterprise. Dr. DePasquale's OAIC funded research project titled, “Individual and dyadic factors associated with older dialysis patients’ physical resilience” currently does not intentionally seek to examine minority groups or racial differences, but the nature of her work does heavily focus on African Americans given that they are disproportionately burdened with chronic kidney disease/renal failure. This pilot project serves as an add-on component to the Shared Kidney Care Study and expands the parent study’s existing strengths by adding a new and unique focus on physical resilience. It will examine how kidney failure dyads work together (or not) to maintain, regain, or optimize older patients’ physical function amid dialysis initiation and its negative downstream effects for patients and family care partners alike.

Minority Grant(s):
1. Project Title: FLUAD? vs. Fluzone? High-Dose Study
  Leader(s): SCHMADER, KENNETH
    DUKE UNIVERSITY
    Centers for Disease Control and Prevention 200-2012-53663 / (2016-2021)
  The objective of this randomized controlled clinical trial is to compare the reactogenicity, safety, and effect on functional status and quality of life in older adults of the high dose influenza vaccine (Fluzone?) versus the MF-59 adjuvanted influenza vaccine (FLUAD?). In this randomized safety trial of 757 older adults (adjuvanted inactivated influenza vaccine, trivalent [aIIV3], 378; high dose inactivated influenza vaccine [HD-IIV3], 379), the proportion of participants with moderate-to-severe injection-site pain (primary outcome) was not higher after aIIV3 than HD-IIV3. No vaccine-related serious adverse events occurred. Post-vaccination HRQOL impact was similar between aIIV3 and IIV3-HD groups. From a safety standpoint, aIIV3 or HD-IIV3 is an acceptable option to prevent influenza in older adults.
 
2. Project Title: The Impact of Reactogenicity of the Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults
  Leader(s): SCHMADER, KENNETH
    DUKE UNIVERSITY
    Glaxo Smith Kline GSK Zoster 063 / (2017-2019)
  Herpes zoster and its related complications are associated with significant medical burden, which negatively affects quality of life and daily functioning of older patients. The recently licensed recombinant zoster vaccine (RZV) offers high efficacy but is associated with local and systemic reactions. This study assessed the impact of RZV on the quality of life and daily functioning of 400 older participants. Grade 3 reactogenicity occurred in 9.5% of participants and was associated with a transient clinically important decrease in SF-36 Physical Functioning score (affecting activities such as walking, carrying groceries, climbing stairs) and the EQ-5D-5L on Days 1 and 2 post-first vaccination. No clinically meaningful reductions in mean SF-36 Physical Functioning scale scores from pre- to post-RZV dose-1 were observed over a 7 day period post-vaccination.
 
3. Project Title: EXPLORING THE EFFECTS OF EXERCISE TRAINING ON PTSD SYMPTOMS AND PHYSICAL HEALTH IN OLDER VETERANS WITH PTSD
  Leader(s): HALL, KATHERINE SHEPARD
    DURHAM VA MEDICAL CENTER
    VA I01RX003120 / (2020-2024)
  Posttraumatic stress disorder (PTSD) is prevalent among military Veterans, and affects over 30% of older, Vietnam-era Veterans. These servicemembers have endured nearly 40 years with these symptoms, and as a result, have significantly poorer health, higher rates of chronic disease and obesity, and an excess mortality rate 3 times higher than the general population. Clearly PTSD is more than just a psychological disorder. There is evidence to suggest that the pathway from PTSD to poor health is mediated by behavioral risk factors, such as exercise. Structured exercise is a highly effective, pluripotent strategy for the prevention, treatment, and management of chronic physical and psychological health conditions in older adults. To date, only a few pilot studies of exercise and PTSD have been published, and all suffer a major limitation: a singular focus on outcomes ?above the neck.? These studies do not report the impact of exercise on physical health- and mobility-related outcomes that contribute to long-term impairment and disability in Veterans with PTSD. There have been no studies of exercise and PTSD done in older adults, representing a significant research gap. This research examines a wellness-based approach to promoting health in older Veterans with PTSD, targeting exercise, a major modifiable risk factor. The objective of this study is to compare the impact of a supervised exercise program on PTSD symptoms and related health outcomes versus a healthy aging attention control group (HA-ATC). This study will be a randomized controlled trial of a 6-month, supervised exercise program among 188 Veterans ?60 years of age with PTSD at the Durham VAHCS. Participants will be randomly assigned to Supervised Exercise or HA-ATC. The exercise arm will include 3 weekly exercise sessions, each one lasting approximately 60 minutes, led by an exercise specialist. The HA-ATC will receive a health education program and materials modeled on the 10 KeysTM to Healthy Aging curriculum and the National Council on Agings Aging Mastery Program. The HA-ATC will include an 8-week face-to-face group program followed by 4 monthly sessions, the latter of which will be further supplemented with mailed informational packets, email newsletters, webinars, and group video telehealth sessions. Participants in the Exercise intervention arm will receive an individualized exercise prescription based on the individual?s exercise history, current exercise capacity, personal preferences, and current health status. This will be a multicomponent program that includes a selection of 8 to 12 strengthening, balance, and flexibility exercises targeting the major muscle groups as well as primary joints. Participants will also be instructed in endurance exercise, including treadmill walking or recumbent bicycle. The exercise protocol will consist of a 5-10 minute warm-up, followed by a series of progressive aerobic and strengthening exercises, and will end with a 5 minute cool-down. The primary outcome for this study will be PTSD symptoms assessed with the CAPS-5. Physical function, another outcome of primary interest will be measured objectively with a Physical Performance Battery. This test battery assesses aspects of daily function including balance (single leg stance), gait speed (4 meter walk), and chair stands (# in 30 seconds). Aerobic endurance, the investigators primary functional outcome, will be assessed with the 6-minute walk test (6MWT). Secondary outcomes include depression, sleep, and cognitive function. Outcomes will be assessed at baseline, 3 months, and 6 months. Assessments will be repeated 12 weeks post-intervention (9 months) to examine whether any observed exercise intervention effects are maintained. Mixed linear models will be used to compare outcomes for the two study arms.
 
4. Project Title: THE AMPK/ULK1/P27KIP1 AXIS REGULATES AUTOPHAGY AND CELL SURVIVAL IN AGED SATELLITE CELLS
  Leader(s): WHITE, JAMES P.
    DUKE UNIVERSITY
    NIH K01AG056664 / (2017-2022)
  a. Project summary/abstract:Sarcopenia is the age-related loss in skeletal muscle mass and strength; it leads to a host of co-morbiditiesincluding loss of physical function and overall resilience. One such perturbation in persons with sarcopenia isthe diminished ability to regenerate muscle after injury. Muscle stem cells, referred to as satellite cells, arerequired to activate, proliferate and differentiate to regenerate muscle and restore physical function. Agedsatellite cells are slower to activate upon injury; susceptible to apoptosis; and less efficient in repairing injuredmuscle. The AMPK/ULK1/p27Kip1 pathway appears critical for successful transition from quiescence to entryinto the cell cycle. Our preliminary data identify perturbations in the AMPK/ULK1/p27Kip1 pathway withadvanced age. This award period will investigate the role of the AMPK/ULK1/p27Kip1 pathway in thephenotype of satellite cell aging in both human and mouse models. In Aim1, we will test the hypothesis thatactivation of AMPK and its downstream targets ULK1 and p27Kip1 regulate the autophagy/apoptosis decisionin aged satellite cells. We will use molecular assays to rescue the functional loss of this pathway in aged cellsand return proliferative capacity. In Aim 2, we will test the hypothesis that exercise, a physiological inducer ofAMPK and autophagy, stimulates the AMPK/ULK1/p27Kip1 pathway, thereby enhancing proliferation andmetabolic function in aging murine and human satellite cells. Aim 3 will test the hypothesis thatAMPK/ULK1/p27Kip1 signaling will regulate the beneficial effects of caloric restriction on aged satellite cells.Together, the experiments in this proposal will test the hypothesis that the AMPK/ULK1/p27Kip1 pathway isimpaired in aging satellite cells resulting in a reduction in autophagy and susceptibility to apoptosis. Keyaspects of Dr. White's career enhancement will be: to learn how to coordinate clinical exercise trials; to trainin methods of satellite cell isolation and metabolic analysis, especially in the context of the aging organism.The training program will entail dedicated internal and external scientific presentations; pertinent coursework/workshops in stem cell biology and aging; and intensive career mentorship to ensure progress towardindependence. The research and career development plan detailed in this proposal will be conducted with ateam of outstanding mentors. Dr. William E. Kraus, a professor at the Duke Medical School is an establishedexpert in clinical exercise studies and muscle/satellite cell biology; he will serve as the primary mentor. Drs.Kenneth Schmader, Deborah Muoio (Duke) and Amy Wagers (Harvard) will serve as co-mentors; they willfacilitate training in aging biology, cell metabolism and aging stem cell biology, respectively. The environmentat the Duke School of Medicine is ideal for the research and training activities outlined in this proposal. Thisaward will provide Dr. White with optimal training to ensure an outstanding start to his career as anindependent investigator.
 
5. Project Title: DEPRESCRIBING CENTRAL NERVOUS SYSTEM MEDICATIONS IN HOSPITALIZED OLDER ADULTS
  Leader(s): PAVON, JULIESSA M
    DUKE UNIVERSITY
    NIH K23AG058788 / (2019-2024)
  This K23 Career Development Award in Aging focuses on the development of Dr. Juliessa Pavon, a hospital-based geriatrician, and on reducing central nervous system (CNS) medication use in hospitalized older adults.Dr. Pavon?s long-term goal is to improve the resilience of older adults against the acute stressors ofhospitalization. She has built her research program on investigating hazards of hospitalization, and a majorthreat is high-risk medication exposure. Sub-optimal CNS medication use during hospitalization is a keymodifiable risk factor for poor health outcomes; common classes include opioids, anxiolytics, anti-depressants,antipsychotics, and hypnotics. Our preliminary data suggests that nearly 40% of hospitalized older adults areexposed to anxiolytics and 60% to opioids during their hospital stay. De-prescribing is a systematic process oftapering or reducing medications. Interventions to facilitate de-prescribing that target specific medicationclasses, like CNS medications, or specific populations, like those with existing cognitive impairment, have notbeen well-studied in the inpatient setting. This gap represents a key opportunity to reduce potentiallyinappropriate CNS medications and their debilitating side effects in vulnerable patients--in line with the NationalInstitute of Aging?s priorities to improve medication use in older adults. Dr. Pavon?s K23 award proposes todevelop and pilot test a de-prescribing intervention that is informed by a theoretical model of behavioralchange. Aim 1 results will inform the epidemiology of the problem and identify target populations forrecruitment. Aim 2 will use qualitative methods to examine barriers and facilitators of hospital de-prescribing.Results will inform the intervention delivery strategies best suited to facilitate CNS medication de-prescribing ina well-tolerated, feasible manner. Aim 3 will develop and pilot test a multi-component hospital-based de-prescribing intervention that uses health informatics for content delivery, and provider behavior change andpatient activation strategies. This work will advance understanding of 1) which patients and CNS medicationclasses to target for de-prescribing interventions, 2) whether there are unique barriers to de-prescribing in thehospital setting, and 3) the optimal delivery strategy for safely de-prescribing. During this K23 grant period, Dr.Pavon will also complete additional training in Markov modeling statistical techniques, interventiondevelopment, health informatics, and leadership. Dr. Pavon?s mentor team will provide scientific support withexpertise in aging, pharmacology, hospital medicine, and research methodology. This career developmentplan will give Dr. Pavon the skills in conducting intervention development studies within the hospital setting.This training and resulting data will establish Dr. Pavon as a strong candidate for an R01 intervention designedto facilitate de-prescribing of CNS medications for the nearly 1 in 2 older adults that will experience exposure toa CNS medication during hospitalization.
 
6. Project Title: METABOLOMIC & RADIOGRAPHIC MARKERS OF FRACTURE RISK AMONG OLDER ADULTS WITH DIABETES
  Leader(s): LEE, RICHARD H.
    DUKE UNIVERSITY
    NIH K23AG058797 / (2018-2023)
  ABSTRACTAmong its medical complications, type 2 diabetes mellitus in older adults is associated with atwo-fold increase in the risk of hip and other low-trauma bone fractures. Paradoxically, thisincreased risk occurs despite a higher average bone mineral density. This increased fracturerisk is likely multifactorial, stemming from metabolic dysfunction that results in both increasedfalls risk and decreased bone strength. However, fracture risk stratification currently is limitedlargely to bone density testing and clinical risk tools that do not perform adequately for adultswith diabetes. Because bone is both a metabolic and structural tissue, metabolomics andbiomechanical analyses would be particularly useful for developing and assessing newmeasures of fracture risk. The objective of this application is to develop and evaluateradiographic and laboratory biomarkers of fracture risk among older adults with diabetes,utilizing biomechanical and translational measures. The proposed research has the followingaims: 1) Determine the association between metabolomic profiles and incident clinical fractureamong older adults with diabetes; 2) Compare geometric and biomechanical measures at thefemoral neck and intertrochanteric region among older adults with diabetes, with and without hipfracture. This application builds upon the prior published work and clinical expertise of thePrinciple Investigator, Dr. Richard Lee, and provides him additional research skills to assist withhis career development goal of understanding the interaction of chronic medical conditions onthe bone health of older adults, focusing on diabetes. Dr. Lee is a dual-trained Geriatrician andEndocrinologist with expertise in metabolic bone disease. The primary training goals of thisproposal include the following: 1) Develop laboratory and analytical skills in translational sciencethat will be used in the development and evaluation of clinical biomarkers, including ?omicstechnologies; 2) Acquire principles and skills in biomechanical engineering and materialsscience to integrate with clinical and epidemiological analyses. By integrating biomechanicalengineering and metabolomics approaches with epidemiologic research to identify new markersof fracture risk, this application addresses a significant source of morbidity and mortality amongan increasing proportion of older adults.
 
7. Project Title: NEURO-INFLAMMATION IN POSTOPERATIVE COGNITIVE DYSFUNCTION: CSF AND FMRI STUDIES
  Leader(s): BERGER, MILES
    DUKE UNIVERSITY
    NIH K76AG057022 / (2017-2022)
  This is a K76 Beeson career development award for Dr. Miles Berger, a geriatric neuro-anesthesiologist with a focus on postoperative cognitive disorders. Each year >16 million olderAmericans undergo anesthesia and surgery, and up to 40% of these patients developpostoperative cognitive dysfunction (POCD), a syndrome of postoperative thinking and memorydeficits. Although distinct from delirium, POCD (like delirium) is associated with decreased qualityof life, long term cognitive decline, early retirement, increased mortality, and a possible increasedrisk for developing dementia such as Alzheimer?s disease. We need strategies to prevent POCD,but first, we need to understand what causes it. A dominant theory holds that brain inflammationcauses POCD, but little work has directly tested this theory in humans. Our preliminary datastrongly suggest that there is significant postoperative neuro-inflammation in older adults whodevelop POCD. In this K76 award, we will prospectively obtain pre- and post-operative cognitivetesting, fMRI imaging and CSF samples in 200 surgical patients over age 65. This will allow us toevaluate the role of specific neuro-inflammatory processes in POCD, its underlying brainconnectivity changes, and postoperative changes in cerebrospinal fluid (CSF) Alzheimer?sdisease (AD) biomarkers, such as the microtubule-associated protein tau. This project willadvance understanding of neuro-inflammatory processes in POCD and clarify the potential link(s)between these processes and postoperative changes in AD pathology, in line with the NationalInstitute of Aging?s mission to understand aging and fight cognitive decline due to AD. During thisK76 grant period, Dr. Berger will also complete an individually tailored MS degree in TranslationalResearch that will include training in immunology methods, fMRI imaging, cognitive neuroscience,geroscience, and physician leadership. This career development plan will give Dr. Berger thetransdisciplinary skills to pursue his longer term goal of improving postoperative cognitive functionfor the more than 16 million older Americans who have anesthesia and surgery each year.
 
8. Project Title: NORTH CAROLINA DIABETES RESEARCH CENTER
  Leader(s): NEWGARD, CHRISTOPHER B
    WAKE FOREST UNIVERSITY HEALTH SCIENCES
    NIH P30DK124723 / (2020-2021)
  PROJECT SUMMARY/ABSTRACT ? METABOLOMICS CORE Comprehensive metabolic analysis, or ?metabolomics?, is a technology that defines the chemical phenotype of living systems. Given that metabolic fluxes and metabolite levels are downstream of genomic, transcriptomic, and proteomic variability, metabolomics provides a highly integrated profile of biological status. As such, it has unique potential for discovery of biomarkers that predict disease incidence, severity, and progression, and for casting new light on underlying mechanistic abnormalities. Metabolomic analyses are challenging, however, due to the complexity inherent in measuring large numbers of intermediary metabolites with diverse chemical properties in a quantitatively rigorous and reproducible fashion. The DMPI Metabolomics Core Lab has a long history of collaborative research and has established a strong and reliable infrastructure for conducting measurements for investigators at Duke and at outside institutions. Thus, it is well poised to become the NCDRC Metabolomics Core. While Duke has world-renowned facilities for metabolomics, its use by diabetes investigators outside of Duke (such as WF and UNC researchers) has been limited by bottlenecks, particularly in the analysis and interpretation of data, which the NCDRC seeks to address by establishing the NCDRC Metabolomics Core with support from Research Navigators.
 
9. Project Title: AGING IN 1000 HEALTHY YOUNG ADULTS: THE DUNEDIN STUDY
  Leader(s): MOFFITT, TERRIE E ; CASPI, AVSHALOM ;
    DUKE UNIVERSITY
    NIH R01AG032282 / (2009-2020)
  DESCRIPTION (provided by applicant): Declining fertility rates, aging of the baby-boomers, and increasing life expectancy are leading to population aging. As the population ages, this increases the public-health burden of age-related conditions, such as cardiovascular disease, type 2 diabetes, and dementia. Treating un-prevented diseases in late life has proven costly and ineffective. It is now known that potentially preventable risk exposures and physiological causes of age-related disease emerge in childhood. This recognition lends new scientific significance to studies that have followed cohorts from childhood. It is also now known that the pathogenesis of age-related diseases involves gradually accumulating decline in organ systems, beginning in the first half of the life course. Consequently, new interventions aiming to prevent age-related diseases will have to be applied to individuals while they are yet young, before they reach midlife. Translation of basic-science geronotology discoveries into interventions for young humans is lacking because virtually nothing is known about the process of biological aging during the first half of the life course. This prompts our proposal to study the pace of biologicalaging from the twenties forward. We will use the Dunedin Multidisciplinary Health & Development Study, a longitudinal study of a birth cohort now entering its fifth decade. This study combines methods of demographic/economic surveys, clinical- quality health assessments, biobanking, and linkage to nationwide administrative records (health, welfare, finances). We propose to administer a full-day data-collection protocol to the 1004 living members of the birth cohort. To assess each cohort member's pace of biological aging we will: (a) measure biomarkers across multiple organ systems, and (b) statistically model correlated change in these biomarkers assessed at ages 26, 32, 38, and 45 years. We will describe individual variation in the pace of aging, plus its developmental origins, genomic signatures, functional consequences, and economic costs. We will identify attributes that set apart individuals whose bodies are months or years younger than their chronological age. The proposed work will improve knowledge by generating findings to support future interventions to slow aging, prevent age-related disease, and improve the quality of longer lives.
 
10. Project Title: NEURAL SIGNATURES OF HEALTHY AND UNHEALTHY AGING
  Leader(s): HARIRI, AHMAD R ; MOFFITT, TERRIE E ;
    DUKE UNIVERSITY
    NIH R01AG049789 / (2015-2020)
  DESCRIPTION (provided by applicant): Declining fertility rates, aging of the baby-boomers, and increasing life expectancy are leading to population aging. As the population ages, this increases the public-health impact of age-related conditions, such as cardiovascular disease, type 2 diabetes, and dementia. Treating un-prevented diseases in late life has proven costly and ineffective. Consequently, effective strategies are needed in midlife to prevent age-related diseases and to improve the quality of longer lives. It is now known that potentially preventable risk exposures and physiological causes of age-related disease emerge in childhood. This recognition lends new scientific significance to studies that have followed cohorts from childhood. It is also now known that the pathogenesis of age-related diseases involves gradually accumulating damage to organ systems, beginning in the first half of the life course. Of these organ systems, the central nervous system is integral, prompting our proposal to add neuroimaging to the Dunedin Multidisciplinary Health & Development Study, a longitudinal study of both problematic and positive processes of adult development and aging, in a birth cohort now entering its fifth decade. This study combines methods of demographic/economic surveys, clinical-quality health assessments, biobanking, and linkage to nationwide administrative records (health, welfare, finances). We propose to administer a multimodal MRI protocol to the 1004 living members of the birth cohort. Our proposed neuroimaging protocol will measure individual variation in brain function, structure, and connectivity. We focus on the hubs of four neural circuits and the core behavioral capacities each supports: (1) the amygdala and emotion/threat, (2) the ventral striatum and motivation/reward, (3) the hippocampus and memory, and (4) the dorsolateral prefrontal cortex and executive control. With the resulting midlife neural measures, we propose three primary aims that will generate findings about problematic and successful aging: Aim 1 tests whether prospectively ascertained early- life adversity is linked to midlife neural measures. Aim 2 tests whether neural measures are linked to real-world behaviors (e.g., saving behavior) necessary to prepare for successful aging. Aim 3 tests if neural measures are related to the accelerated pace of biological aging. The proposed work will improve knowledge by generating findings about the neural correlates of age-related diseases and successful healthy aging. These findings are expected to support preventing disease and enhancing preparedness for wellbeing in late life. Beyond the proposed 5-year project, follow-up neuroimaging is envisaged. This project thus brings neuroimaging into three timely and vigorous areas of aging science: the study of early-life programming of lifelong health, the study of midlife preparation for successful aging, and mind-body research linking brain function to physical health.
 
11. Project Title: EPIGENETIC MECHANISMS PROMOTING LONGEVITY
  Leader(s): KRAUS, VIRGINIA
    DUKE UNIVERSITY
    NIH R01AG054840 / (2018-2023)
  AbstractCirculating small regulatory RNAs (sRNAs) are short non-coding RNAs (typically ~19-25nt in size). They mediatea broad spectrum of biological processes through regulation of gene expression. Our experimental evidenceindicates that serum levels of miRNAs (one form of sRNA) change considerably, the vast majority increasingwith age. The ability of circulating sRNAs to travel among tissues enables them to transmit signals and regulatea broad spectrum of biological functions. sRNAs exist in a variety of RNase-insensitive ribonucleoprotein or lipidcomplexes, or are encapsulated inside different types of extracellular vesicles. Consequently, in contrast tomessenger RNA, sRNAs are protected from extracellular RNases and are measurable and stable in samplesstored for decades. Despite numerous recent developments, we are far from understanding the role of sRNAsin aging. An understanding of their role in aging mammals, and in humans in particular, is still very limited dueto the increased complexity and longer life-spans of mammals compared with invertebrates. This projectleverages existing human sample resources from three completed NIH-funded studies (EPESE, STRRIDE andCALERIE), to discover and validate longevity-associated miRNAs in humans. Our preliminary analysis of 175circulating microRNA--in the NIA-funded Duke Established Populations for Epidemiologic Studies of the Elderly(Duke EPESE) community-based cohort of elders--identified 32 differentially expressed circulating miRNAs(p<0.05) associated with longevity; in all cases, their concentrations at baseline were higher in long-termsurvivors (>10 years) compared with age, sex and race matched but short-term survivors (<2 years); a subsetof these miRNAs predicted longevity independent of age, gender, race and functional status. The Duke EPESEcohort was aged 71 and older at the time of blood sampling and now has 25 years of longitudinal mortality data(through 2016) with which to address key questions about sRNAs and longevity in humans. sRNA discoveriesin Duke EPESE will be validated in plasma and muscle samples from completed human clinical trials of relevanceto longevity that investigated the health-promoting effects of exercise (STRRIDE cohort) and caloric restriction(CALERIE cohort). A human three-dimensional muscle tissue organ system will be used to understand theirmechanisms of action (with and without simulated exercise and caloric restriction), by testing sRNA mimics andinhibitors. Our preliminary analyses of 7 of our top longevity-related miRNA in this model system demonstratedproduction and secretion of all of them by muscle and statistically significantly increased secretion of two of themwith simulated muscle exercise. Together our approach will permit us to determine if sRNAs associated withlongevity are favorably modulated in tissue and blood in humans by exercise and/or caloric restriction, and ifthey appear to mediate any of the observed health benefits of these interventions. The totality of the data(generated in vivo and in vitro), will be systematically examined to identify pathways of sRNA action in humansand profiles of sRNA that could serve as biomarkers to predict longevity status.
 
12. Project Title: GENOMIC ANALYSIS OF THE CALERIE TRIAL TO GENERATE NEW KNOWLEDGE FOR GEROSCIENCE
  Leader(s): BELSKY, DANIEL WALKER
    COLUMBIA UNIVERSITY HEALTH SCIENCES
    NIH R01AG061378 / (2019-2024)
  SUMMARYThe graying global population makes interventions to extend healthy lifespan (healthspan) a public heathpriority. Therapies targeting basic biological processes of aging show proof-of-concept in animals: early-to-midlife intervention can delay disease onset and prolong healthspan. But translating these geroprotectivetherapies to humans faces the barrier that human clinical trials of midlife geroprotective therapy wouldrequire decades of follow-up to measure healthspan extension. An alternative is a short-term acceleratedgeroprotector trial that tests if geroprotective intervention can slow the rate of biological aging. Biologicalaging is the gradual and progressive decline in system integrity that occurs with advancing chronologicalage. This process is thought to be the root cause of increases in morbidity and disability in later life. Newresearch shows that biological aging can be measured in humans and that measures of biological agingpredict human healthspan. Geroprotective therapies that target basic biological processes of aging arehypothesized to slow the rate of biological aging. But this has not been tested. Our study will test if the best-established geroprotective intervention in animals, long-term caloric restriction, slows the rate of biologicalaging in midlife humans, who are still young enough for age-related disease to be delayed or prevented.We will conduct new assays of stored biospecimens from the National Institute on Aging's recently-completed CALERIE Trial, which randomized 220 non-obese adults to 25% caloric restriction (CR, N=145)or ad libitum normal diet (AL, N=75) for a period of 2 years. We have already shown that CR slows aging-related deterioration in organ-system integrity. Now, we propose to extend this test to genomic measures ofbiological aging. We will assay whole-genome DNA methylation (using Illumina chips) and gene expression(using RNA sequencing) from blood samples collected at CALERIE baseline, and at 12-, and 24-monthfollow-ups. We will use this 3-time-point repeated-measures multi-omics dataset to test (i) Does CR slowsthe rate of biological aging as measured from DNA methylation? (ii) Does CR cause changes to geneexpression in the pathways known to mediate healthspan-extending effects of CR in animals, e.g. themTOR pathway? (iii) Do changes to DNA methylation and gene expression mediate effects of CR on organsystem functioning? We will share the multi-omics data we generate with the CALERIE Biorepository,making the resource freely available to all interested researchers. The proposed project will generate newknowledge about effects of caloric restriction on biological aging in humans and test proof of concept for anaccelerated geroprotector trial design that can speed translation of new age-delaying therapies fromanimals to humans. Open data sharing through the CALERIE Biorepository will enable research beyond thescope of this project to improve understanding of caloric restriction and advance the field of geroscience.
 
13. Project Title: FUNCTIONAL LIMITATIONS AND DISABILITY AMONG MIDDLE-AGED ADULTS
  Leader(s): BOWLING, CHRISTOPHER BARRETT
    DUKE UNIVERSITY
    NIH R01AG062502 / (2020-2023)
  Project summary/Abstract The burden of functional limitations (restrictions in basic physical actions) and disability (problems with daily activities and life participation) may be more common in middle-aged US adults than previously recognized. However, studies of middle-age populations have not typically included functional assessments. The Coronary Artery Risk Development in Young Adults (CARDIA) study provides a unique opportunity to study functional status in a diverse, aging cohort. The Year 35 in-person exam is scheduled for 2020 and 2021, at which time, participants will be 53 to 65 years old. We propose a CARDIA ancillary study to obtain measures of function by self-report and physical performance to be paired with the existing data collected from early adulthood through middle age to address the following aims: 1. To quantify the burden of functional limitations and disability in middle age and assess the degree to which this can be attributed to the accumulation of chronic conditions, 2. To assess domains of functional limitations and disability captured by physical performance versus self-report, 3. To identify health-related risk factors in early adulthood for functional limitations and disability in middle-age, 4. To identify health-related, socioeconomic, and psychosocial factors that contribute to between- and within- race differences in functional limitations and disability among middle-aged adults. We will add measures of physical performance (fast and usual gait speed, single leg balance, timed chair stands, 6-minute walk test, and grip strength) to the CARDIA Year 35 exam (projected N=3,270; 1,563 black, 1,707 white). Also, self- reported functional limitations (Patient-Reported Outcomes Measurement Information System [PROMIS] Physical Function Short Form 20a) and disability measures (basic and instrumental activities of daily living) will be added to the Year 35 exam and annual telephone calls (1 call prior to and 2 after the Year 35 exam). As studies of younger populations have not often included functional assessments, the conceptualization, measurement approaches, risk factors, and implications of functional limitations and disability are poorly understood. Filling this knowledge gap by adding appropriate functional measures to an ongoing population based cohort, that represents the next wave of aging black and white adults will lead to new approaches to prevent functional decline and improve population health.
 
14. Project Title: QUALIFICATION OF PROGNOSTIC AND DIAGNOSTIC BIOMARKERS OF KNEE OSTEOARTHRITIS
  Leader(s): KRAUS, VIRGINIA
    DUKE UNIVERSITY
    NIH R01AR071450 / (2017-2020)
  AbstractA cure for osteoarthritis (OA) remains elusive. This is due in large part to two major obstacles, inability todetect OA sufficiently early before the onset of irreversible signs and recalcitrant symptoms, and inability toidentify individuals at high risk of progression based on traditionally used metrics (age, sex, body mass index,knee pain and joint space width). The latter challenge is responsible for low powering of clinical trials andnumerous drug trial failures. Using a systematic, unbiased and iterative approach, we have created a multiplereaction monitoring (MRM) proteomic panel for serum-based prediction of knee OA structural progression anddiagnosis of knee OA. The selection of proteins was based on results of extensive discovery proteomic studiesin synovial fluid, urine, and serum from knee OA radiographic progressors and non-progressors (with 3-4 yearfollow-up) and controls. The ultimate goals of this work are to qualify these new biomarker candidates in thecontexts of knee OA progression and OA diagnosis in larger well-phenotyped cohorts from the OsteoarthritisInitiative, the Johnston County Osteoarthritis Project and the Chingford cohorts. With this further qualification,these new biomarker tools will be very significant for their potential utility for clinical trial and clinical use toinform strategies for phenotyping and earlier identification and treatment of OA patients. We also intend topursue formal Food and Drug Administration (FDA) qualification of the optimal marker set yielded by thisproposal to facilitate their use as drug development tools.
 
15. Project Title: MECHANOTRANSDUCTION IN MENISCUS HEALTH AND REPAIR
  Leader(s): MCNULTY, AMY L
    DUKE UNIVERSITY
    NIH R01AR073221 / (2019-2023)
  ABSTRACT.Meniscal injuries are a significant clinical problem as each year 850,000 meniscal surgeries are performed in theUnited States and nearly twice as many worldwide. Meniscal tears in the avascular inner zone of the tissue donot heal well with suturing or conservative treatments and can ultimately lead to the development of osteoarthritis(OA). Therefore, new strategies are needed to enhance endogenous meniscus repair and tissue regeneration.The menisci play a critical biomechanical role in the knee, providing load support, joint stability, and congruity.Meniscus tissue is maintained through a balance of anabolic and catabolic activities of meniscus cells. Thesecellular activities are controlled not only by biochemical factors in the joint but also by physical factors associatedwith joint loading. Mechanobiology, which is the influence of mechanical factors on the biologic response of cells,is important in converting physical signals into metabolic and inflammatory responses in meniscus. However,the mechanisms by which mechanical signals are transduced in meniscus cells have yet to be identified. Ouroverall goal is to identify critical meniscus mechanotransduction pathways and modulate thesepathways to promote meniscus repair and prevent OA development.Our work has shown that transient receptor potential vanilloid 4 (TRPV4) is a critical component in cartilagemechanotransduction and metabolism. The activation of TRPV4 can block IL-1 induced catabolic responses andalso increases cell migration and proliferation, which are important processes to enhance tissue repair. Whilewe have found that TRPV4 is expressed in the meniscus, the function of this mediator in meniscus health anddisease is currently unknown. In this proposal, we will determine how mechanotransduction occurs throughTRPV4 in meniscus and identify modulators of this pathway that will be used to enhance tissue repair and preventOA development. We hypothesize that mechanotransduction by TRPV4 plays a key role in meniscus metabolismand can be modulated to enhance meniscus repair and prevent the development of OA. In this proposal, we willdetermine the effects of mechanical stimulation on TRPV4-mediated metabolism in healthy meniscus cells.Next, we will elucidate alterations in TRPV4-mediated mechanotransduction pathways in meniscus pathology.Finally, we will enhance integrative meniscus repair and prevent the development of OA by modulation ofmechanotransduction pathways. In this proposal, we will identify the key signaling pathways downstream ofTRPV4 that may function as novel drug targets to 1) treat patients with immobilized joints to simulate exerciseand maintain joint health; 2) enhance meniscus tissue regeneration using tissue engineering strategies; and 3)enhance meniscus repair and prevent the development of OA. Novel therapeutic targets identified in thisproposal can subsequently be developed into drugs to enhance meniscus repair and prevent the developmentof OA.
 
16. Project Title: ADHERENCE TO VENOUS THROMBOEMBOLISM PROPHYLAXIS GUIDELINES IN HOSPITALIZED ELDERS
  Leader(s): PAVON, JULIESSA M
    DUKE UNIVERSITY
    NIH R03AG048007 / (2014-2016)
  DESCRIPTION (provided by applicant): There are important public health concerns related to inappropriate use of venous thromboembolism (VTE) prophylaxis among medically ill hospitalized elderly patients with low risk of VTE occurrence. Specifically, use of anticoagulants (heparin products) for VTE prophylaxis when not medically indicated may be harmful, and is a major patient safety issue that also has a significant cost effect on health systems. To this end, the American College of Chest Physician (ACCP) 9th Edition guidelines explicitly recommend a risk-stratification approach, rather than universal use of anticoagulants for VTE prophylaxis. Even though many medical inpatients are at high risk for VTE, there are others whom do not have sufficient risk to warrant prophylaxis, and use in this population is inappropriate. The firstaim of this application proposes to determine the magnitude and scope of inappropriate use of anticoagulant VTE prophylaxis in low risk older adults. This aim will be achieved by using data abstraction from the Duke University Health System electronic records to determine (1) the prevalence of low risk elders using criteria proposed by ACCP guidelines, and (2) anticoagulant VTE prophylaxis use in this group. Guideline directed use of pharmacologic VTE prophylaxis also emphasizes mobility evaluation. Mobility is a key component of risk stratification. Poor mobility evaluation by providers may be a significant barrier to appropriate use of VTE prophylaxis. Our second aim proposes to determine whether level of mobility during hospitalization is being used to influence use and duration of VTE prophylaxis among medically ill hospitalized elders. To achieve this aim, we will collect prospective observational data to objectively measure inpatient mobility using patient mounted accelerometers during patient hospital stays. Our goal is to improve the appropriateness of use of VTE prophylaxis among those in which the risks of harm may outweigh the benefit. Results from our study will provide important insights about use of risk assessment, and the relationship between patient mobility and VTE prophylaxis. These results are critical to understanding how to take the next steps toward improving the appropriate use and safety of anticoagulants in hospitalized older adults. Information from this study could be used in future proposals to study interventions to ultimately improve hospital practice in the care of older adults. Our investigative team at Duke is unique since we have expertise in all key fields of study: geriatrics, hospital medicine, hematology, and physical activity, that also have a longstanding history of working well with each other. As such, this collaborative team and research plan is designed to provide the principal investigator with a foundation from which to pursue an independent career in geriatric and hospital medicine research.
 
17. Project Title: METABOLOMICS OF LOW-TRAUMA FRACTURE AMONG OLDER WOMEN WITH DIABETES
  Leader(s): LEE, RICHARD H.
    DUKE UNIVERSITY
    NIH R03AG048119 / (2014-2017)
  DESCRIPTION (provided by applicant): Among its associated medical complications, diabetes is associated with low-trauma bone fracture: Compared to older women without diabetes, older women with diabetes have 2-times the fracture risk. Paradoxically, this increased risk occurs despite diabetic women having a higher average bone mineral density. The long-term goal is to understand how diabetes among older adults contributes to osteoporosis and low-trauma bone fractures. The objective of this application is to identify, among older, diabetic women, candidate fracture-related metabolic profiles. The central hypothesis is that compared to older, diabetic women without a fracture history, the metabolic profiles of those women with a low-trauma fracture will be significantly different. As prior studie have shown, there are significant differences in metabolic profiles, related to fatty acid and amino acid metabolism, associated with diabetes. Additionally, in an animal-based model of osteoporosis, significant differences were observed in the levels of fatty acids and branched chain amino acids, using targeted metabolomics. The rationale for the proposed study is that the contribution to incident fracture risk among older women with diabetes can be determined in prospective studies, once candidate metabolic profiles are known in this population. In this proposed, cross-sectional study of diabetic women, age 65 years, recruited from general endocrine and primary care clinics, the following aims will be addressed: 1) Assess the levels of amino acids, organic acids, and acylcarnitines in older women with diabetes, both with and without a history of low-trauma fracture; 2) Compare the metabolic profiles of older, diabetic women without a history of low-trauma fracture to those with a history of fracture. Under the firstaim, after controlling for both measures of bone metabolism and functional status, the association between a history of low-trauma fracture and the levels of branched-chain amino acids and acylcarnitines, will be measured using targeted metabolomics. Under the second aim, the association between a history of low-trauma fracture and other metabolite classes will be measured using non-targeted metabolomics. The approach is innovative in identifying candidate, fracture-associated metabolic profiles, by utilizing metabolomics. Given the increasing prevalence of diabetes and substantial fracture-related morbidity among older adults, the proposal is significant because it is critically important to understand the key factors in thi population that contribute to low-trauma fractures. The results from the proposed study will inform the design of future studies to develop clinically applicable prospective screening tools toidentify at-risk individuals.
 
18. Project Title: EFFECTS OF AGING AND THE URINARY MICROBIOME ON RECURRENT URINARY TRACT INFECTIONS
  Leader(s): SIDDIQUI, NAZEMA Y
    DUKE UNIVERSITY
    NIH R03AG060082 / (2018-2020)
  PROJECT SUMMARY/ABSTRACT Urinary tract infections (UTIs) are one of the most commonly diagnosed infections in olderadults. UTIs cost $1.6 billion annually, impair health-related quality of life, and can have serioussequellae such as hospitalization, sepsis, or death. At all ages, UTIs are more prevalent inwomen than men, with up to 50% of all women experiencing a UTI during their lifetime. Theincidence of UTI rises in older women with over 10% of women older than 65 and almost 30% ofwomen older than 85 reporting a UTI within the prior 12 months. Among women with UTIs, there exists a subgroup with recurrent UTIs, defined as 3 or moreculture proven infections within 12 months, or >2 culture proven infections in a 6 month period.Recurrent UTI is not only more common in women, but especially more common in the post-menopausal life stage. In some women with recurrent UTIs, genetic factors facilitate bacterialadherence and repeated infection. However, recurrent UTI prevalence rises significantly in post-menopausal women, suggesting additional non-genetic mechanisms associated with aging. The urinary microbiome is one potential non-genetic factor that could influence recurrentUTIs with aging. We now have significant evidence that a urinary microbiome exists, and thatdysbiosis may be associated with health versus disease. Our long-term goal is to improve ourunderstanding of the microbes that occupy the urinary niche, how these microbes change withaging, and to determine whether particular microbial community types are associated withrecurrent UTI. We aim to compare urinary lactobacilli in populations of women without recurrentUTIs to assess how lactobacilli change with aging and with the presence of vaginal estrogentherapy. Next, we aim to assess whether urinary lactobacilli or other microbes are associatedwith recurrent UTI in postmenopausal women who are using vaginal estrogen. Finally, we aim todetermine whether there are distinct microbial community types that are associated withrecurrent UTI in older women.
 
19. Project Title: A PILOT STUDY TO ADVANCE TRANSLATION OF MOLECULAR SIGNATURES OF BIOLOGICAL AGING
  Leader(s): BELSKY, DANIEL WALKER
    COLUMBIA UNIVERSITY HEALTH SCIENCES
    NIH R21AG054846 / (2017-2020)
  PROJECT SUMMARYThe broad aim of this proposal is to determine if any of several proposed methods to quantify biological agingin humans are promising for use in trials of interventions to increase healthy lifespan. The biological processof aging is thought to drive risk for many disabling health conditions and mortality. There is evidence thattrajectories of aging begin to diverge as early in life as young adulthood. If this process can be measured, itwill speed development of interventions to prevent disease and disability and prolong healthy life. Onemeasurement approach is to calculate a ?biological age.? In contrast to a person's chronological age, whichcounts time since birth, a person's biological age reflects the condition of their body and mind relative to theirpeers. For example a 30-year-old person with the body and mind of an average 50-year-old would have abiological age of 50. Interventions shown to reduce biological age or slow its increase would thus be strongcandidates for increasing healthy lifespan. But in order to identify such interventions, measures of biologicalage are needed. Several algorithms have been proposed to calculate a person's biological age from panelsof clinical biomarkers and whole-genome data on blood DNA methylation and RNA expression. Thesealgorithms represent highly-scaleable methods ideal for implementation in intervention trials. But a criticalknowledge gap is whether the algorithms actually measure the process of biological aging that, if modified,would extend healthy lifespan. The research proposed in this application aims to fill that knowledge gap byimplementing and testing five of the most promising algorithms in an already-created database, the DunedinStudy. The Dunedin Study follows a population-representative birth cohort now in it's fifth decade of life. Thedatabase includes genome-wide DNA-methylation, RNA-expression, SNP, and clinical biomarker data on 954individuals along with extensive physical and cognitive function testing. Research aims will test if the differentalgorithms measure a common process of biological aging that drives disease and disability. Studying all ofthe algorithms together in a young, still-healthy cohort followed over time will answer three questions: 1) Arethe different algorithms related to one another, i.e. do they measure the same thing? 2) Can they measurechanges occurring in young adults as their trajectories of aging begin to diverge ? the time interventionswould likely have their greatest benefit? and 3) Do they measure real-life experiences of health decline inaging ? deficits in physical and cognitive functions and subjective perceptions of aging? Results will informwhich, if any, of the proposed biological aging algorithms show promise for implementation in interventiontrials. This could lead immediately to their implementation in archived biospecimens from completed trials.Results will also inform future approaches to developing measures of biological aging by identifying whatworks and what doesn't.
 
20. Project Title: EVALUATING EFFECTS OF AGE-RELATED MICROBIOTA MODULATIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
  Leader(s): SUNG, ANTHONY ; CHAO, NELSON J. ;
    DUKE UNIVERSITY
    NIH R21AG066388 / (2019-2021)
  Allogeneic hematopoietic stem cell transplant (HCT) has the potential to cure patients with hematologicmalignancies. However, HCT is associated with significant treatment related mortality (TRM) ranging from 20-30%. (1). TRM is particularly high in patients with advanced age (hazard ratio 1.84, age >60 years vs. <20) anddecreased physical function (hazard ratio 2.94, bottom quartile vs. top quartile). A major cause of TRM is graft-versus-host disease (GVHD), which affects 40-60% of patients. We hypothesis that age related microbiomechanges will affect the HCT clinical outcomes, and in addition to age other factors such as diet, physical activityand the care environment can influence the microbiome profiles as well. Correlations between GVHD and disruptions in the gut microbiota have been reported in several studies,though it remains unclear how the microbiota causes or prevents GVHD. While lengthy hospitalizations arestandard for HCT patients, caring for patients in a more normal care environment may preserve the naturalmicrobiota. We hypothesized that shifting the care environment from the hospital to a more normal environmentlike the home can preserve the gut microbiota, thereby decreasing intestinal inflammation and GVHD. We havesuccessfully piloted home HCT in a phase 1 trial (co-PIs Chao, Sung, clinicaltrials.gov NCT01725022) and haveexpanded our pilot into a randomized phase 2 study of home vs. standard care (clinicaltrials.gov NCT02218151,co-PIs Chao, Sung) funded by NCI 1R01CA203950 (PI Chao, co-I Sung). While age cannot be changed, other strategies to overcome the negative effects of aging-relatedmicrobiome changes can be the use of dietary and physical activity interventions. We have started a Phase I/II,pre- and peri-HCT optimization program (PPOP). PPOP has two pieces: a clinical component (C-PPOP), whichestablishes a new standard of care for the pre-HCT evaluation of all Duke HCT patients, and a researchcomponent (R-PPOP), which includes additional assessments and interventions to optimize health and functionincluding diet and physical activity. In this proposed project we aim to: 1) evaluate the age related microbiomechanges and their implications on HCT outcomes including TRM (primary endpoint), infections, GVHD, andimmune function; 2) evaluate the effects of a dietary and physical activity intervention on the aged microbiomeand implications on HCT outcomes. For this study will be able to utilize existing samples from the Duke Hematologic MalignanciesBiorepository. This study can provide new insights into the underlying mechanisms of GVHD in Leukemia andother malignant diseases. If successful, this study will identify the impact of age related microbiome changes onHCT outcomes and the immune system, as well as strategies to target the aged microbiome to promote betteroutcomes for HCT patients.
 
21. Project Title: DEVELOPING RESEARCH AT THE INTERFACE OF HIV AND AGING
  Leader(s): HIGH, KEVIN P.
    WAKE FOREST UNIVERSITY HEALTH SCIENCES
    NIH R24AG044325 / (2013-2019)
  DESCRIPTION (provided by applicant): Effective antiretroviral therapy (ART) has resulted in many people with chronic HIV surviving into middle and old age. However, even those with controlled HIV viral replication, are more likely than uninfected subjects to experience premature chronic illness, multi-morbidity and functional decline. For example, 58% of HIV- infected subjects age >= 50 years have one or more of the following: renal failure, diabetes mellitus, bone fracture, hypertension or overt cardiovascular disease vs. only 35% of HIV-uninfected controls. Further, geriatric syndromes such as frailty and falls are becoming more prevalent in HIV-infected adults. While the need for research in HIV and aging is widely recognized, challenges in methodology, data acquisition and sharing, and research workforce education/training have hampered this goal. Multi-morbidity, functional decline and disability are typically research domains of geriatrics and gerontology. The Claude D. Pepper Older Americans Independence Centers (OAlCs; aka 'Pepper Centers') were established to advance research into the causes, mechanisms, prevention and treatment of functional decline with age, but lack expertise in HIV. In contrast, the Centers for AIDS Research (CFARs) have unparalleled expertise in HIV- related basic, clinical and social/behavioral research, but lack resources or expertise in aging biology, clinical phenotypes, or functional measures. This proposal leverages CFAR/OAIC expertise to create a shared research platform, enhancing and accelerating investigation at the interface of HIV and aging by: 1) Harmonizing processes for data collection across OAlCs and CFARs and providing a coordinated platform for data collection; 2) Validating key instruments/measures of function and geriatric phenotypes in HIV- infected subjects age > 50 years; 3) Supporting pilot projects at the interface of HIV and aging; 4) Identifying and mentoring junior faculty with a research focus in HIV and aging; and 5) Disseminating information and data sharing opportunities to the larger scientific community. Accomplishing these aims will efficiently amplify NIAID investment in the CFARs, NIA investment in the OAlCs, and, more importantly, address critical healthcare needs in a rapidly growing population aging with HIV.
 
22. Project Title: EPIGENETIC MECHANISMS PROMOTING LONGEVITY
  Leader(s): KRAUS, VIRGINIA
    DUKE UNIVERSITY
    NIH R56AG054840 / (2017-2018)
  AbstractCirculating sRNAs are short non-coding RNAs (typically ~19-25nt in size). They mediate a broad spectrum ofbiological processes through regulation of gene expression. Experimental evidence indicates that the serumlevels of sRNAs change considerably--the vast majority increasing?with age. The ability of circulating miRNAsto travel among tissues enables them to transmit signals and regulate a broad spectrum of biological functions.sRNAs exist in a variety of RNase-insensitive ribonucleoprotein or lipid complexes, or are encapsulated insidedifferent types of extracellular vesicles. Consequently, in contrast to messenger RNA, sRNAs are protectedfrom extracellular RNases and are measurable and stable in samples stored for decades. Despite numerousrecent developments, we are far from understanding the role of sRNAs in aging. An understanding of their rolein aging mammals, and humans in particular, is still very limited due to the increased complexity and longerlife-spans of mammals compared with invertebrates. This project leverages existing human sample resourcesfrom three completed NIH-funded studies (EPESE, STRRIDE and CALERIE) to discover and validatelongevity-associated sRNAs in humans. Our preliminary analysis of 175 circulating microRNA--in the NIA-funded Duke Established Populations for Epidemiologic Studies of the Elderly (Duke EPESE) community-based cohort of elders--identified 32 differentially expressed circulating miRNAs (p<0.05) associated withlongevity; in all cases, their concentrations at baseline were higher in long-term survivors (10+ years)compared with age, sex and race matched but short-term survivors (<2 years); a subset of these miRNAspredicted longevity independent of age, gender, race and functional status. The Duke EPESE cohort was aged71 and older at the time of blood sampling and now has nearly 25 years of longitudinal life-span data withwhich to address key questions about sRNA and longevity in humans. sRNA discoveries in Duke EPESE willbe validated in samples from completed human clinical trials of relevance to longevity that investigated thehealth promoting effects of exercise (STRRIDE cohort) and caloric restriction (CALERIE cohort). A humanthree-dimensional muscle tissue organ system will be used to understand their mechanisms of action (with andwithout simulated exercise and calorie restriction) by testing sRNA mimics and inhibitors. Together these aimswill determine if sRNAs associated with longevity are favorably modulated in humans by exercise and/orcaloric restriction; and if they appear to mediate any of the observed health benefits of these interventions.The totality of the data (in vivo and in vitro generated), will be systematically examined to identify pathways ofsRNA action in humans and profiles of sRNA and other factors that could serve as biomarkers to predictlongevity status.
 
23. Project Title: EXTRACELLULAR VESICLES AND THEIR ROLE IN HALLMARKS OF AGING
  Leader(s): KRAUS, VIRGINIA
    DUKE UNIVERSITY
    NIH R56AG060895 / (2018-2019)
  AbstractExtracellular vesicles (EVs) are membranous particles released from nearly all cell types into all bodily fluidsevaluated to date ? including serum and plasma. Depending on tissue of origin, health state and organismage, they carry a variety of complex cargo consisting of nucleic acids (5,000 microRNA documented to date),proteins (93,000 documented to date including cytokines) and metabolites. Due to their coordinate regulationof tissue homeostasis and biological processes through intercellular trafficking of microRNA and protein cargo,EVs are particularly attractive for this project because they can potentially serve as DIRECT biomarkers ofaging, namely indicators AND mediators of the aging process. The goal of this project is to establish EVswith their microRNA and protein constituents as biomarkers of healthspan and lifespan and to informbiological mechanisms promoting healthspan and lifespan. We focus particularly on three of the hallmarksof aging, epigenetic alterations, cellular senescence and altered inter-cellular communication. Increasingevidence suggests that EVs secreted from senescent cells have unique characteristics and contribute tomodulating the phenotype of recipient cells; thus, they have been newly deemed novel senescence associatedmolecular pattern (SASPs). We hypothesize expression of different amounts and different compositions of EVsare associated with different lifespan and healthspan of humans, and with different senescence states inmurine models. In collaboration with Meso Scale Diagnostics, LLC (MSD), a premier developer of highlyreliable and highly sensitive biomarker assays, we will develop new biomarkers of EVs informing agingmechanisms and test their function in vitro. These biomarkers will be qualified in the context of aging in ourexisting extensive human sample sets: individuals (n=3056) from multiple longitudinal cohort studies (EPESEaged >71 years; PALS aged 20-100 years) and NIH-funded controlled trials of geroprotective interventions(STRRIDE exercise aged 18-70 years; and CALERIE caloric restriction aged 22-45 years). Complementingthis new biomarker development work, we will validate and qualify: the new S-PLEX high sensitivity (femtomolelevel detection) assays by MSD for soluble cytokines and circulating microRNAs we have identified asassociated with healthspan and lifespan in elders. Taken together, we believe our broad expertise inbiomarkers and aging, our interdisciplinary team and our partnership with a company with the capability tocommercialize assays provide a unique project responsive to RFA-AG-18-018 for ?Development of validreliable markers of aging-related biologic mechanisms for human studies?.
 
24. Project Title: MOLECULAR TRANSDUCERS OF PHYSICAL ACTIVITY AND HEALTH: NC CONSORTIUM CLINICAL SITE
  Leader(s): KRAUS, WILLIAM E ; HOUMARD, JOSEPH A ; NICKLAS, BARBARA J ;
    DUKE UNIVERSITY
    NIH U01AR071128 / (2016-2022)
  ABSTRACT Exercise is a powerful physiological stimulus contributing to disease prevention and intervention. Theprotective and preventive effects of exercise are well-documented for metabolic, neurodegenerative, andcardiovascular diseases, and certain cancers. While scientists acknowledge the extensive benefits ofexercise, there is still insufficient understanding about the underlying mechanisms by which exercise preventsdisease and improves health across diverse organ systems. The NIH Common Fund has developed aforward-looking funding mechanism ? six tethered RFA's tied to creating a research consortium, the MolecularTransducers of Physical Activity Consortium (MoTrPAC) ? to create resources and critical information forexercise and health investigators well into the future. Two products of the MoTrPAC collective efforts will be apublically available data resource that will enhance and accelerate subsequent mechanistic research ondiseases and conditions affected by physical activity; and a biorepository of clinical and animal model samplesto be used in studying exercise biology. Based on prior collaborative efforts, our group believes that we areideally positioned to propose a protocol that will respond directly to the RFA, while at the same time executethe large volume of tests to complete the ~450 people required at each site within the MoTrPAC consortium.To accomplish all of our Clinical Center goals, we have developed a consortium ? the North Carolina ClinicalSite Consortium (NCCSC). The NCCSC consists of the experienced research teams Duke University Schoolof Medicine; East Carolina University (ECU); and Wake Forest School of Medicine (WFSM). As described inthe study plan, the NCCSC weighed a number of alternatives for training regimens, timing, and type of tissuesampling, sample sizes for the four obligated study groups, and other factors, while staying within budgetconstraints. The following Aims will maximize the value of the data and sample repositories; this will beaccomplished with the enrollment of 540 individuals and finishing 450. ? Aim 1: To determine the response of molecular transducers to a single acute bout of either aerobic or resistance training. ? Aim 2: To determine the responses of molecular transducers to a chronic exercise training program of either aerobic or resistance training. ? Aim 3: To determine the responses of molecular transducers to a detraining period following either aerobic or resistance training.
 
25. Project Title: PHYSICAL RESILIENCIES: INDICATORS AND MECHANISMS IN THE ELDERLY COLLABORATIVE
  Leader(s): COLON-EMERIC, CATHLEEN S ; WHITSON, HEATHER E. ;
    DUKE UNIVERSITY
    NIH UH2AG056925 / (2017-2019)
  ABSTRACTThe overarching objectives of the PRIME Collaborative (Physical Resilience: Indicators and Mechanisms inthe Elderly) are to characterize specific resilience phenotypes, elucidate biological mechanisms, and validateclinically valuable predictive tools and measures of physical resilience. The application focuses on resilience inthree systems that are central to older adults' overall health: musculoskeletal, cognitive, and immune. Thecentral hypothesis of this application is that resilience to physical stressors is influenced by biologicalmechanisms at the molecular level. We will examine whether mechanisms associated with one or more of theseven ?Pillars of Aging,? which have been described by the trans-NIH Geroscience Interest Group, underlie amore generalized capacity for recovery that applies across multiple stressor/response scenarios. An inter-professional team of aging researchers from has been assembled to accomplish these objectives; the teamrepresents expertise from six NIA-funded Older American Independence Centers (OAICs) and leverages otherexisting resources. The PRIME Collaborative team will use a two-phased approach. In Phase 1, workgroupswill define specific resilience phenotypes in existing datasets using latent class trajectory analysis of sequentialoutcome measures following a stressor. The three resilience phenotypes, selected for their over-archingrelevance to late life health as well as our team's expertise, are: musculoskeletal recovery after orthopedicsurgery, immune recovery after infection, and cognitive recovery after surgery/anesthesia. We will conduct pilotstudies to identify novel clinical tests and biomarkers associated with each of these resiliencies. Feasibility andresponse data from pilot studies will inform the design of a larger cohort study in Phase 2. In the final 6months of Phase 1, the most promising predictive tests and markers will be selected and will inform twoparallel activities in Phase 2. First, a longitudinal cohort study of older patients undergoing elective surgery willbe conducted to validate predictors in a more diverse population. The Phase 2 cohort study will also allow us toassess synergy and interactions between different types of predictors (provocative tests, physiologic outputmeasures, biomarkers) and different types of resilience (musculoskeletal, cognitive, immune). Second,biological mechanisms underpinning resilience will be identified using newly developed mouse resiliencemodels, and in vitro human and mouse myotubule systems. These model systems are suitable for interventionstudies. The Phase 2 biological studies will be designed to identify pathways related to one or more Pillars ofAging so that they are likely to underpin multiple types of resilience, and suggest therapeutic targets and novel,resilience-bolstering interventions.
 
26. Project Title: PHYSICAL RESILIENCIES: INDICATORS AND MECHANISMS IN THE ELDERLY COLLABORATIVE
  Leader(s): COLON-EMERIC, CATHLEEN S
    DUKE UNIVERSITY
    NIH UH3AG056925 / (2017-2022)
  ABSTRACTThe overarching objectives of the PRIME Collaborative (Physical Resilience: Indicators and Mechanisms inthe Elderly) are to characterize specific resilience phenotypes, elucidate biological mechanisms, and validateclinically valuable predictive tools and measures of physical resilience. The application focuses on resilience inthree systems that are central to older adults' overall health: musculoskeletal, cognitive, and immune. Thecentral hypothesis of this application is that resilience to physical stressors is influenced by biologicalmechanisms at the molecular level. We will examine whether mechanisms associated with one or more of theseven ?Pillars of Aging,? which have been described by the trans-NIH Geroscience Interest Group, underlie amore generalized capacity for recovery that applies across multiple stressor/response scenarios. An inter-professional team of aging researchers from has been assembled to accomplish these objectives; the teamrepresents expertise from six NIA-funded Older American Independence Centers (OAICs) and leverages otherexisting resources. The PRIME Collaborative team will use a two-phased approach. In Phase 1, workgroupswill define specific resilience phenotypes in existing datasets using latent class trajectory analysis of sequentialoutcome measures following a stressor. The three resilience phenotypes, selected for their over-archingrelevance to late life health as well as our team's expertise, are: musculoskeletal recovery after orthopedicsurgery, immune recovery after infection, and cognitive recovery after surgery/anesthesia. We will conduct pilotstudies to identify novel clinical tests and biomarkers associated with each of these resiliencies. Feasibility andresponse data from pilot studies will inform the design of a larger cohort study in Phase 2. In the final 6months of Phase 1, the most promising predictive tests and markers will be selected and will inform twoparallel activities in Phase 2. First, a longitudinal cohort study of older patients undergoing elective surgery willbe conducted to validate predictors in a more diverse population. The Phase 2 cohort study will also allow us toassess synergy and interactions between different types of predictors (provocative tests, physiologic outputmeasures, biomarkers) and different types of resilience (musculoskeletal, cognitive, immune). Second,biological mechanisms underpinning resilience will be identified using newly developed mouse resiliencemodels, and in vitro human and mouse myotubule systems. These model systems are suitable for interventionstudies. The Phase 2 biological studies will be designed to identify pathways related to one or more Pillars ofAging so that they are likely to underpin multiple types of resilience, and suggest therapeutic targets and novel,resilience-bolstering interventions.